

# BOB CHAMPION CANCER TRUST

England & Wales · Charity number 1024664

## Details

---

**Status** Registered

**Legal form** Other

**Registered** 1993-08-05

**Register** [View on the Charity Commission register](#)

## Contact

---

**Address** Bob Champion Cancer Trust  
7 Square Rigger Row  
Plantation Wharf  
London  
SW11 3TZ

**Phone** 02079243553

**Email** [lucy@bobchampion.org.uk](mailto:lucy@bobchampion.org.uk)

**Website** [www.bobchampion.org.uk](http://www.bobchampion.org.uk)

## Activities

---

**Objects:** TO SUPPORT RESEARCH INTO THE CAUSATION NATURE AND TREATMENT OF PATIENTS WITH TESTICULAR CANCER AND OTHER FORMS OF MALIGNANT DISEASE PARTICULARLY IN CHILDREN AND YOUNG ADULTS INCLUDING HODGKINS DISEASE AND NON-HODGKIN LYMPHOMA AND IN PARTICULAR THE RESEARCH AND PATIENT CARE UNDERTAKEN BY THE ROYAL MARSDEN HOSPITAL DOWNS ROAD SUTTON SURREY

**Activities:** To support research into the causation nature and treatment of patients with testicular cancer and other forms of malignant disease, particularly prostate cancer. Having built a laboratory with the Institute of Cancer Research there is a greater element of research into prostate cancer. The Bob Champion Research and Education Building was opened at the Norwich Research Park in February 2015.

## Classification

---

- **How:** Makes Grants To Organisations, Sponsors Or Undertakes Research
- **What:** The Advancement Of Health Or Saving Of Lives
- **Who:** Children/young People, Elderly/old People, Other Charities Or Voluntary Bodies, Other Defined Groups, The General Public/mankind

## Geography

- **Area of benefit:** NATIONAL
- Throughout England And Wales

## Finances

Period end	Income	Expenditure	Assets	Employees
2025-06-30	£555,470	£430,103	£1,893,273	1
2024-06-30	£615,935	£395,820	£1,861,310	1
2023-06-30	£230,372	£329,956	-	-
2022-06-30	£337,551	£351,540	-	-
2021-06-30	£246,847	£342,334	-	-

## Trustees

Name	Role	Appointed
Alexandra Embiricos		2012-02-12
Andrew Franklin		2014-03-15
Bridget Rosser		2014-03-15
CAROLLYN JANE ZETTER-WELLS		2013-06-23
Catherine McAleavey		2019-09-01
Catherine Nash		2016-09-09
Luke Arthur Ponsonby		2011-06-02
MICHAEL CATTERMOLE		2011-06-01
Susie Janet Burrage		2022-03-22
TIMOTHY GEORGE FOX		2013-06-23

**BOB CHAMPION CANCER TRUST**

England & Wales - Charity number 1024664

---

# Accounts

---

**Bob Champion Cancer Trust**

**Unaudited**

**Trustees' Report and Financial Statements**

**For the year ended 30 June 2025**

---

**Bob Champion Cancer Trust**

---

**Contents**

---

	Page
Reference and administrative details of the Charity, its Trustees and advisers	1
Trustees' report	2 - 8
Trustees' responsibilities statement	9
Independent examiner's report	10
Statement of financial activities	11
Balance sheet	12
Statement of cash flows	13
Notes to the financial statements	14 - 28

---

## **Bob Champion Cancer Trust**

---

### **Reference and administrative details of the Charity, its Trustees and advisers For the year ended 30 June 2025**

---

#### **Founder**

Professor Sir Michael Peckham MD FRCP FRCR (deceased October 2021)

#### **President**

Bob Champion, C.B.E.

#### **Medical Advisor**

Professor David Dearnaley

#### **Vice Presidents**

Clare Balding, O.B.E.

Willie Carson, O.B.E.

Kristina Cook

David Gower, M.B.E.

Chris Hughes

Jonjo O'Neill

Greg Rusedski, Esq.

Peter Shilton, O.B.E.

Nick Skelton, C.B.E.

#### **Trustees**

Michael I Cattermole, Esq. (Chairman)

Susie Burrage, O.B.E.

Alex Embiricos

Timothy Fox, Esq.

Andrew Franklin, Esq.

Catherine McAleavey

Catherine Nash

Luke Ponsonby, Esq.

Bridget Rosser

Carolyn Jane Zetter Wells

#### **Trust Officer**

Mrs. Lucienne Wilkinson

#### **Charity registered number**

1024664

#### **Principal Office**

7 Square Rigger Row

Plantation Wharf

London

SW11 3TZ

#### **Accountants**

UHY Hacker Young

Chartered Accountants

Thames House

Roman Square

Sittingbourne

Kent ME10 4BJ

---

## **Bob Champion Cancer Trust**

---

### **Trustees' report (continued) For the year ended 30 June 2025**

---

The Trustees present their report and the accounts for the year ended 30 June 2025.

The financial statements comply with the charity's Trust Deed, the Charities Act 2011 and Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019) (Charities SORP (FRS 102)).

#### **Administrative Details**

A Declaration of Trust formed the Charity on 29 June 1993 registered number 1024664. The purpose of the establishment of this charitable trust was to take over and enlarge the work of the Bob Champion Cancer Trust that was set up by a Declaration of Trust dated 20 January 1983.

The number of Trustees shall not be less than three or more than ten. The power of appointing new Trustees is vested in the Trustees and may be exercised by a resolution in writing signed by all of the current Trustees and the new Trustee. The Trustees meet four times per calendar year in person or online.

Please see page 1 for Trustee details, legal and other administrative detail.

#### **Structure, Governance and Management**

The Trust was set up to support research into the causation, nature and treatment of patients with testicular cancer and other forms of malignant disease including those of the prostate.

The Trustees acknowledge their responsibility for ensuring that the major risks to which the Charity is exposed are identified and systems designed to mitigate those risks. During the year the Trustees completed a formal risk management process to assess business risks and risk management strategies.

The Trust has an independent Medical Advisor, Professor David Dearnaley, to advise the board in their selection of grant awards and allow the Charity to operate in open competition with peer review.

#### **Objectives and Activities**

The Bob Champion Cancer Trust currently supports cancer research within the Institute of Cancer Research, The Royal Marsden Hospital in Sutton, Surrey and the Bob Champion Research and Education Building, situated in the Norwich Research Park at the University of East Anglia. The focus of this support is on urological cancers, especially those of the prostate.

The Trust opened in collaboration with the Institute of Cancer Research the Bob Champion Research Centre in 2000, which formed part of the first male dedicated cancer research centre, in Europe. This centre is based at The Institute of Cancer Research in Sutton, Surrey.

In February 2015 the Trust, with The University of East Anglia (UEA), opened the Bob Champion Research and Education Building at The Norwich Research Park, this facility is operated by the UEA in partnership with the Norfolk & Norwich Hospital. This centre provides state-of-the-art laboratories for researchers to explore new treatments, not only for prostate cancer research but for diseases from antibiotic resistance to musculo-skeletal and gastrointestinal diseases. This £19 million facility includes a unique bio-bank facility to store DNA and tissue samples plus teaching facilities suitable for training medical practitioners in rooms reflecting the functions of operational hospital bays.

---

## **Bob Champion Cancer Trust**

---

### **Trustees' report (continued) For the year ended 30 June 2025**

---

The Trust is self-supporting and relies totally upon donations from the public that may be in the form of a legacy or donation with the benefit of claiming Gift Aid if applicable. Income is raised from a full fundraising calendar, with major events being held annually or biennially, supported by event committees, active social media platforms and direct promotional mailings and a News Letter. The fundraising events range from themed parties, horse shows and race nights to personal challenges such as sponsored rides, marathons, including the London Marathon and the Shetland Pony Grand National. Hopefully offering something for all our supporters, which also helps to attract new interest to the cause, active involvement from members of the public to support us by organising their own events is also encouraged.

An annual charity raceday at Plumpton Racecourse is held, now in its eighth year, which is an established and extremely popular fundraiser. During the day a Shetland Pony race is held as an extra attraction which helps raise further funds as well as the traditional auctions and raffles. Another very successful event is a carol service - Carols and Champagne - held at Chelsea Old Church in London every other year. A traditional church service is followed by a drinks party in the church hall attached and is very popular with the order of service raising extra funds from advertisers. The Trust is hoping to establish a second raceday which could host a charity race.

The Trust is delighted to be continuing its long-standing involvement with the Shetland Pony Grand National (SPGN), now for the ninth year. The SPGN is a major part of the London International Horse Show held at the ExCel Exhibition Centre, with the SPGN grand finale, a highlight of the four day event. Bob Champion himself is heavily involved during the year, helping the young riders through their heats, and attends, as well as appearing in the show ring every day during the Show. The ten jockeys (aged between 9-14 years) once they qualify to compete via the heats commit to raise a minimum of £1,000 sponsorship in support of the Trust, although, with determined future jockeys, nearly all participants way surpass this goal.

Since 1988 the Trust has produced its own, especially commissioned, double sided Christmas card and since 2021 a second smaller card. The cards not only raise vital funds for research work but spreads awareness of the Trust and it's work and helps keep racing's greatest fairy tale of Bob Champion and Aldaniti's 1981 win alive. The artists are selected each year and kindly donate their work and time in support of the Trust. The larger card offers a more classic choice with the smaller card being more fun. The Trust has found that sales have suffered due to continuing increased postage costs but the cards still represent an important part of the Trusts awareness message.

Bob Champion was awarded a CBE in The Queen's New Year Honours 2021 for his charitable works. He still attends many of the events himself, despite continued health issues, and continues to play an integral part in raising funds, and awareness, not only of the Charity's aims, but also of the disease itself. All events are organised from the office, often with the help of a specific event committee made up from volunteers and keen supporters. The Trust is always open to new fundraising ideas and how to offer help to cancer sufferers, their families and friends.

### **Public Benefit**

The Trustees confirm that they given due consideration to the Charity Commission's published guidance on the Public Benefit requirement under the Charities Act 2011 when reviewing the aims and objectives, and in planning future activities.

---

## Bob Champion Cancer Trust

---

### Trustees' report (continued) For the year ended 30 June 2025

---

#### Achievements and performance

Each year 64,000 men in the UK will be diagnosed with prostate cancer and more than 12,000 will die from their disease. At present we do not have good markers to predict who will have prostate cancer that behaves in an aggressive way and causes mortality.

For many cancers the fundamental mechanism of cancer development has been unravelled. Such studies reveal that the disease develops because of alterations or mutations within 'cancer genes'. Although cancer genes responsible for the development of, for example, colon cancer and breast cancer are well characterised, relatively little is known about the fundamental development of prostate cancer.

The Bob Champion Research Trust funded researchers have worked together as part of international consortium, called The Pan Prostate Cancer Group, set up by Professor Colin Cooper at The University of East Anglia (UEA) and Professor Ros Eeles the Institute of Cancer Research (ICR) to analyse genetic data from prostate cancer samples across nine countries.

Application of Artificial Intelligence to results obtained in the UK has helped scientists reveal two distinct forms of prostate cancer called Evotypes, with one being very aggressive prostate cancer. These results could revolutionise how the disease is diagnosed and managed, since it is important that treatment is targeted to aggressive disease.

Crucially, the team aims to develop a genetic test that, when combined with conventional staging and grading, can provide a more precise prognosis for each patient, allowing tailored treatment decisions.

The researchers used AI to study changes in the DNA of prostate cancer samples (using whole genome sequencing) from 159 patients. They identified two distinct cancer groups among these patients using an AI technique called neural networks. These two groups were confirmed by using two other mathematical approaches applied to different aspects of the data. This finding was validated in other independent datasets from Canada and Australia.

The work published in the Journal Cancer Genomics in 2024 was carried out in collaboration with Dr Dan Woodcock at the University of Oxford and Professor David Wedge at the University of Manchester who led the research. The team hope their findings could save thousands of lives in future and revolutionise how prostate cancer is diagnosed and treated. Ultimately, it could provide tailored treatments to each individual patient according to a genetic test which will also be delivered using AI.

Although prostate cancer is responsible for a large proportion of all male cancer deaths, it is more commonly a disease men die with rather than from. This means that unnecessary treatment can often be avoided, sparing men from side-effects such as incontinence and impotence.

These studies are important as until now, it was thought that prostate cancer was just one type of disease. But now, with advancements in artificial intelligence, the researchers have been able to show that there are actually two different subtypes at play.

Hopefully the findings will not only save lives through better diagnosis and tailored treatments in the future, but they may help researchers working in other cancer fields better understand other types of cancer too.

---

## Bob Champion Cancer Trust

---

### Trustees' report (continued) For the year ended 30 June 2025

---

Professor Ros Eeles, Professor of Oncogenetics at The Institute of Cancer Research, London, and Honorary Consultant in Clinical Oncology and Cancer Genetics at The Royal Marsden NHS Foundation Trust, confirms that this study has utilised the enormous genomic dataset from The Pan Prostate Cancer Group which is a powerhouse of information about prostate cancer from around the world.

The Trust also supports Professor Ros Eeles with a three year grant for the UKGPCS collection of germline DNA and data. The aim of this project is to analyse whole exome sequence from a unique and large collection of prostate cancer cases: 20,000 germline DNA samples from the UKGPCS in order to identify rare variants and their contribution to the risk of developing prostate cancer with specific phenotypes and potentially predict response to various treatments.

The UKGPCS was established in 1992, recruiting men from The Royal Marsden NHS Foundation Trust and Collaborative Centres (NHS Trust hospitals) throughout the UK and Northern Ireland, over 180 of which are from the National Cancer Research Network (NCRN).

The UKGPCS have collected a rich phenotype dataset for most of these samples: date of birth, diagnosis, and death if applicable; mode of detection; TNM Stage; Gleason score; primary treatment; vital status; geographic region based on referring hospital, or treatment hospital if information on the referring hospital was not available; self-reported BMI; self-reported ethnicity; and PSA at diagnosis for all patients, as well as for relatives, if available. The information on risk factors for prostate cancer, demographic characteristics, and clinical data are also collected routinely as part of medical care and clinical follow-up. Over 78% of the cohort has clinical data on treatment and outcomes are being followed up at 2, 5 and 10 years post diagnosis; this collection is still in process.

For sequencing of whole exomes in germline samples a high-throughput automated approach will be used to prepare high-quality genomic DNA for exome capture. The exome will be captured and sequenced on the latest technology in use at the Regeneron Genetics Centre.

The latest study 'Whole Exome Rare Variant Association' focuses on identifying rare genetic variants that may influence the risk and development of any prostate cancer (PrCa), or aggressive disease with poorer prognosis, through association testing. The primary data used in this investigation are Whole Exome Sequencing (WES) data from the UK Genetic Prostate Cancer Study (UKGPCS). An additional objective involves the comparison of germline mutation frequencies in UKGPCS PrCa cases to the UK population using data from UK Biobank (UKBB).

The Trust extended the original three year grant for a further three years for Annie Gao, a Senior Radiotherapy Clinical Trials Co-ordinator and awarded a three year grant to Lily Gilder as Trial Assistant, at the Bob Champion Unit, Royal Marsden Hospital, Sutton

The Unit has supported and lead the PACE trials which looks to use stereotactic body radiotherapy to deliver to the patient the prostate cancer treatment in 5 visits over 1-2 weeks. This pioneering treatment can target the cancer with pinpoint accuracy. This means a reduction in healthy tissue damage and enables men to complete and recover from treatment much faster than ever before. Initial results from the PACE-B trial have been published, showing that there were low rates of side effects after 2 years and suggesting that curative treatment can be given over a much-shortened period. This has positive implications for the patient's experience of cancer treatment and subsequent quality of life.

---

**Bob Champion Cancer Trust**

---

**Trustees' report (continued)**  
**For the year ended 30 June 2025**

---

Critical to the success of all these studies is the long-term follow-up of men after their initial radiotherapy treatment. Confidence that a patient is truly cured takes 10 years in men with localised prostate cancer as side effects can continue to develop over many years, a full estimation of the risks and benefits of a new treatment requires years of careful data collection.

Annie Gao and her team focus particularly on the long-term follow-up of patients. This enables the ICR to continue to monitor men for signs of cancer recurrence and side effects for long enough to be sure that the innovative radiotherapy treatment being tested is advantageous. The Unit continues to publish results in the highest calibre journals and publications.

**Key trials in long term follow-up:**

- The **IMRT (Intensity-Modulated Radiotherapy) trial** (495 patients) looked at targeting the prostate cancer more accurately, which in turn allowed for a larger dose of radiotherapy to be given. There were 5 groups of patients, each receiving slightly different doses of radiotherapy. The continued review of this comprehensive dataset enables us to learn more about which patients are likely to be cured with standard treatments and which require further escalation of therapy. Blood and biopsy translational work from this trial also sheds new light on the evolutionary genetics of prostate cancer.
- The **CHHiP trial** (398 patients recruited at RMH out of 3,200 in multi-centre trial) follows patients for up to 15 years after their treatment and is enabling us to know with greater certainty that shorter treatments are better for men with localised prostate cancer. The trial introduced prostate IMRT in the UK. This ongoing data collection has enabled the review of over 2000 prostate cancer samples to further investigate the effects of radiotherapy dose on prostate cancer in the laboratory.
- The **DELINEATE trial** (316 patients), looks at new ways of planning and giving radiotherapy for localised prostate cancer. New types of scanning techniques have allowed us to differentiate between the cancer and normal prostate tissue with greater certainty. The aim is to target the cancerous area with increased accuracy and a higher dose without risking damage to the normal prostate tissue. The Trust has directly impacted this trial by allowing it to extend the patient follow-up period from 5 to 10 years. This data collection is critical as the cure rates have so far been unprecedented with up to 96.7 % of patients being free of any prostate cancer at the 5-year follow-up timepoint. Further follow-up of these patients is necessary to ensure these excellent results are maintained at 10 years.
- The **PACE-C trial** compares stereotactic body radiotherapy (5 visits – SBRT uses precise daily image guidance to give remarkably accurate radiotherapy) with the now conventional IMRT (20 visits – see IMRT trials above). Since the application last year, recruitment to this trial has exceeded expectations and the trial closed early having already met its target of 1182 patients. These men are now in long-term follow-up, assessing side effects, patient quality of life and long-term cancer control.

**Publications:-****Distinct druggable biological processes in early-onset prostate cancer**

**Authors:** Stephanie T Schmidt<sup>1†</sup>, Zsofia Kote-Jarai<sup>2†</sup>, Adrian Larkeryd<sup>2†</sup>, Byrum Ozer<sup>2†</sup>, Questa Karlsson<sup>2</sup>, James Campbell<sup>3</sup>, Sue Merson<sup>2</sup>, Nicola Dennis<sup>4</sup>, Steven Hazell<sup>4</sup>, Costas Mitsopoulos<sup>5</sup>, Colin Cooper<sup>6</sup>, The ICGC-UK<sup>§</sup>, TCGA Consortium<sup>§</sup>, Paul Workman<sup>5</sup>, Rosalind A Eeles<sup>2,4\*</sup>, Bissan Al-Lazikani<sup>1,7\*</sup>

---

**Bob Champion Cancer Trust**

---

**Trustees' report (continued)  
For the year ended 30 June 2025**

---

Esentürk E, Sahli A, Haberland V, Ziuboniewicz A, Wirth C, Bova GS, Bristow RG, Brook MN, Brors B, Butler A, Cancel-Tassin G, Cheng KC, Cooper CS, Corcoran NM, Cussenot O, Eeles RA, Favero F, Gerhäuser C, Gihawi A, Girma EG, Gnanapragasam VJ, Gruber AJ, Hamid A, Hayes VM, He HH, Hovens CM, Imada EL, Jakobsdottir GM, Jung CH, Khani F, Kote-Jarai Z, Lamy P, Leeman G, Loda M, Lutsik P, Marchionni L, Molania R, Papenfuss AT, Pellegrina D, Pope B, Queiroz LR, Rausch T, Reimand J, Robinson B, Schlomm T, Sørensen KD, Uhrig S, Weischenfeldt J, Xu Y, Yamaguchi TN, Zanettini C, Lynch AG, Wedge DC, Brewer DS, Woodcock DJ. Causes of evolutionary divergence in prostate cancer. *arXiv* [Preprint]. 2025 Mar 17; arXiv:2503.13189v1. PMID: 40166741.

Gheybi K, Soh PXY, Jiang J, Mbeki TMN, Louw M, Burns D, Mundra P, Kiriy D, Hasan MM, Jaratlersiri W, Lebelo MT, Campbell RA, Radzuma MB, Nenzhelele M, Obida M, Obida M, Ombuki WM, Oyaro MO, Patrick SM, Loda M, Wedge DC, Bristow RG, Brewer DS, Cooper CS, Reimand J, Cancel-Tassin G, Cussenot O, Hovens CM, Corcoran NM, Stricker PD, Schlomm T, Prins GS, Sørensen KD; Pan Prostate Cancer Group; HEROIC PCaPH Africa1K; Weischenfeldt J, Mutambirwa SBA, Ngugi PM, Thomas DM, Kote-Jarai Z, Eeles RA, Bornman MSR, Hayes VM. Pathogenic variants reveal candidate genes for prostate cancer germline testing for men of African ancestry. *Nat Commun*. 2025 Oct 2;16(1):8799. doi:10.1038/s41467-025-63865-6. PMID: 41038821.

Smith SF, Mills RD, Cooper CS, Brewer DS. Molecular and genetic biomarkers in prostate cancer active surveillance: recent developments and future perspectives. *Genes (Basel)*. 2026 Jan 6;17(1):71. doi:10.3390/genes17010071. PMID: 41595491.

Gihawi A, Wood HM, Clark J, O'Grady J, Eeles RA, Wedge DC, Jakobsdottir GM, Magiorkinis G, Schache AG, Masterson L, Lechner M, Fenton TR, Jones TM, Flanagan AM, De Noon S, Rubinsteyn A, Hurst R, Cooper CS, Brewer DS. The landscape of microbial associations in human cancer. *Sci Transl Med*. 2025 Sep 3;17(814):eads6166. doi:10.1126/scitranslmed.ads6166. PMID: 40901921.

Gruber A, Olsen AV, Girma EG, Hernando B, Torres Lázaro M, Macintyre G, Cheng K, Kiriy D, Reimand J, Pellegrina D, Gerhäuser C, Eeles R, Cooper C, Bristow R, Wedge D, Schlomm T, Fernandez-Sanroman A, Roldan-Romero JM, Lamy P, Sorensen K, Cancel-Tassin G, Cussenot O, Rausch T, Brors B, Uhrig S, Lutsik P, Yamaguchi T, Barton L, Jakobsdottir G, Sahli A, Simon R, Sauter G, Brewer D, He H, Bova S, Corcoran N, Hayes V, Brook M, Kote-Jarai Z, Hamid A, Hovens C, Jung CH, Pope B, Gnanapragasam V, Molania R, Papenfuss A, Imada EL, Khani F, Loda M, Marchionni L, Queiroz L, Robinson B, Zanettini C, Butler A, Leeman G, Xu Y, Favero F, Gihawi A. Integrated signatures define mutational processes in prostate cancer. *Nature. In press*.

Kiriy D, Favero F, Olsen AV, Gerhäuser C, Heilmann J, Lutsik P, Gruber A, Hernando B, Macintyre G, Cheng K, Reimand J, Pellegrina D, Cooper C, Schlomm T, Girma EG, Cancel-Tassin G, Cussenot O, Lamy P, Sorensen K, Imada EL, Khani F, Loda M, Marchionni L, Queiroz L, Robinson B, Zanettini C, Hovens C, Hamid A, Gnanapragasam V, Corcoran N, Brors B, Uhrig S, Jakobsdottir G, Rausch T, Yamaguchi T, Bristow R, Sahli A, Wedge D, Pope B, Jung CH, Brewer D, Gihawi A, He H, Bova GS, Hayes V, Brook M, Eeles R, Kote-Jarai Z, Molania R, Papenfuss A, Butler A, Leeman G, Xu Y, Pan

Prostate Cancer Group (PPCG), Jespersen J, Rodriguez-Gonzalez F, Locallo A. Recurrent mechanisms of biallelic epigenetic inactivation reveal new putative tumour suppressor genes in prostate cancer. *Nat Commun. In press*.

---

## Bob Champion Cancer Trust

---

### Trustees' report (continued) For the year ended 30 June 2025

---

#### Financial Review

The Trust incurred an overall surplus for the year of £31,963 (2024: £332,459). Included within the income and expenditure of the Trust for the year is a surplus on fundraising events of £118,662 (2024: £184,412) and dividends received of £52,752 (2024: £46,708). In addition, the unrealised loss on investments for the year to 30 June 2025 was £93,404 (2024: gain £112,344).

The Trustees are satisfied that the charity's funds are available and adequate to fulfil its obligations in relation to their commitments.

The Declaration of Trust, signed on the 29th June 1993, states that "any money available for investment may be so invested in the names of the Trustees or their nominees in any way whatsoever, whether or not producing income, as the Trustees shall in their absolute discretion think fit, as if they were absolutely entitled to the Trust Fund beneficially."

It is the policy of the charity to hold reserves in its General Fund that have not yet been committed or designated for any particular purpose. The Trustees have set aside these reserves in order to protect the future operations of the charity from the effects of any unforeseen variations in its income streams as part of a policy of good financial management practice.

#### Plans for the Future

The Trustees continue to work towards the aims of the deed of declaration of Trust to find a cure for urological cancers, particularly prostate cancer, through scientific and clinical research at the Institute of Cancer Research and The Norwich Medical Research Park at UEA. To establish a clinical test to detect prostate cancer cells remains at the forefront of the Trusts current plans.

To establish a clinical test to detect aggressive prostate cancer cells remains at the forefront of the Trust's plans.

The Trust has approved two grants at the ICR involving AI powered technology - The Nick & Valda Embiricos Award. The first project under the award will focus on accelerating MRI with trustworthy AI that could reduce prostate screening times to just five minutes. The second project utilises advanced AI to analyse routine biopsy samples helping clinicians predict aggressive prostate disease and which prostate cancer patients are most likely to have a recurrence.

The funding for the work of the Trust will continue to be raised from a full fundraising calendar run by the Executive Officer of the Charity, donations and legacies and the interest from the investment funds if required.

#### Approval

This report was approved by the Trustees and signed on its behalf by:

DocuSigned by:  
  
D17B32C730044CE...  
**Michael Cattermole**  
Trustee

DocuSigned by:  
  
079866F1D2FDACA...  
**Luke Ponsonby**  
Trustee

Date: 02 April 2026

---

## Bob Champion Cancer Trust

---

### Statement of Trustees' responsibilities For the year ended 30 June 2025

---

The Trustees are responsible for preparing the Trustees' report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

The law applicable to charities in England & Wales requires the Trustees to prepare financial statements for each financial period which give a true and fair view of the state of affairs of the Charity and of its incoming resources and application of resources, including its income and expenditure, for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles of the Charities SORP (FRS 102);
- make judgments and accounting estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards (FRS 102) have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Charity will continue in business.

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the Charity's transactions and disclose with reasonable accuracy at any time the financial position of the Charity and enable them to ensure that the financial statements comply with the Charities Act 2011, the Charity (Accounts and Reports) Regulations 2008 and the provisions of the Trust Deed. They are also responsible for safeguarding the assets of the Charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Approved by order of the members of the board of Trustees and signed on its behalf by:

DocuSigned by:  
  
D17B32C730044CE...

**Michael Cattermole**  
Trustee  
Date: 02 April 2026

DocuSigned by:  
  
079866F1D2FD4CA...

**Luke Ponsonby**  
Trustee

---

## Bob Champion Cancer Trust

---

### Independent Examiner's Report For the year ended 30 June 2025

---

#### Independent Examiner's Report to the Trustees of Bob Champion Cancer Trust ('the Charity')

I report to the charity Trustees on my examination of the accounts of the Charity for the year ended 30 June 2025.

#### Responsibilities and Basis of Report

As the Trustees of the Charity you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ('the 2011 Act').

I report in respect of my examination of the Charity's accounts carried out under section 145 of the 2011 Act and in carrying out my examination I have followed the applicable Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

#### Independent Examiner's Statement

Since the Charity's gross income exceeded £250,000 your examiner must be a member of a body listed in section 145 of the 2011 Act. I confirm that I am qualified to undertake the examination because I am a member of the Institute of Chartered Accountants England and Wales, which is one of the listed bodies.

Your attention is drawn to the fact that the Charity has prepared the accounts in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) in preference to the Accounting and Reporting by Charities: Statement of Recommended Practice issued on 1 April 2005 which is referred to in the extant regulations but has been withdrawn.

I understand that this has been done in order for the accounts to provide a true and fair view in accordance with the Generally Accepted Accounting Practice effective for reporting periods beginning on or after 1 January 2015.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the Charity as required by section 130 of the 2011 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

This report is made solely to the Charity's Trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008. My work has been undertaken so that I might state to the Charity's Trustees those matters I am required to state to them in an Independent examiner's report and for no other purpose. To the fullest extent permitted by law, I do not accept or assume responsibility to anyone other than the Charity and the Charity's Trustees as a body, for my work or for this report.

Signed:   
1102ED52BDD84BD...

Dated: 02 April 2026

Tracey Moore BFP ACA

**UHY Hacker Young**

Chartered Accountants

---

**Bob Champion Cancer Trust**


---

**Statement of financial activities**  
**For the year ended 30 June 2025**


---

	Note	Unrestricted funds 2025 £	Total funds 2025 £	Total funds 2024 £
<b>Income from:</b>				
Donations and legacies	4	253,529	253,529	209,883
Other trading activities - Fundraising	5	249,189	249,189	359,344
Investments	6	52,752	52,752	46,708
<b>Total income</b>		<u>555,470</u>	<u>555,470</u>	<u>615,935</u>
<b>Expenditure on:</b>				
Raising funds	7	130,527	130,527	174,932
Charitable activities		299,576	299,576	220,888
<b>Total expenditure</b>		<u>430,103</u>	<u>430,103</u>	<u>395,820</u>
<b>Net income before net (losses)/gains on investments</b>		125,367	125,367	220,115
Net (losses)/gains on investments		(93,404)	(93,404)	112,344
<b>Net movement in funds</b>		<u>31,963</u>	<u>31,963</u>	<u>332,459</u>
<b>Reconciliation of funds:</b>				
Total funds brought forward		1,861,310	1,861,310	1,528,851
Net movement in funds		31,963	31,963	332,459
<b>Total funds carried forward</b>	18	<u>1,893,273</u>	<u>1,893,273</u>	<u>1,861,310</u>

The Statement of Financial Activities includes all gains and losses recognised in the year.

The notes on pages 14 to 28 form part of these financial statements.

---

**Bob Champion Cancer Trust**


---

**Balance sheet**  
**As at 30 June 2025**


---

	Note	2025 £	2024 £
<b>Fixed assets</b>			
Tangible assets	13	1,183	1,571
Investments	14	1,850,136	1,693,539
		<u>1,851,319</u>	<u>1,695,110</u>
<b>Current assets</b>			
Debtors	15	1,216	1,861
Cash at bank and in hand		120,777	192,340
		<u>121,993</u>	<u>194,201</u>
<b>Current liabilities</b>			
Creditors: amounts falling due within one year	16	(80,039)	(28,001)
<b>Net current assets</b>		<u>41,954</u>	<u>166,200</u>
<b>Total net assets</b>		<u><u>1,893,273</u></u>	<u><u>1,861,310</u></u>
<b>Charity funds</b>			
Unrestricted funds	18	1,893,273	1,861,310
<b>Total funds</b>		<u><u>1,893,273</u></u>	<u><u>1,861,310</u></u>

The financial statements were approved and authorised for issue by the Trustees and signed on their behalf by:

DocuSigned by:  
  
 D17B32C730044CE...

**Michael Cattermole**  
 Trustee

Date: 02 April 2026

DocuSigned by:  
  
 079866F1D2FD4CA...

**Luke Ponsonby**  
 Trustee

The notes on pages 14 to 28 form part of these financial statements.

---

**Bob Champion Cancer Trust**


---

**Statement of cash flows**  
**For the year ended 30 June 2025**


---

	<b>Note</b>	<b>2025</b> <b>£</b>	<b>2024</b> <b>£</b>
<b>Cash flows from operating activities</b>			
Net cash used in operating activities	20	125,685	131,029
<b>Cash flows from investing activities</b>			
Dividends, interests and rents from investments		52,752	46,708
Purchase of property, plant and equipment		-	(935)
Purchase of investments		(250,000)	(75,000)
<b>Net cash (used in)/provided by investing activities</b>		<b>(197,248)</b>	<b>(29,227)</b>
<b>Change in cash and cash equivalents in the year</b>			
Cash and cash equivalents at the beginning of the year		192,340	90,538
<b>Cash and cash equivalents at the end of the year</b>	21	<b>120,777</b>	<b>192,340</b>

The notes on pages 14 to 28 form part of these financial statements

---

## **Bob Champion Cancer Trust**

---

### **Notes to the financial statements For the year ended 30 June 2025**

---

#### **1. General information**

Bob Champion Cancer Trust is a registered charity in England and Wales registered under the charity number 1024664. The registered office is 7 Square Rigger Row, Plantation Wharf, London, SW11 3TZ.

#### **2. Accounting policies**

##### **2.1 Basis of preparation of financial statements**

The financial statements have been prepared in accordance with the Charities SORP (FRS 102) - Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Charities Act 2011.

The financial statements have been prepared to give a 'true and fair' view and have departed from the Charities (Accounts and Reports) Regulations 2008 only to the extent required to provide a 'true and fair' view. This departure has involved following the Charities SORP (FRS 102) published in October 2019 rather than the Accounting and Reporting by Charities: Statement of Recommended Practice effective from 1 April 2005 which has since been withdrawn.

Bob Champion Cancer Trust meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

The charity has taken advantage of the exemption available to smaller charities from preparing a cash flow statement.

##### **2.2 Basis of non-consolidation**

In the opinion of the Trustees, the charity and its subsidiary undertaking comprise a small group. The subsidiary has been excluded as its inclusion would not be material from the point of view of providing a true and fair view.

##### **2.3 Going concern**

The Trustees consider that there are no material uncertainties about the Trust's ability to continue as a going concern for a period of at least twelve months after the date of signature of these accounts. The accounts have therefore been prepared on the going concern basis.

---

**Bob Champion Cancer Trust**

---

**Notes to the financial statements  
For the year ended 30 June 2025**

---

**2. Accounting policies (continued)****2.4 Income**

All income is recognised once the Charity has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably.

Donated services or facilities are recognised when the charity has control over the item, any conditions associated with the donated item have been met, the receipt of economic benefit from the use of the charity of the item is probable and that economic benefit can be measured reliably. In accordance with the Charities SORP (FRS 102), the general volunteer time is not recognised and refer to the Trustees' report for more information about their contribution.

Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Income tax recoverable in relation to investment income is recognised at the time the investment income is receivable.

**2.5 Expenditure**

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Staff costs are allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset's use.

Fundraising costs are those incurred in seeking voluntary contributions and do not include the costs of disseminating information in support of the charitable activities. Support costs are those costs incurred directly in support of expenditure on the objects of the charity and include management carried out by the Executive Officer. The Trust office is based on an office share which is donated to the Trust by the building owner.. Governance costs are those incurred in connection with administration of the charity and compliance with constitutional and statutory requirements.

Grants payable are charged in the year when the offer is made except in those cases where the offer is conditional, such grants being recognised as expenditure when the conditions attaching are fulfilled. Grants offered subject to conditions which have not been met at the year end are noted as a commitment, but not accrued as expenditure.

All expenditure is inclusive of irrecoverable VAT.

---

**Bob Champion Cancer Trust**

---

**Notes to the financial statements  
For the year ended 30 June 2025**

---

**2. Accounting policies (continued)****2.6 Interest receivable**

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the Charity; this is normally upon notification of the interest paid or payable by the institution with whom the funds are deposited.

**2.7 Tangible fixed assets and depreciation**

Tangible fixed assets are initially recognised at cost. After recognition, under the cost model, tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. All costs incurred to bring a tangible fixed asset into its intended working condition should be included in the measurement of cost.

Depreciation is charged so as to allocate the cost of tangible fixed assets less their residual value over their estimated useful lives, on a reducing balance basis.

Depreciation is provided on the following basis:

Fixtures and fittings	-	20% reducing balance
Computer equipment	-	25% reducing balance

**2.8 Investments**

Fixed asset investments are a form of financial instrument and are initially recognised at their transaction cost and subsequently measured at fair value at the Balance sheet date, unless the value cannot be measured reliably in which case it is measured at cost less impairment. Investment gains and losses, whether realised or unrealised, are combined and presented as 'Gains/(Losses) on investments' in the Statement of financial activities.

Investments in subsidiaries are valued at cost less provision for impairment.

**2.9 Debtors**

Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

**2.10 Cash at bank and in hand**

Cash at bank and in hand includes cash and short-term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

---

## **Bob Champion Cancer Trust**

---

### **Notes to the financial statements For the year ended 30 June 2025**

---

#### **2. Accounting policies (continued)**

##### **2.11 Liabilities and provisions**

Liabilities are recognised when there is an obligation at the Balance sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably.

Liabilities are recognised at the amount that the Charity anticipates it will pay to settle the debt or the amount it has received as advanced payments for the goods or services it must provide.

Provisions are measured at the best estimate of the amounts required to settle the obligation. Where the effect of the time value of money is material, the provision is based on the present value of those amounts, discounted at the pre-tax discount rate that reflects the risks specific to the liability. The unwinding of the discount is recognised in the Statement of financial activities as a finance cost.

##### **2.12 Financial instruments**

The Charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

##### **2.13 Pensions**

The Charity operates a defined contribution pension scheme and the pension charge represents the amounts payable by the Charity to the fund in respect of the year.

##### **2.14 Fund accounting**

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the Charity and which have not been designated for other purposes.

Investment income, gains and losses are allocated to the appropriate fund.

#### **3. Critical accounting estimates and areas of judgment**

Estimates and judgments are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

Critical accounting estimates and assumptions:

The Trustees have not applied any significant estimates or judgments in the preparation of these financial statements.

---

**Bob Champion Cancer Trust**


---

**Notes to the financial statements**  
**For the year ended 30 June 2025**


---

**4. Income from donations and legacies**

	<b>Unrestricted funds 2025 £</b>	<b>Total funds 2025 £</b>	<i>Total funds 2024 £</i>
Donations	6,640	6,640	10,148
Legacies	246,889	246,889	199,735
<b>Total 2025</b>	<u>253,529</u>	<u>253,529</u>	<u>209,883</u>

In both the current and prior year all income from donations and legacies was in relation to unrestricted funds.

**5. Income from other trading activities - fundraising**
**Income from fundraising events**

	<b>Unrestricted funds 2025 £</b>	<b>Total funds 2025 £</b>	<i>Total funds 2024 £</i>
General Fundraising	32,227	32,227	35,528
Christmas Season	22,480	22,480	30,046
Carols and Champagne	-	-	60,918
Shetland Pony Grand National	40,889	40,889	12,000
Plumpton Raceday	122,279	122,279	122,749
Wincanton Raceday	-	-	98,103
South Downs Way Ride	10,794	10,794	-
Golf Day	432	432	-
Sandringham Holts	20,088	20,088	-
<b>Total 2025</b>	<u>249,189</u>	<u>249,189</u>	<u>359,344</u>

In both the current and prior year all income from fundraising was in relation to unrestricted funds.

---

**Bob Champion Cancer Trust**


---

**Notes to the financial statements**  
**For the year ended 30 June 2025**


---

**6. Investment income**

	<b>Unrestricted funds 2025 £</b>	<b>Total funds 2025 £</b>	<i>Total funds 2024 £</i>
Listed securities	50,231	50,231	43,799
Bank deposits	2,521	2,521	2,909
<b>Total 2025</b>	<u>52,752</u>	<u>52,752</u>	<u>46,708</u>

In both the current and prior year all income from investments was in relation to unrestricted funds.

**7. Expenditure on raising funds**
**Publicity and fundraising expenses**

	<b>Unrestricted funds 2025 £</b>	<b>Total funds 2025 £</b>	<i>Total funds 2024 £</i>
General Fundraising costs	18,403	18,403	14,340
Christmas Season	15,696	15,696	13,780
Carols and Champagne	-	-	14,753
Shetland Pony Grand National	1,634	1,634	952
Plumpton Raceday	50,458	50,458	46,104
Wincanton Raceday	-	-	41,341
Publicity and direct administrative costs	44,336	44,336	43,662
	<u>130,527</u>	<u>130,527</u>	<u>174,932</u>
<i>Total 2024</i>	<u>174,932</u>	<u>174,932</u>	

**Bob Champion Cancer Trust**

**Notes to the financial statements  
For the year ended 30 June 2025**

**8. Research Grants**

	<b>Grants to Institutions 2025 £</b>	<b>Total funds 2025 £</b>	<i>Total funds 2024 £</i>
Professor Rosalind Eeles grant - Institute of Cancer Research (ICR)	144,734	144,734	84,998
Professor Colin Cooper grant - UEA	8,985	8,985	13,588
Clinician Annie Gao	59,765	59,765	31,543
<b>Total 2025</b>	<u>213,484</u>	<u>213,484</u>	<u>130,129</u>

Professor Ros Eeles, Prostate Cancer Sequencing Germline DNA Project at the ICR, to predict who will develop aggressive or lethal prostate cancer commenced in August 2019 at cost of £282,509 over the three year grant period. Due to Covid-19 delays the grant ended, and was then extended for a further three years in October 2023 at the cost of £349,294.

Professor Colin Cooper, The Role of Bacterial Infection in the Development of Human Prostate Cancer grant for Rachel Hurst was awarded initially in January 2020 for two years at a cost of £80,000. The BCCT continued to fund this project with Rachel Hurst to 31 December 2024 with BCCT paying 75% of the total grant, approximately £50,000 per annum. The Trust then extended the grant, including the appointment of a Phd student, to gain further evidence that bacteria are causally involved in the development of aggressive prostate cancer, as a first step towards launching the PathoProsect Clinical Trial. To assess whether using bacteria can improve the prediction of aggressive disease when using the PUR test. Extended in February 2025 for three years at a combined cost of £66,050 per year.

Dan Brewer within Professor Colin Cooper's team on the DESNT project this grant covers the project for one year at £30,000, with a deadline of completion of December 2023.

In July 2021 a three year grant was awarded to Annie Gao within the Bob Champion Unit at the ICR/RMH. The agreed funding for £42,000 per year (including standard on-costs) commenced 1st September. This grant was extended for a further three years in July 2024 including for a Trials Assistant, Lily Gilder, at a combined cost of £56,44 per year.

The Trustees are satisfied that the charity will have sufficient resources to fulfil future research grant commitments. The charity has a strong balance sheet position, which includes listed investments of £1,693,539 that can be turned into cash as required.

---

**Bob Champion Cancer Trust**


---

**Notes to the financial statements**  
**For the year ended 30 June 2025**


---

**9. Charitable expenditure**

	<b>Grant funding of activities 2025 £</b>	<b>Support costs 2025 £</b>	<b>Total funds 2025 £</b>	<i>Total funds 2024 £</i>
Grants to institutions (note 8)	213,484	-	213,484	130,129
Staff costs	59,668	-	59,668	63,360
Depreciation	388	-	388	483
Premises costs	4,657	-	4,657	5,755
Travel costs	695	-	695	1,041
Computer and IT costs	2,990	-	2,990	3,049
General office costs	8,038	-	8,038	7,650
Governance costs	9,656	-	9,656	9,421
	<u>299,576</u>	<u>-</u>	<u>299,576</u>	<u>220,888</u>
<i>Total 2024</i>	<u>130,129</u>	<u>90,759</u>	<u>220,888</u>	

Governance costs comprise Trustees' indemnity insurance and independent examiner's fees.

**10. Independent examiner's remuneration**

	<b>2025 £</b>	<i>2024 £</i>
Fees payable to the Charity's independent examiner for the independent examination of the Charity's annual accounts	<u>5,250</u>	<u>5,100</u>

---

**Bob Champion Cancer Trust**


---

**Notes to the financial statements**  
**For the year ended 30 June 2025**


---

**11. Staff costs**

	<b>2025</b>	2024
	<b>£</b>	<b>£</b>
Wages and salaries	56,500	60,000
Social security costs	1,473	1,618
Contribution to defined contribution pension schemes	1,695	1,742
	<u>59,668</u>	<u>63,360</u>

The average number of persons employed by the Charity during the year was as follows:

	<b>2025</b>	2024
	<b>No.</b>	<b>No.</b>
Employees	<u>1</u>	<u>1</u>

No employee received remuneration amounting to more than £60,000 in either year.

Key management personnel comprise of the Trustees and the Executive Director. Total employment benefits (including social security contributions and employers' pension contributions) of key management personnel during the year were £59,668 (2024: £63,360).

**12. Trustees' remuneration and expenses**

During the year, no Trustees received any remuneration or other benefits (2024 - £NIL).

During the year, no donations were given by Trustees (2024: £1,698).

---

**Bob Champion Cancer Trust**


---

**Notes to the financial statements**  
**For the year ended 30 June 2025**


---

**13. Tangible fixed assets**

	<b>Fixtures and fittings £</b>	<b>Office equipment £</b>	<b>Total £</b>
<b>Cost</b>			
At 1 July 2024	118	7,599	7,717
At 30 June 2025	<u>118</u>	<u>7,599</u>	<u>7,717</u>
<b>Depreciation</b>			
At 1 July 2024	24	6,122	6,146
Charge for the year	19	369	388
At 30 June 2025	<u>43</u>	<u>6,491</u>	<u>6,534</u>
<b>Net book value</b>			
At 30 June 2025	<u>75</u>	<u>1,108</u>	<u>1,183</u>
<i>At 30 June 2024</i>	<u>94</u>	<u>1,477</u>	<u>1,571</u>

---

**Bob Champion Cancer Trust**


---

**Notes to the financial statements  
For the year ended 30 June 2025**


---

**14. Fixed asset investments**

	Investments in subsidiary companies £	Listed investments £	Total £
<b>Cost or valuation</b>			
At 1 July 2024	2	1,693,538	1,693,540
Additions	-	250,000	250,000
Revaluations	-	(93,404)	(93,404)
At 30 June 2025	2	1,850,134	1,850,136

At 30 June 2025, CCLA Fund Managers Limited, an investment management company external to the charity, valued the investments held by the charity at £1,850,134 (2024: £1,693,538). This valuation was made on the basis of the value of the units on the open market in which they are traded. The gain/(loss) is included in the statement of financial activities.

**Subsidiary undertakings**

The following was a subsidiary undertaking of the Charity:

Name	Holding	Included in consolidation
Aldaniti Trading Company Limited	100%	No

The financial results of the subsidiary for the year were:

Name	Net assets £
Aldaniti Trading Company Limited	2

Aldaniti Trading Company Limited, a company incorporated in England and Wales, ceased trading on 30 June 2004 and has not traded since. On this date its trade and assets were transferred to the charity.

**15. Debtors**

	2025 £	2024 £
Prepayments	1,216	1,861

---

**Bob Champion Cancer Trust**


---

**Notes to the financial statements**  
**For the year ended 30 June 2025**


---

**16. Creditors: Amounts falling due within one year**

	<b>2025</b>	<i>2024</i>
	<b>£</b>	<b>£</b>
Trade creditors	-	1,649
Amounts owed to group undertakings	2	2
Other taxation and social security	468	662
Other creditors	436	3,327
Accruals and deferred income	79,133	22,361
	<u>80,039</u>	<u>28,001</u>
	<b>2025</b>	<i>2024</i>
	<b>£</b>	<b>£</b>
Deferred income at 1 July 2024	8,967	12,975
Events income deferred during the year	20,512	8,967
Amounts released from previous periods	(8,967)	(12,975)
	<u>20,512</u>	<u>8,967</u>

**17. Financial instruments**

	<b>2025</b>	<i>2024</i>
	<b>£</b>	<b>£</b>
<b>Financial assets</b>		
Financial assets measured at fair value through income and expenditure	<u>1,850,134</u>	<u>1,693,538</u>

Financial assets measured at fair value through income and expenditure comprise fixed asset investments. Fair value has been determined on the basis of the value of the investment units on the open market in which they are traded.

**Bob Champion Cancer Trust**

**Notes to the financial statements  
For the year ended 30 June 2025**

**18. Statement of funds**

**Statement of funds - current year**

	<b>Balance at 1 July 2024</b>	<b>Income</b>	<b>Expenditure</b>	<b>Gains/ (Losses)</b>	<b>Balance at 30 June 2025</b>
	£	£	£	£	£
<b>Unrestricted funds</b>					
Reserves	1,861,310	555,470	(430,103)	(93,404)	1,893,273
	<u>1,861,310</u>	<u>555,470</u>	<u>(430,103)</u>	<u>(93,404)</u>	<u>1,893,273</u>

**Statement of funds - prior year**

	<i>Balance at 1 July 2022</i>	<i>Income</i>	<i>Expenditure</i>	<i>Gains/ (Losses)</i>	<i>Balance at 30 June 2024</i>
	£	£	£	£	£
<b>Unrestricted funds</b>					
Reserves	1,528,851	615,935	(395,820)	112,344	1,861,310
	<u>1,528,851</u>	<u>615,935</u>	<u>(395,820)</u>	<u>112,344</u>	<u>1,861,310</u>

**19. Analysis of net assets between funds**

	<b>Unrestricted funds 2025</b>	<b>Total funds 2025</b>	<i>Total funds 2024</i>
	£	£	£
Tangible fixed assets	1,183	1,183	1,571
Fixed asset investments heading	1,850,136	1,850,136	1,693,539
Current assets	121,993	121,993	194,201
Creditors due within one year	(80,039)	(80,039)	(28,001)
	<u>1,893,273</u>	<u>1,893,273</u>	<u>1,861,310</u>

---

**Bob Champion Cancer Trust**


---

**Notes to the financial statements**  
**For the year ended 30 June 2025**


---

**20. Reconciliation of net movement in funds to net cash flow from operating activities**

	<b>2025</b>	<b>2024</b>
	<b>£</b>	<b>£</b>
Net income for the year (as per Statement of Financial Activities)	31,963	332,459
<b>Adjustments for:</b>		
Depreciation charges	388	483
Gains/(losses) on investments	93,403	(112,344)
Dividends, interests and rents from investments	(52,752)	(46,708)
Decrease in debtors	645	2,421
Increase/(decrease) in creditors	52,038	(45,282)
<b>Net cash provided by operating activities</b>	<b>125,685</b>	<b>131,029</b>

**21. Analysis of cash and cash equivalents**

	<b>2025</b>	<b>2024</b>
	<b>£</b>	<b>£</b>
Cash in hand	120,777	192,340
<b>Total cash and cash equivalents</b>	<b>120,777</b>	<b>192,340</b>

**22. Analysis of changes in net debt**

	<b>At 1 July</b>	<b>Cash flows</b>	<b>At 30 June</b>
	<b>2024</b>	<b>£</b>	<b>2025</b>
	<b>£</b>	<b>£</b>	<b>£</b>
Cash at bank and in hand	192,340	(71,563)	120,777
	<b>192,340</b>	<b>(71,563)</b>	<b>120,777</b>

**23. Pension commitments**

The group operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the group in an independently administered fund. The pension cost charge represents contributions payable by the charity to the fund and amounted to £1,695 (2024: £1,680). Contributions totaling £338 (2024: £327) were payable to the fund at the balance sheet date and are included in creditors.

---

**Bob Champion Cancer Trust**

---

**Notes to the financial statements  
For the year ended 30 June 2025**

---

**24. Related party transactions**

During the year, the charity paid £23,324 (2024: £29,387) to the president of the charity, Mr. Bob Champion, in relation to fees and expenses incurred in fulfilling his duties. The amount outstanding at the year end was £7,095 (2024: £7,274). Bob Champion's retainer has been approved by the Charity Commission.

**BOB CHAMPION CANCER TRUST**

England & Wales - Charity number 1024664

---

# Accounts

---

# **Bob Champion Cancer Trust**

**Unaudited**

**Trustees' Report and Financial Statements**

**For the year ended 30 June 2024**

---

## **Bob Champion Cancer Trust**

---

### **Contents**

---

	Page
Reference and administrative details of the Charity, its Trustees and advisers	1
Trustees' report	2 - 8
Trustees' responsibilities statement	9
Independent examiner's report	10
Statement of financial activities	11
Balance sheet	12
Statement of cash flows	13
Notes to the financial statements	14 - 28

## **Bob Champion Cancer Trust**

---

### **Reference and administrative details of the Charity, its Trustees and advisers For the year ended 30 June 2024**

---

#### **Co-Founders**

Professor Sir Michael Peckham MD FRCP FRCR (deceased October 2021)  
Nicholas Embiricos (deceased November 2018)

#### **President**

Bob Champion, C.B.E.

#### **Medical Advisor**

Professor David Dearnaley

#### **Vice Presidents**

Clare Balding, C.B.E.

Willie Carson, O.B.E.

Kristina Cook

David Gower, O.B.E.

Chris Hughes

Jonjo O'Neill

Greg Rusedski

Peter Shilton, O.B.E.

Nick Skelton, C.B.E.

#### **Trustees**

Michael Cattermole (Chairman)

Susie Burrage, O.B.E.

Alex Embiricos

Timothy Fox

Andrew Franklin

Catherine McAleavey

Catherine Nash

Luke Ponsonby

Bridget Rosser

Carolyn Zetter Wells

#### **Trust Officer**

Mrs. Lucienne Wilkinson

#### **Charity registered number**

1024664

#### **Principal Office**

7 Square Rigger Row

Plantation Wharf

London

SW11 3TZ

#### **Accountants**

UHY Hacker Young

Chartered Accountants

Thames House

Roman Square

Sittingbourne

Kent ME10 4BJ

---

## **Bob Champion Cancer Trust**

---

### **Trustees' report For the year ended 30 June 2024**

---

The Trustees present their report and the accounts for the year ended 30 June 2024.

The financial statements comply with the charity's Trust Deed, the Charities Act 2011 and Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019) (Charities SORP (FRS 102)).

#### **Structure, Governance and Management**

The Trust was set up to support research into the causation, nature and treatment of patients with testicular cancer and other forms of malignant disease including those of the prostate.

A Declaration of Trust formed the Charity on 29 June 1993 registered number 1024664. The purpose of the establishment of this charitable trust was to take over and enlarge the work of the Bob Champion Cancer Trust that was set up by a Declaration of Trust dated 20 January 1983.

The number of Trustees shall not be less than three or more than ten. The power of appointing new Trustees is vested in the Trustees and may be exercised by a resolution in writing signed by all of the current Trustees and the new Trustee. The Trustees meet four times per calendar year in person or online.

Please see page 1 for Trustee details, legal and other administrative detail.

The Trustees acknowledge their responsibility for ensuring that the major risks to which the Charity is exposed are identified and systems designed to mitigate those risks. During the year the Trustees completed a formal risk management process to assess business risks and risk management strategies.

The Trust has an independent Medical Advisor, Professor David Dearnaley, to advise the board in their selection of grant awards and allow the Charity to operate in open competition with peer review.

#### **Background to the Trust**

Bob Champion was one of the UK's top five jump jockeys when, in July 1979, he discovered he had cancer in two parts of his body and was given eight months to live. His doctors, at the Royal Marsden Hospital, suggested his only chance was a drastic new type of treatment, he readily agreed. The one thing that gave him the will to keep fighting during those gruelling months of treatment was the dream of riding Aldaniti in the Grand National.

In 1981, less than two years from diagnosis, that dream came true as Bob Champion and Aldaniti won the 1981 Grand National - racing's greatest fairytale. His victory led to the foundation in 1983 of the Bob Champion Cancer Trust.

The Trust's first project was to open its own Unit within the Royal Marsden Hospital, which was achieved five years, nearly to the day, after their Aintree victory. The Trust then concentrated on funding cancer research projects at the Institute of Cancer Research, opening in conjunction with the ICR in 2000, the first male dedicated cancer research facility in Europe – The Bob Champion Cancer Trust Research Centre. In 2015 The Bob Champion Research and Education Building was opened, a state-of-the-art research facility on the University of East Anglia campus costing, in excess, of £19 million.

---

## Bob Champion Cancer Trust

---

### Trustees' report (continued) For the year ended 30 June 2024

---

#### Objectives and Activities

The Bob Champion Cancer Trust currently supports cancer research within the Institute of Cancer Research, The Royal Marsden Hospital in Sutton, Surrey and the Bob Champion Research and Education Building, situated in the Norwich Research Park at the University of East Anglia. The focus of this support is on urological cancers, especially those of the prostate.

The Trust opened in collaboration with the Institute of Cancer Research the Bob Champion Research Centre in 2000, which forms part of the first male dedicated cancer research centre, in Europe. This centre is based at The Institute of Cancer Research in Sutton, Surrey.

In February 2015 the Trust, with The University of East Anglia (UEA), opened the Bob Champion Research and Education Building at The Norwich Research Park, this facility is operated by the UEA in partnership with the Norfolk & Norwich Hospital. This centre provides state-of-the-art laboratories for researchers to explore new treatments, not only for prostate cancer research but for diseases from antibiotic resistance to musculo-skeletal and gastrointestinal diseases. This £19 million facility includes a unique bio-bank facility to store DNA and tissue samples plus teaching facilities suitable for training medical practitioners in rooms reflecting the functions of operational hospital bays.

The Trust is self-supporting and relies totally upon donations from the public that may be in the form of a legacy or donation with the benefit of claiming Gift Aid if applicable. Income is raised from a full fundraising calendar, with major events being held annually or biennially, supported by event committees, promotional mailings and active social media campaigns. The events range from themed event and parties, horse shows and race nights to personal challenges such as sponsored rides, marathons, including the London Marathon, and cycling events, these hopefully offer something for all our supporters and helps to attract new interest to the cause. An annual charity raceday at Plumpton Racecourse is held, now in its seventh year, which is an established and extremely popular fundraiser. During the day a Shetland Pony race is held as an extra attraction which helps raise further funds as well as the traditional auctions and raffles. Another very successful event is a carol service - Carols and Champagne - held at Chelsea Old Church in London every other year. A traditional church service is followed by a drinks party in the church hall attached and is very popular with the order of service raising extra funds from advertisers. The Trust is hoping to establish an annual golf tournament, two have been held so far with another planned for 2025 plus aims to hold a second raceday in the Spring.

The Trust is delighted to be continuing its involvement with the Shetland Pony Grand National (SPGN), now for the eighth year. The SPGN is a major part of the London International Horse Show held at the ExCel Exhibition Centre, with the SPGN grand finale a highlight of the four days. Bob Champion himself is heavily involved during the year, helping the young riders through their heats, and attends, as well as appearing in the show ring every day during the Show. The ten jockeys (aged between 9-14 years) once they qualify for the Show via the heats commit to raise a minimum of £1,000 sponsorship in support of the Trust, although, with determined future jockeys, nearly all participants way surpass this goal.

Since 1988 the Trust has produced its own, especially commissioned, double sided Christmas card. The card not only raises vital funds but spreads awareness of the cause and the work of the Trust. The artist is selected each year and kindly donates their work and time in support of the Trust. In 2021 a second, smaller card, was added to create a choice for our supporters, again, double sided and kindly painted for us and donated by the artist. The larger card offers a more classic choice with the smaller card being more fun. The Trust has found that sales have suffered due to increased postage costs but the cards still represents an important part of the Trusts awareness message.

---

## **Bob Champion Cancer Trust**

---

### **Trustees' report (continued) For the year ended 30 June 2024**

---

Bob Champion was awarded a CBE in The Queen's New Year Honours 2021 for his charitable works. He attends many of the events himself and continues to play an integral part in raising funds, and awareness, not only of the Charity's aims, but also of the disease itself. All events are organised from the office, often with the help of a specific event committee made up from volunteers and keen supporters. The Trust is always open to new fundraising ideas and how to offer help to cancer sufferers, their families and friends.

### **Public Benefit**

The Trustees confirm that they given due consideration to the Charity Commission's published guidance on the Public Benefit requirement under the Charities Act 2011 when reviewing the aims and objectives, and in planning future activities.

### **Achievements and performance**

Each year 52,000 men in the UK will be diagnosed with prostate cancer and more than 12,000 will die from their disease. At present we do not have good markers to predict who will have prostate cancer that behaves in an aggressive way and causes mortality.

For many cancers the fundamental mechanism of cancer development has been unravelled. Such studies reveal that the disease develops because of alterations or mutations within 'cancer genes'. Although cancer genes responsible for the development of, for example, colon cancer and breast cancer are well characterised, relatively little is known about the fundamental development of prostate cancer.

The Bob Champion Research Trust funded researchers have worked together as part of international consortium, called The Pan Prostate Cancer Group, set up by Professor Colin Cooper at The University of East Anglia (UEA) and Professor Ros Eeles the Institute of Cancer Research (ICR) to analyse genetic data from prostate cancer samples across nine countries.

Application of Artificial Intelligence to results obtained in the UK has helped scientists reveal two distinct forms of prostate cancer called Evotypes, with one being very aggressive prostate cancer. These results could revolutionise how the disease is diagnosed and managed, since it is important that treatment is targeted to aggressive disease. Crucially, the team aims to develop a genetic test that, when combined with conventional staging and grading, can provide a more precise prognosis for each patient, allowing tailored treatment decisions.

The researchers used AI to study changes in the DNA of prostate cancer samples (using whole genome sequencing) from 159 patients. They identified two distinct cancer groups among these patients using an AI technique called neural networks. These two groups were confirmed by using two other mathematical approaches applied to different aspects of the data. This finding was validated in other independent datasets from Canada and Australia.

The work published in the Journal Cancer Genomics in 2024 was carried out in collaboration with Dr Dan Woodcock at the University of Oxford and Professor David Wedge at the University of Manchester who led the research. The team hope their findings could save thousands of lives in future and revolutionise how prostate cancer is diagnosed and treated. Ultimately, it could provide tailored treatments to each individual patient according to a genetic test which will also be delivered using AI.

---

## Bob Champion Cancer Trust

---

### Trustees' report (continued) For the year ended 30 June 2024

---

Although prostate cancer is responsible for a large proportion of all male cancer deaths, it is more commonly a disease men die with rather than from. This means that unnecessary treatment can often be avoided, sparing men from side-effects such as incontinence and impotence.

These studies are important as until now, it was thought that prostate cancer was just one type of disease. But now, with advancements in artificial intelligence, the researchers have been able to show that there are actually two different subtypes at play.

Hopefully the findings will not only save lives through better diagnosis and tailored treatments in the future, but they may help researchers working in other cancer fields better understand other types of cancer too.

Professor Ros Eeles, Professor of Oncogenetics at The Institute of Cancer Research, London, and Honorary Consultant in Clinical Oncology and Cancer Genetics at The Royal Marsden NHS Foundation Trust, confirms that this study has utilised the enormous genomic dataset from The Pan Prostate Cancer Group which is a powerhouse of information about prostate cancer from around the world.

The Trust also supports Professor Ros Eeles with a three year grant for the UKGPCS collection of germline DNA and data. The aim of this project is to analyse whole exome sequence from a unique and large collection of prostate cancer cases: 20,000 germline DNA samples from the UKGPCS in order to identify rare variants and their contribution to the risk of developing prostate cancer with specific phenotypes and potentially predict response to various treatments.

The UKGPCS was established in 1992, recruiting men from The Royal Marsden NHS Foundation Trust and Collaborative Centres (NHS Trust hospitals) throughout the UK and Northern Ireland, over 180 of which are from the National Cancer Research Network (NCRN).

The UKGPCS have collected a rich phenotype dataset for most of these samples: date of birth, diagnosis, and death if applicable; mode of detection; TNM Stage; Gleason score; primary treatment; vital status; geographic region based on referring hospital, or treatment hospital if information on the referring hospital was not available; self-reported BMI; self-reported ethnicity; and PSA at diagnosis for all patients, as well as for relatives, if available. The Information on risk factors for prostate cancer, demographic characteristics, and clinical data are also collected routinely as part of medical care and clinical follow-up. Over 78% of the cohort has clinical data on treatment and outcomes are being followed up at 2, 5 and 10 years post diagnosis; this collection is still in process.

For sequencing of whole exomes in germline samples a high-throughput automated approach will be used to prepare high-quality genomic DNA for exome capture. The exome will be captured and sequenced on the latest technology in use at the Regeneron Genetics Centre.

The Trust is in its final year of a three year grant for Annie Gao, a Senior Radiotherapy Clinical Trials Co-ordinator at the Bob Champion Unit, Royal Marsden Hospital, Sutton.

The Unit has supported and lead the PACE trials which looks to use stereotactic body radiotherapy to deliver to the patient the prostate cancer treatment in 5 visits over 1-2 weeks. This pioneering treatment can target the cancer with pinpoint accuracy. This means a reduction in healthy tissue damage and enables men to complete and recover from treatment much faster than ever before. Initial results from the PACE-B trial have been published, showing that there were low rates of side effects after 2 years and suggesting that curative treatment can be given over a much-shortened period. This has positive implications for the patients experience of cancer treatment and subsequent quality of life.

---

**Bob Champion Cancer Trust**

---

**Trustees' report (continued)**  
**For the year ended 30 June 2024**

---

Critical to the success of all these studies is the long-term follow-up of men after their initial radiotherapy treatment. Confidence that a patient is truly cured takes 10 years in men with localised prostate cancer as side effects can continue to develop over many years, a full estimation of the risks and benefits of a new treatment requires years of careful data collection.

Annie Gao focusses particularly on the long-term follow-up of patients. This enables the ICR to continue to monitor men for signs of cancer recurrence and side effects for long enough to be sure that the innovative radiotherapy treatment being tested is advantageous. The Unit continues to publish results in the highest calibre journals and publications.

**Key trials in long term follow-up:**

- **The IMRT (Intensity-Modulated Radiotherapy) trial** (495 patients) looked at targeting the prostate cancer more accurately, which in turn allowed for a larger dose of radiotherapy to be given. There were 5 groups of patients, each receiving slightly different doses of radiotherapy. The continued review of this comprehensive dataset enables us to learn more about which patients are likely to be cured with standard treatments and which require further escalation of therapy. Blood and biopsy translational work from this trial also sheds new light on the evolutionary genetics of prostate cancer. The **CHHiP trial** (398 patients recruited at RMH out of 3,200 in multi-centre trial) follows patients for up to 15 years after their treatment and is enabling us to know with greater certainty that shorter treatments are better for men with localised prostate cancer. The trial introduced prostate IMRT in the UK. This ongoing data collection has enabled the review of over 2000 prostate cancer samples to further investigate the effects of radiotherapy dose on prostate cancer in the laboratory.
- **The CHHiP trial** (398 patients recruited at RMH out of 3,200 in multi-centre trial) follows patients for up to 15 years after their treatment and is enabling us to know with greater certainty that shorter treatments are better for men with localised prostate cancer. The trial introduced prostate IMRT in the UK. This ongoing data collection has enabled the review of over 2000 prostate cancer samples to further investigate the effects of radiotherapy dose on prostate cancer in the laboratory.
- **The PACE-C trial** compares stereotactic body radiotherapy (5 visits – SBRT uses precise daily image guidance to give remarkably accurate radiotherapy) with the now conventional IMRT (20 visits – see IMRT trials above). Since the application last year, recruitment to this trial has exceeded expectations and the trial closed early having already met its target of 1182 patients. These men are now in long-term follow-up, assessing side effects, patient quality of life and long-term cancer control.

**Publications:-****Genomic evolution shapes prostate cancer disease type.**

Woodcock DJ, Sahli A, Teslo R, Bhandari V, Gruber AJ, Ziubroniewicz A, Gundem G, Xu Y, Butler A, Anokian E, Pope BJ, Jung CH, Tarabichi M, Dentro SC, Farmery JHR; CRUK ICGC Prostate Group; Van Loo P, Warren AY, Gnanapragasam V, Hamdy FC, Bova GS, Foster CS, Neal DE, Lu YJ, Kote-Jarai Z, Fraser M, Bristow RG, Boutros PC, Costello AJ, Corcoran NM, Hovens CM, Massie CE, Lynch AG, Brewer DS, Eeles RA, Cooper CS, Wedge DC. Cell Genom. 2024 ;4(3):100511. doi: 10.1016/j.xgen.2024.100511.

---

## Bob Champion Cancer Trust

---

### Trustees' report (continued) For the year ended 30 June 2024

---

#### **Cancer invasion and anaerobic bacteria: new insights into mechanisms.**

Hurst R, Brewer DS, Gihawi A, Wain J, Cooper CS. J Med Microbiol. 2024;73(3):001817. doi: 10.1099/jmm.0.001817.

#### **Applications of Urinary Extracellular Vesicles in the Diagnosis and Active Surveillance of Prostate Cancer.**

Smith SF, Brewer DS, Hurst R, Cooper CS. Cancers (Basel). 2024 ;16(9):1717. doi: 10.3390/cancers16091717.

#### **Major data analysis errors invalidate cancer microbiome findings.**

Gihawi A, Ge Y, Lu J, Puiu D, Xu A, Cooper CS, Brewer DS, Pertea M, Salzberg SL. mBio. 2023;14(5):e0160723. doi: 10.1128/mbio.01607-23.

#### **Gene-Transcript Expression in Urine Supernatant and Urine Cell-Sediment Are Different but Equally Useful for Detecting Prostate Cancer.**

Yazbek Hanna M, Winterbone M, O'Connell SP, Olivan M, Hurst R, Mills R, Cooper CS, Brewer DS, Clark J. Cancers (Basel). 2023 ;15(3):789. doi: 10.3390/cancers15030789.

There are currently 11 papers under review.

### Financial Review

The Trust incurred an overall surplus for the year of £332,459 (2023: deficit of £44,860). The surplus for the year was given a significant boost by a generous legacy received in the year totalling £199,735 (2023: £1,393). Also included within the income and expenditure of the Trust for the year is a surplus on fundraising events of £184,412 (2023: £71,655) and dividends received of £46,708 (2022: £46,366). In addition, the unrealised gain on investments for the year to 30 June 2024 was £112,344 (202: £54,724).

The Trustees are satisfied that the Trust's funds are available and adequate to fulfil its obligations in relation to their commitments.

The Declaration of Trust, signed on the 29th June 1993, states that "any money available for investment may be so invested in the names of the Trustees or their nominees in any way whatsoever, whether or not producing income, as the Trustees shall in their absolute discretion think fit, as if they were absolutely entitled to the Trust Fund beneficially."

It is the policy of the Trust to hold reserves in its General Fund that have not yet been committed or designated for any particular purpose. The Trustees have set aside these reserves in order to protect the future operations of the charity from the effects of any unforeseen variations in its income streams as part of a policy of good financial management practice.

---

**Bob Champion Cancer Trust**

---

**Trustees' report (continued)  
For the year ended 30 June 2024**

---

**Plans for the Future**

The Trustees continue to work towards the aims of the deed of declaration of Trust to find a cure for urological cancers, particularly prostate cancer, through scientific and clinical research at the Institute of Cancer Research and The Norwich Medical Research Park at UEA. To establish a clinical test to detect prostate cancer cells remains at the forefront of the Trusts current plans.

The funding for the work of the Trust will continue to be raised from a full fundraising calendar run by the Executive Officer of the Charity, donations and legacies and the interest from the investment funds if required.

**Approval**

This report was approved by the Trustees and signed on its behalf by:

DocuSigned by:  
*Michael Cattermole*  
D17B32C730044CE...

**Michael Cattermole**  
Trustee

DocuSigned by:  
*Luke Ponsonby*  
079866F1D2FD4CA...

**Luke Ponsonby**  
Trustee

Date: 23 April 2025

---

## Bob Champion Cancer Trust

---

### Statement of Trustees' responsibilities For the year ended 30 June 2024

---

The Trustees are responsible for preparing the Trustees' report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

The law applicable to charities in England & Wales requires the Trustees to prepare financial statements for each financial which give a true and fair view of the state of affairs of the Charity and of its incoming resources and application of resources, including its income and expenditure, for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles of the Charities SORP (FRS 102);
- make judgments and accounting estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards (FRS 102) have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Charity will continue in business.

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the Charity's transactions and disclose with reasonable accuracy at any time the financial position of the Charity and enable them to ensure that the financial statements comply with the Charities Act 2011, the Charity (Accounts and Reports) Regulations 2008 and the provisions of the Trust Deed. They are also responsible for safeguarding the assets of the Charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Approved by order of the members of the board of Trustees and signed on its behalf by:

DocuSigned by:  
  
D17B32C730044CE...

**Michael Cattermole**

Trustee

Date: 23 April 2025

---

## Bob Champion Cancer Trust

---

### Independent Examiner's Report For the year ended 30 June 2024

---

#### Independent Examiner's Report to the Trustees of Bob Champion Cancer Trust ('the Charity')

I report to the charity Trustees on my examination of the accounts of the Charity for the year ended 30 June 2024.

#### Responsibilities and Basis of Report

As the Trustees of the Charity you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ('the 2011 Act').

I report in respect of my examination of the Charity's accounts carried out under section 145 of the 2011 Act and in carrying out my examination I have followed the applicable Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

#### Independent Examiner's Statement

Since the Charity's gross income exceeded £250,000 your examiner must be a member of a body listed in section 145 of the 2011 Act. I confirm that I am qualified to undertake the examination because I am a member of the Institute of Chartered Accountants England and Wales, which is one of the listed bodies.

Your attention is drawn to the fact that the Charity has prepared the accounts in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) in preference to the Accounting and Reporting by Charities: Statement of Recommended Practice issued on 1 April 2005 which is referred to in the extant regulations but has been withdrawn.

I understand that this has been done in order for the accounts to provide a true and fair view in accordance with the Generally Accepted Accounting Practice effective for reporting periods beginning on or after 1 January 2015.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the Charity as required by section 130 of the 2011 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

This report is made solely to the Charity's Trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008. My work has been undertaken so that I might state to the Charity's Trustees those matters I am required to state to them in an Independent examiner's report and for no other purpose. To the fullest extent permitted by law, I do not accept or assume responsibility to anyone other than the Charity and the Charity's Trustees as a body, for my work or for this report.

Signed:  Signed by:  
1102ED52BDD84BD...

Dated: 24 April 2025

Tracey Moore BFP ACA

**UHY Hacker Young**

Chartered Accountants

---

**Bob Champion Cancer Trust**


---

**Statement of financial activities**  
**For the year ended 30 June 2024**


---

	Note	Unrestricted funds 2024 £	Total funds 2024 £	Total funds 2023 £
<b>Income from:</b>				
Donations and legacies	4	209,883	209,883	6,295
Other trading activities - Fundraising	5	359,344	359,344	177,711
Investments	6	46,708	46,708	46,366
<b>Total income</b>		<u>615,935</u>	<u>615,935</u>	<u>230,372</u>
<b>Expenditure on:</b>				
Raising funds	7	174,932	174,932	106,056
Charitable activities		220,888	220,888	223,900
<b>Total expenditure</b>		<u>395,820</u>	<u>395,820</u>	<u>329,956</u>
<b>Net income/(expenditure) before net gains on investments</b>		220,115	220,115	(99,584)
Net gains on investments		112,344	112,344	54,724
<b>Net movement in funds</b>		<u>332,459</u>	<u>332,459</u>	<u>(44,860)</u>
<b>Reconciliation of funds:</b>				
Total funds brought forward		1,528,851	1,528,851	1,573,711
Net movement in funds		332,459	332,459	(44,860)
<b>Total funds carried forward</b>		<u>1,861,310</u>	<u>1,861,310</u>	<u>1,528,851</u>

The Statement of Financial Activities includes all gains and losses recognised in the year.

The notes on pages 14 to 28 form part of these financial statements.

---

**Bob Champion Cancer Trust**


---

**Balance sheet**  
**As at 30 June 2024**


---

	Note	2024 £	2023 £
<b>Fixed assets</b>			
Tangible assets	13	1,571	1,119
Investments	14	1,693,539	1,506,195
		<u>1,695,110</u>	<u>1,507,314</u>
<b>Current assets</b>			
Debtors	15	1,861	4,282
Cash at bank and in hand		192,340	90,538
		<u>194,201</u>	<u>94,820</u>
Creditors: amounts falling due within one year	16	(28,001)	(73,283)
		<u>166,200</u>	<u>21,537</u>
<b>Net current assets</b>		<u>166,200</u>	<u>21,537</u>
<b>Total net assets</b>		<u><u>1,861,310</u></u>	<u><u>1,528,851</u></u>
<b>Charity funds</b>			
Unrestricted funds	18	1,861,310	1,528,851
<b>Total funds</b>		<u><u>1,861,310</u></u>	<u><u>1,528,851</u></u>

The financial statements were approved and authorised for issue by the Trustees and signed on their behalf by:

DocuSigned by:  
  
 D17B32C730044CE...

**Michael Cattermole**  
 Trustee

Date: 23 April 2025

DocuSigned by:  
  
 079866F1D2FD4CA...

**Luke Ponsonby**  
 Trustee

The notes on pages 14 to 28 form part of these financial statements.

---

**Bob Champion Cancer Trust**


---

**Statement of cash flows**  
**For the year ended 30 June 2024**


---

	<b>Note</b>	<b>2024</b> £	<b>2023</b> £
<b>Cash flows from operating activities</b>			
Net cash used in operating activities	20	131,029	(141,381)
<b>Cash flows from investing activities</b>			
Dividends, interests and rents from investments		46,708	46,366
Purchase of property, plant and equipment		(935)	-
Proceeds from sale of investments		-	125,000
Purchase of investments		(75,000)	-
<b>Net cash (used in)/provided by investing activities</b>		<b>(29,227)</b>	<b>171,366</b>
<b>Change in cash and cash equivalents in the year</b>		<b>101,802</b>	<b>29,985</b>
Cash and cash equivalents at the beginning of the year		90,538	60,553
<b>Cash and cash equivalents at the end of the year</b>	21	<b>192,340</b>	<b>90,538</b>

The notes on pages 14 to 28 form part of these financial statements

---

## **Bob Champion Cancer Trust**

---

### **Notes to the financial statements For the year ended 30 June 2024**

---

#### **1. General information**

Bob Champion Cancer Trust is a registered charity in England and Wales registered under the charity number 1024664. The registered office is 7 Square Rigger Row, Plantation Wharf, London, SW11 3TZ.

#### **2. Accounting policies**

##### **2.1 Basis of preparation of financial statements**

The financial statements have been prepared in accordance with the Charities SORP (FRS 102) - Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Charities Act 2011.

The financial statements have been prepared to give a 'true and fair' view and have departed from the Charities (Accounts and Reports) Regulations 2008 only to the extent required to provide a 'true and fair' view. This departure has involved following the Charities SORP (FRS 102) published in October 2019 rather than the Accounting and Reporting by Charities: Statement of Recommended Practice effective from 1 April 2005 which has since been withdrawn.

Bob Champion Cancer Trust meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

The charity has taken advantage of the exemption available to smaller charities from preparing a cash flow statement.

##### **2.2 Basis of non-consolidation**

In the opinion of the Trustees, the charity and its subsidiary undertakings comprise a small group. The subsidiary has been excluded as its inclusion would not be material from the point of view of providing a true and fair view.

##### **2.3 Going concern**

The Trustees consider that there are no material uncertainties about the Trust's ability to continue as a going concern for a period of at least twelve months after the date of signature of these accounts. The accounts have therefore been prepared on the going concern basis.

---

## Bob Champion Cancer Trust

---

### Notes to the financial statements For the year ended 30 June 2024

---

## 2. Accounting policies (continued)

### 2.4 Income

All income is recognised once the Charity has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably.

Donated services or facilities are recognised when the charity has control over the item, any conditions associated with the donated item have been met, the receipt of economic benefit from the use of the charity of the item is probable and that economic benefit can be measured reliably. In accordance with the Charities SORP (FRS 102), the general volunteer time is not recognised and refer to the Trustees' report for more information about their contribution.

On receipt, donated professional services and facilities are recognised on the basis of the value of the gift to the charity which is the amount it would have been willing to pay to obtain services or facilities of equivalent economic benefit on the open market; a corresponding amount is then recognised and refer to the Trustees' report for more information about their contribution.

Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Income tax recoverable in relation to investment income is recognised at the time the investment income is receivable.

### 2.5 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Staff costs are allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset's use.

Fundraising costs are those incurred in seeking voluntary contributions and do not include the costs of disseminating information in support of the charitable activities. Support costs are those costs incurred directly in support of expenditure on the objects of the charity and include management carried out by the Executive Officer. The Trust office is based on an office share which is donated to the Trust by the building owner.. Governance costs are those incurred in connection with administration of the charity and compliance with constitutional and statutory requirements.

Expenditure on raising funds includes all expenditure incurred by the Charity to raise funds for its charitable purposes and includes costs of all fundraising activities events and non-charitable trading.

Expenditure on charitable activities is incurred on directly undertaking the activities which further the Charity's objectives, as well as any associated support costs.

Grants payable are charged in the year when the offer is made except in those cases where the offer is conditional, such grants being recognised as expenditure when the conditions attaching are fulfilled. Grants offered subject to conditions which have not been met at the year end are noted as a commitment, but not accrued as expenditure.

All expenditure is inclusive of irrecoverable VAT.

---

**Bob Champion Cancer Trust**

---

**Notes to the financial statements  
For the year ended 30 June 2024**

---

**2. Accounting policies (continued)****2.6 Interest receivable**

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the Charity; this is normally upon notification of the interest paid or payable by the institution with whom the funds are deposited.

**2.7 Tangible fixed assets and depreciation**

Tangible fixed assets are initially recognised at cost. After recognition, under the cost model, tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. All costs incurred to bring a tangible fixed asset into its intended working condition should be included in the measurement of cost.

Depreciation is charged so as to allocate the cost of tangible fixed assets less their residual value over their estimated useful lives, on a reducing balance basis.

Depreciation is provided on the following basis:

Fixtures and fittings	-	20% reducing balance
Computer equipment	-	25% reducing balance

**2.8 Investments**

Fixed asset investments are a form of financial instrument and are initially recognised at their transaction cost and subsequently measured at fair value at the Balance sheet date, unless the value cannot be measured reliably in which case it is measured at cost less impairment. Investment gains and losses, whether realised or unrealised, are combined and presented as 'Gains/(Losses) on investments' in the Statement of financial activities.

Investments in subsidiaries are valued at cost less provision for impairment.

**2.9 Debtors**

Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

**2.10 Cash at bank and in hand**

Cash at bank and in hand includes cash and short-term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

---

**Bob Champion Cancer Trust**

---

**Notes to the financial statements  
For the year ended 30 June 2024**

---

**2. Accounting policies (continued)****2.11 Liabilities and provisions**

Liabilities are recognised when there is an obligation at the Balance sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably.

Liabilities are recognised at the amount that the Charity anticipates it will pay to settle the debt or the amount it has received as advanced payments for the goods or services it must provide.

Provisions are measured at the best estimate of the amounts required to settle the obligation. Where the effect of the time value of money is material, the provision is based on the present value of those amounts, discounted at the pre-tax discount rate that reflects the risks specific to the liability. The unwinding of the discount is recognised in the Statement of financial activities as a finance cost.

**2.12 Financial instruments**

The Charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

**2.13 Pensions**

The Charity operates a defined contribution pension scheme and the pension charge represents the amounts payable by the Charity to the fund in respect of the year.

**2.14 Fund accounting**

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the Charity and which have not been designated for other purposes.

Investment income, gains and losses are allocated to the appropriate fund.

**3. Critical accounting estimates and areas of judgment**

Estimates and judgments are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

Critical accounting estimates and assumptions:

The Trustees have not applied any significant estimates or judgments in the preparation of these financial statements.

---

**Bob Champion Cancer Trust**


---

**Notes to the financial statements**  
**For the year ended 30 June 2024**


---

**4. Income from donations and legacies**

	<b>Unrestricted funds 2024 £</b>	<b>Total funds 2024 £</b>	<i>Total funds 2023 £</i>
Donations	10,148	10,148	4,902
Legacies	199,735	199,735	1,393
<b>Total 2024</b>	<u>209,883</u>	<u>209,883</u>	<u>6,295</u>

In both the current and prior year all income from donations and legacies was in relation to unrestricted funds.

**5. Income from other trading activities - fundraising**
**Income from fundraising events**

	<b>Unrestricted funds 2024 £</b>	<b>Total funds 2024 £</b>	<i>Total funds 2023 £</i>
General Fundraising	35,528	35,528	23,787
Christmas Season	30,046	30,046	12,670
Carols and Champagne	60,918	60,918	-
Shetland Pony Grand National	12,000	12,000	30,012
Plumpton Raceday	122,749	122,749	111,242
Wincanton Raceday	98,103	98,103	-
<b>Total 2024</b>	<u>359,344</u>	<u>359,344</u>	<u>177,711</u>

In both the current and prior year all income from fundraising was in relation to unrestricted funds.

---

**Bob Champion Cancer Trust**


---

**Notes to the financial statements**  
**For the year ended 30 June 2024**


---

**6. Investment income**

	<b>Unrestricted funds 2024 £</b>	<b>Total funds 2024 £</b>	<i>Total funds 2023 £</i>
Listed securities	43,799	43,799	46,293
Bank deposits	2,909	2,909	73
<b>Total 2024</b>	<u>46,708</u>	<u>46,708</u>	<u>46,366</u>

In both the current and prior year all income from investments was in relation to unrestricted funds.

**7. Expenditure on raising funds****Publicity and fundraising expenses**

	<b>Unrestricted funds 2024 £</b>	<b>Total funds 2024 £</b>	<i>Total funds 2023 £</i>
General Fundraising costs	14,340	14,340	6,724
Christmas Season	13,780	13,780	11,284
Carols and Champagne	14,753	14,753	-
Shetland Pony Grand National	952	952	819
Plumpton Raceday	46,104	46,104	44,554
Wincanton Raceday	41,341	41,341	-
Publicity and direct administrative costs	43,662	43,662	42,675
	<u>174,932</u>	<u>174,932</u>	<u>106,056</u>
<i>Total 2023</i>	<u>106,056</u>	<u>106,056</u>	

---

**Bob Champion Cancer Trust**


---

**Notes to the financial statements**  
**For the year ended 30 June 2024**


---

**8. Research Grants**

	<b>Grants to Institutions 2024 £</b>	<b>Total funds 2024 £</b>	<i>Total funds 2023 £</i>
Professor Rosalind Eeles grant - Institute of Cancer Research (ICR)	84,998	84,998	72,574
Professor Colin Cooper grant - UEA	13,588	13,588	31,317
Clinician Annie Gao	31,543	31,543	31,543
<b>Total 2024</b>	<u>130,129</u>	<u>130,129</u>	<u>135,434</u>

Professor Ros Eeles, Prostate Cancer Sequencing Germline DNA Project at the ICR, to predict who will develop aggressive or lethal prostate cancer commenced in August 2019 at cost of £282,509 over the three year grant period. Due to Covid-19 delays the grant ended, and was then extended for a further three years in October 2023 at the cost of £349,294.

Professor Colin Cooper, The Role of Bacterial Infection in the Development of Human Prostate Cancer grant for Rachel Hurst was awarded initially in January 2020 for two years at a cost of £80,000. The BCCT continued to fund this project with Rachel Hurst with funds being taken up to, but no later, than 31 December 2024. The BCCT will pay 75% of the total grant, approximately £50,000 per annum.

Dan Brewer within Professor Colin Cooper's team on the DESNT project this grant covers the project for one year at £30,000, with a deadline of completion of December 2023.

Furthermore, in July 2021 a grant was offered to Annie Gao within the Bob Champion Unit, ICR/Royal Marsden Hospital. The agreed funding for £42,000 per year is for 3 years (including standard on-costs) commencing from 1 September 2021.

The Trustees are satisfied that the charity will have sufficient resources to fulfil future research grant commitments. The charity has a strong balance sheet position, which includes listed investments of £1,693,539 that can be turned into cash as required.

---

**Bob Champion Cancer Trust**


---

**Notes to the financial statements**  
**For the year ended 30 June 2024**


---

**9. Charitable expenditure**

	<b>Grant funding of activities 2024 £</b>	<b>Support costs 2024 £</b>	<b>Total funds 2024 £</b>	<i>Total funds 2023 £</i>
Grants to institutions (note 8)	130,129	-	130,129	135,434
Staff costs	-	63,360	63,360	59,337
Depreciation	-	483	483	641
Premises costs	-	5,755	5,755	3,737
Travel costs	-	1,041	1,041	744
Computer and IT costs	-	3,049	3,049	4,174
General office costs	-	7,650	7,650	7,924
Governance costs	-	9,421	9,421	11,909
	<u>130,129</u>	<u>90,759</u>	<u>220,888</u>	<u>223,900</u>
<i>Total 2023</i>	<u>135,434</u>	<u>88,466</u>	<u>223,900</u>	

Governance costs comprise Trustees' indemnity insurance and independent examiner's fees (2023: Trustees' indemnity insurance, legal fees and independent examiner's fees).

**10. Independent examiner's remuneration**

	<b>2024 £</b>	<i>2023 £</i>
Fees payable to the Charity's independent examiner for the independent examination of the Charity's annual accounts	<u>5,100</u>	<u>4,950</u>

---

**Bob Champion Cancer Trust**


---

**Notes to the financial statements**  
**For the year ended 30 June 2024**


---

**11. Staff costs**

	<b>2024</b>	<i>2023</i>
	<b>£</b>	<b>£</b>
Wages and salaries	60,000	56,000
Social security costs	1,618	1,657
Contribution to defined contribution pension schemes	1,742	1,680
	<u>63,360</u>	<u>59,337</u>

The average number of persons employed by the Charity during the year was as follows:

	<b>2024</b>	<i>2023</i>
	<b>No.</b>	<b>No.</b>
Employees	<u>1</u>	<u>1</u>

No employee received remuneration amounting to more than £60,000 in either year.

Key management personnel comprise of the Trustees and the Executive Director. Total employment benefits (including social security contributions and employers' pension contributions) of key management personnel during the year were £63,422 (*2023: £59,337*).

**12. Trustees' remuneration and expenses**

During the year, no Trustees received any remuneration or other benefits (*2023 - £NIL*).

During the year, donations given by trustees totalled £1,698 (*2023: £Nil*).

---

**Bob Champion Cancer Trust**


---

**Notes to the financial statements**  
**For the year ended 30 June 2024**


---

**13. Tangible fixed assets**

	Fixtures and fittings £	Office equipment £	Total £
<b>Cost</b>			
At 1 July 2023	-	6,782	6,782
Additions	118	817	935
At 30 June 2024	<u>118</u>	<u>7,599</u>	<u>7,717</u>
<b>Depreciation</b>			
At 1 July 2023	-	5,663	5,663
Charge for the year	24	459	483
At 30 June 2024	<u>24</u>	<u>6,122</u>	<u>6,146</u>
<b>Net book value</b>			
At 30 June 2024	<u>94</u>	<u>1,477</u>	<u>1,571</u>
At 30 June 2023	<u>-</u>	<u>1,119</u>	<u>1,119</u>

**Bob Champion Cancer Trust**

**Notes to the financial statements  
For the year ended 30 June 2024**

**14. Fixed asset investments**

	<b>Investments in subsidiary companies £</b>	<b>Listed investments £</b>	<b>Total £</b>
<b>Cost or valuation</b>			
At 1 July 2023	2	1,506,193	1,506,195
Additions	-	75,000	75,000
Revaluations	-	112,344	112,344
At 30 June 2024	2	1,693,537	1,693,539

At 30 June 2024, CCLA Fund Managers Limited, an investment management company external to the charity, valued the investments held by the charity at £1,693,537 (2023: £1,506,193). This valuation was made on the basis of the value of the units on the open market in which they are traded. The gain/(loss) is included in the statement of financial activities.

**Subsidiary undertakings**

The following was a subsidiary undertaking of the Charity:

<b>Name</b>	<b>Holding</b>	<b>Included in consolidation</b>
Aldaniti Trading Company Limited	100%	No

The financial results of the subsidiary for the year were:

<b>Name</b>	<b>Net assets £</b>
Aldaniti Trading Company Limited	2

Aldaniti Trading Company Limited, a company incorporated in England and Wales, ceased trading on 30 June 2004 and has not traded since. On this date its trade and assets were transferred to the charity.

**15. Debtors**

	<b>2024 £</b>	<b>2023 £</b>
Prepayments	1,861	4,282

---

**Bob Champion Cancer Trust**


---

**Notes to the financial statements**  
**For the year ended 30 June 2024**


---

**16. Creditors: Amounts falling due within one year**

	<b>2024</b>	2023
	£	£
Trade creditors	1,649	2,991
Amounts owed to group undertakings	2	2
Other taxation and social security	662	1,199
Other creditors	3,327	265
Accruals and deferred income	22,361	29,295
Grants committed	-	39,531
	<u>28,001</u>	<u>73,283</u>
	<b>2024</b>	2023
	£	£
Deferred income at 1 July 2023	12,975	-
Events income deferred during the year	8,967	12,975
Amounts released from previous periods	(12,975)	-
	<u>8,967</u>	<u>12,975</u>

**17. Financial instruments**

	<b>2024</b>	2023
	£	£
<b>Financial assets</b>		
Financial assets measured at fair value through income and expenditure	<u>1,693,537</u>	<u>1,506,193</u>

Financial assets measured at fair value through income and expenditure comprise fixed asset investments. Fair value has been determined on the basis of the value of the investment units on the open market in which they are traded.

---

**Bob Champion Cancer Trust**


---

**Notes to the financial statements**  
**For the year ended 30 June 2024**


---

**18. Statement of funds****Statement of funds - current year**

	<b>Balance at 1 July 2023</b>	<b>Income</b>	<b>Expenditure</b>	<b>Gains/ (Losses)</b>	<b>Balance at 30 June 2024</b>
	£	£	£	£	£
<b>Unrestricted funds</b>					
Reserves	1,528,851	615,935	(395,820)	112,344	1,861,310
	<u>1,528,851</u>	<u>615,935</u>	<u>(395,820)</u>	<u>112,344</u>	<u>1,861,310</u>

**Statement of funds - prior year**

	<i>Balance at 1 July 2022</i>	<i>Income</i>	<i>Expenditure</i>	<i>Gains/ (Losses)</i>	<i>Balance at 30 June 2023</i>
	£	£	£	£	£
<b>Unrestricted funds</b>					
Reserves	1,573,711	230,372	(329,956)	54,724	1,528,851
	<u>1,573,711</u>	<u>230,372</u>	<u>(329,956)</u>	<u>54,724</u>	<u>1,528,851</u>

**19. Analysis of net assets between funds**

	<b>Unrestricted funds 2024</b>	<b>Total funds 2024</b>	<i>Total funds 2023</i>
	£	£	£
Tangible fixed assets	1,571	1,571	1,119
Fixed asset investments heading	1,693,539	1,693,539	1,506,195
Current assets	194,201	194,201	94,820
Creditors due within one year	(28,001)	(28,001)	(73,283)
	<u>1,861,310</u>	<u>1,861,310</u>	<u>1,528,851</u>

---

**Bob Champion Cancer Trust**


---

**Notes to the financial statements**  
**For the year ended 30 June 2024**


---

**20. Reconciliation of net movement in funds to net cash flow from operating activities**

	<b>2024</b>	<b>2023</b>
	<b>£</b>	<b>£</b>
Net income/expenditure for the period (as per Statement of Financial Activities)	332,459	(44,860)
<b>Adjustments for:</b>		
Depreciation charges	483	720
Losses on investments	(112,344)	(54,724)
Dividends, interests and rents from investments	(46,708)	(46,366)
Decrease/(increase) in debtors	2,421	(4,008)
Increase/(decrease) in creditors	(45,282)	7,857
<b>Net cash provided by/(used in) operating activities</b>	<b>131,029</b>	<b>(141,381)</b>

**21. Analysis of cash and cash equivalents**

	<b>2024</b>	<b>2023</b>
	<b>£</b>	<b>£</b>
Cash in hand	192,340	90,538
<b>Total cash and cash equivalents</b>	<b>192,340</b>	<b>90,538</b>

**22. Analysis of changes in net debt**

	<b>At 1 July</b>	<b>Cash flows</b>	<b>At 30 June</b>
	<b>2023</b>	<b>£</b>	<b>2024</b>
	<b>£</b>		<b>£</b>
Cash at bank and in hand	90,538	101,802	192,340
	<u>90,538</u>	<u>101,802</u>	<u>192,340</u>
	<u><u>90,538</u></u>	<u><u>101,802</u></u>	<u><u>192,340</u></u>

**23. Pension commitments**

The group operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the group in an independently administered fund. The pension cost charge represents contributions payable by the charity to the fund and amounted to £1,680 (2023: £1,680). Contributions totaling £327 (2023: £265) were payable to the fund at the balance sheet date and are included in creditors.

---

**Bob Champion Cancer Trust**

---

**Notes to the financial statements  
For the year ended 30 June 2024**

---

**24. Related party transactions**

During the year, the charity paid £29,387 (2023: £29,879) to the president of the charity, Mr. Bob Champion, in relation to fees and expenses incurred in fulfilling his duties. The amount outstanding at the year end was £7,274 (2023: £7,479). Bob Champion's retainer has been approved by the Charity Commission.

**BOB CHAMPION CANCER TRUST**

England & Wales - Charity number 1024664

---

# Accounts

---

# **Bob Champion Cancer Trust**

**Unaudited**

**Trustees' Report and Financial Statements**

**For the year ended 30 June 2023**

---

**Bob Champion Cancer Trust**

---

**Contents**

---

	Page
Reference and administrative details of the Charity, its Trustees and advisers	1
Trustees' report	2 - 8
Trustees' responsibilities statement	9
Independent examiner's report	10
Statement of financial activities	11
Balance sheet	12
Notes to the financial statements	13 - 24

---

## **Bob Champion Cancer Trust**

---

### **Reference and administrative details of the Charity, its Trustees and advisers For the year ended 30 June 2023**

---

#### **Founder**

Professor Sir Michael Peckham MD FRCP FRCR (deceased October 2021)

#### **President**

Bob Champion, C.B.E.

#### **Medical Advisor**

Professor David Dearnaley

#### **Vice Presidents**

Clare Balding, O.B.E.

Willie Carson, O.B.E.

Kristina Cook

David Gower, M.B.E.

Chris Hughes

Jonjo O'Neill

Greg Rusedski, Esq.

Peter Shilton, O.B.E.

Nick Skelton, C.B.E.

#### **Trustees**

Michael I Cattermole, Esq. (Chairman)

Susie Burrage, O.B.E.

Alex Embiricos

Timothy Fox, Esq.

Andrew Franklin, Esq.

Catherine McAleavey

Catherine Nash

Luke Ponsonby, Esq.

Bridget Rosser

Carolyn Jane Zetter Wells

#### **Trust Officer**

Mrs. Lucienne Wilkinson

#### **Charity registered number**

1024664

#### **Principal Office**

7 Square Rigger Row

Plantation Wharf

London

SW11 3TZ

#### **Accountants**

UHY Hacker Young

Chartered Accountants

Thames House

Roman Square

Sittingbourne

Kent ME10 4BJ

---

## **Bob Champion Cancer Trust**

---

### **Trustees' report For the year ended 30 June 2023**

---

The Trustees present their report and the accounts for the year ended 30 June 2023.

The financial statements comply with the charity's Trust Deed, the Charities Act 2011 and Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019) (Charities SORP (FRS 102)).

#### **Structure, Governance and Management**

The Trust was set up to support research into the causation, nature and treatment of patients with testicular cancer and other forms of malignant disease including those of the prostate.

A Declaration of Trust formed the Charity on 29 June 1993 registered number 1024664. The purpose of the establishment of this charitable trust was to take over and enlarge the work of the Bob Champion Cancer Trust that was set up by a Declaration of Trust dated 20 January 1983.

The number of Trustees shall not be less than three or more than ten. The power of appointing new Trustees is vested in the Trustees and may be exercised by a resolution in writing signed by all of the current Trustees and the new Trustee. The Trustees meet four times per calendar year in person or online.

Please see page 1 for Trustee details, legal and other administrative detail.

The Trustees acknowledge their responsibility for ensuring that the major risks to which the Charity is exposed are identified and systems designed to mitigate those risks. During the year the Trustees completed a formal risk management process to assess business risks and risk management strategies.

The Trust has an independent Medical Advisor, Professor David Dearnaley, to advise the board in their selection of grant awards and allow the Charity to operate in open competition with peer review.

#### **Objectives and Activities**

The Bob Champion Cancer Trust currently supports cancer research within the Institute of Cancer Research, The Royal Marsden Hospital in Sutton, Surrey and the Bob Champion Research and Education Building, situated in the Norwich Research Park at the University of East Anglia. The focus of this support is on urological cancers, especially those of the prostate and testis.

The Trust opened in collaboration with the Institute of Cancer Research the Bob Champion Research Centre in 2000, which forms part of the first male dedicated cancer research centre, in Europe. This centre is based at The Institute of Cancer Research in Sutton, Surrey.

In February 2015 the Trust with The University of East Anglia (UEA) opened The Bob Champion Research and Education Building at The Norwich Research Park, this facility is operated by the UEA in partnership with the Norfolk & Norwich Hospital. This centre provides state-of-the-art laboratories for researchers to explore new treatments not only for prostate cancer research but for diseases from antibiotic resistance to musculo-skeletal and gastrointestinal diseases.

---

## **Bob Champion Cancer Trust**

---

### **Trustees' report (continued) For the year ended 30 June 2023**

---

The Trust is self-supporting and relies totally upon donations from the public that may be in the form of a legacy or donation with the benefit of claiming Gift Aid if applicable. Income is raised from a full fundraising calendar, with major events being held annually or biennially, supported by event committees, promotional mailings and active social media campaigns. The events range from themed event and parties, horse shows and race nights to personal challenges such as sponsored rides, marathons, including the London Marathon, and cycling events, these hopefully offer something for all our supporters and helps to attract new interest to the cause. A annual charity raceday at Plumpton Racecourse is held, which is now an established and extremely popular fundraiser for the Trust, during which a Shetland Pony race is held to help raise funds as well as the traditional auctions and raffles. Another very successful event is a carol service - Carols and Champagne - held at Chelsea Old Church in London every other year. The calendar had two extra events this year, to be held later in 2023, a charity golf day at Naunton Downs, near Cheltenham, and a further charity raceday, including a charity race, at Wincanton Racecourse.

The Trust is delighted to be continuing its involvement with the Shetland Pony Grand National, now for the seventh year. The Shetland Pony Grand National is a major part of the London International Horseshow held at Excel Exhibition Centre, with the Shetland Pony Grand National grand finale a highlight of the five days. Bob Champion himself is heavily involved during the year, helping the young riders through their heats, and attends, as well as appearing in the show ring every day during the Show in December. The jockeys (aged between 9-14 years) once they qualify for the Show commit to raise a minimum of £1,000 sponsorship in support of the Trust.

Since 1988 the Trust has produced its own, especially commissioned, double sided Christmas card. The card not only raises vital funds but spreads awareness of the cause and the work of the Trust. The artist/s is selected each year and kindly donate their time, or only charges for material costs, and skill in support of the Trust. In 2021 a second, smaller card, was added to create a choice for our supporters, again, double sided and kindly painted for us and donated by the artist. The larger card offers a more classic choice with the smaller card being more fun.

Bob Champion was awarded a CBE in The Queen's New Year Honours 2021 for his charitable works. He attends many of the events himself and continues to play an integral part in raising funds, and awareness, not only of the Charity's aims, but also of the disease itself. All events are organised from the office, often with the help of a specific event committee made up from volunteers and keen supporters. The Trust is always open to new fundraising ideas and how to offer help to cancer sufferers, their families and friends.

### **Public Benefit**

The Trustees confirm that they given due consideration to the Charity Commission's published guidance on the Public Benefit requirement under the Charities Act 2011 when reviewing the aims and objectives, and in planning future activities.

### **Achievements and performance**

Each year 52,000 men in the UK will be diagnosed with prostate cancer and more than 12,000 will die from their disease. At present we do not have good markers to predict who will have prostate cancer that behaves in an aggressive way and causes mortality.

For many cancers the fundamental mechanism of cancer development has been unravelled. Such studies reveal that the disease develops because of alterations or mutations within 'cancer genes'.

---

## **Bob Champion Cancer Trust**

---

### **Trustees' report (continued) For the year ended 30 June 2023**

---

Although cancer genes responsible for the development of, for example, colon cancer and breast cancer are well characterised, relatively little is known about the fundamental development of prostate cancer.

A particular problem is the highly variable natural history of prostate cancer causes significant problems in its clinical management. Over-treatment of prostate cancers is a particular concern leading to impotence in a high proportion of cases. This is especially true for PSA screen-detected cancers that are mostly biologically irrelevant and in the absence of treatment would never become life threatening. Conversely, more conservative approaches to disease detection and management may leave potentially aggressive cancers untreated.

The Trust, within the Bob Champion Education and Research Building is continuing to fund a project aimed at identifying improved clinical markers (biomarkers) which allow radical therapies such as surgery and radiotherapy to be targeted to men with significant cancers, so that the remainder, with biologically unimportant disease, are spared the side-effects of treatment. Professor Cooper, Chair of Cancer Genetics at the University of East Anglia, is co-lead with Professor Ros Eeles (Institute of Cancer Research) on the global initiative PanProstate Cancer Group. The Pan Prostate Cancer Group (PPCG) consists of groups worldwide (UK, Germany, USA, Canada, France, Australia, Finland) that have whole genome, transcriptome and epigenome data from over 2000 prostate tumours linked to rich clinical outcome information. The consortium's data represent both localised and metastatic prostate cancers that also address differences in ethnicity, DNA repair gene carrier status, common germline variant polygenic risk status and variable age groups. Importantly, long-term outcome is also available on many of these patients and so clinic-genomic correlates can be made to determine novel factors that predict biochemical failure-free, and metastasis-free, survival. The major objective of the consortium is to identify markers that will allow us to distinguish between aggressive and non-aggressive prostate cancer at the time of diagnosis or metastasis. This represents a fundamental problem for around half of the 500,000 men diagnosed with prostate cancer in Europe and North America each year. Additionally, the data should provide insights into disease mechanism and identify possible new treatment paradigms.

Professor Cooper remains involved in Strategic Developments at UEA including facilitating translational research between the University and the Norwich Hospital where 5,000 patients are diagnosed with cancer each year including 750 patients with prostate cancer and 10-20 with testicular cancer. These themes form the basis of three projects currently funded by the Trust at UEA/Bob Champion Research and Education Building.

There have been two exciting results from the PUR2 studies. The first is that based on the work that Professor Cooper's team has done the hope to move immediately to accreditation which means patients can receive the test and the feedback will assist the progress of the project. The test can be used to detect expression of 20,000 genes in urine for immediate accreditation as it's the same technique that team used for the Tiger Test. The second is that the genes that are being detected may be reflecting the biology of the prostate as a whole rather than only the cancer. This fits in with a lot of the existing literature but represents a completely new way of detecting aggressive disease. Looking at the prostate as a whole (cancer plus surrounding tissue) rather than just focusing just on the cancer.

This is the first year of the Trust support for Professor Ros Eeles three year grant for the UKGPCS collection of germline DNA and data. The aim of this project is to analyse whole exome sequence from a unique and large collection of prostate cancer cases: 20,000 germline DNA samples from the UKGPCS in order to identify rare variants and their contribution to the risk of developing prostate cancer with specific phenotypes and potentially predict response to various treatments.

---

## Bob Champion Cancer Trust

---

### Trustees' report (continued) For the year ended 30 June 2023

---

The UKGPCS was established in 1992, recruiting men from The Royal Marsden NHS Foundation Trust and Collaborative Centres (NHS Trust hospitals) throughout the UK and Northern Ireland, over 180 of which are from the National Cancer Research Network (NCRN).

The UKGPCS have collected a rich phenotype dataset for most of these samples: date of birth, diagnosis, and death if applicable; mode of detection; TNM Stage; Gleason score; primary treatment; vital status; geographic region based on referring hospital, or treatment hospital if information on the referring hospital was not available; self-reported BMI; self-reported ethnicity; and PSA at diagnosis for all patients, as well as for relatives, if available. The information on risk factors for prostate cancer, demographic characteristics, and clinical data are also collected routinely as part of medical care and clinical follow-up. Over 78% of the cohort has clinical data on treatment and outcomes are being followed up at 2, 5 and 10 years post diagnosis; this collection is still in process.

For sequencing of whole exomes in germline samples a high-throughput automated approach will be used to prepare high-quality genomic DNA for exome capture. The exome will be captured and sequenced on the latest technology in use at the Regeneron Genetics Centre.

#### Publications:-

##### **Caution regarding the specificities of pan-cancer microbial structure.**

Gihawi A, Cooper CS, Brewer DS. *Microb Genom.* 2023 Aug;9(8):mgen001088. doi: 10.1099/mgen.0.001088. PMID: 37555750

##### **Major data analysis errors invalidate cancer microbiome findings.**

Gihawi A, Ge Y, Lu J, Puiu D, Xu A, Cooper CS, Brewer DS, Perteau M, Salzberg SL. *mBio.* 2023 Oct 31;14(5):e0160723. doi: 10.1128/mbio.01607-23. Epub 2023 Oct 9. PMID: 37811944

[Comment: this is a critical already highly cited paper that shows that major work published in the top Journal Nature is incorrect.]

##### **Gene-Transcript Expression in Urine Supernatant and Urine Cell-Sediment Are Different but Equally Useful for Detecting Prostate Cancer.**

Yazbek Hanna M, Winterbone M, O'Connell SP, Olivani M, Hurst R, Mills R, Cooper CS, Brewer DS, Clark J. *Cancers (Basel).* 2023 Jan 27;15(3):789. doi: 10.3390/cancers15030789. PMID: 36765747

##### **Genomic evolution shapes prostate cancer disease type.**

Woodcock DJ, Sahli A, Teslo R, Bhandari V, Gruber AJ, Ziubroniewicz A, Gundem G, Xu Y, Butler A, Anokian E, Pope BJ, Jung CH, Tarabichi M, Dentro SC, Farmery JHR; CRUK ICGC Prostate Group; Van Loo P, Warren AY, Gnanapragasam V, Hamdy FC, Bova GS, Foster CS, Neal DE, Lu YJ, Kote-Jarai Z, Fraser M, Bristow RG, Boutros PC, Costello AJ, Corcoran NM, Hovens CM, Massie CE, Lynch AG, Brewer DS, Eeles RA, Cooper CS, Wedge DC. *Cell Genom.* 2024 Mar 13;4(3):100511. doi: 10.1016/j.xgen.2024.100511. Epub 2024 Feb 29. PMID: 38428419

[Comment: UEA holds a joint patent with Oxford and Manchester to develop this work.]

##### **Combining Molecular Subtypes with Multivariable Clinical Models Has the Potential to Improve Prediction of Treatment Outcomes in Prostate Cancer at Diagnosis.**

Wardale L, Cardenas R, Gnanapragasam VJ, Cooper CS, Clark J, Brewer DS. *Curr Oncol.* 2022 Dec 22;30(1):157-170. doi: 10.3390/curroncol30010013. PMID: 36661662 Free

---

## Bob Champion Cancer Trust

---

### Trustees' report (continued) For the year ended 30 June 2023

---

#### **The architecture of clonal expansions in morphologically normal tissue from cancerous and non-cancerous prostates.**

Buhigas C, Warren AY, Leung WK, Whitaker HC, Luxton HJ, Hawkins S, Kay J, Butler A, Xu Y, Woodcock DJ, Merson S, Frame FM, Sahli A, Abascal F; CRUK-ICGC Prostate Cancer Group; Martincorena I, Bova GS, Foster CS, Campbell P, Maitland NJ, Neal DE, Massie CE, Lynch AG, Eeles RA, **Cooper CS**, Wedge DC, Brewer DS. Mol Cancer. 2022 Sep 22;21(1):183. doi: 10.1186/s12943-022-01644-3. PMID: 36131292

The Trust is in the second year of a three year grant for Annie Gao, a Senior Radiotherapy Clinical Trials Co-ordinator at the Bob Champion Unit, Royal Marsden Hospital, Sutton.

The Unit has supported and lead the PACE trials which looks to use stereotactic body radiotherapy to deliver to the patient the prostate cancer treatment in 5 visits over 1-2 weeks. This pioneering treatment can target the cancer with pinpoint accuracy. This means a reduction in healthy tissue damage and enables men to complete and recover from treatment much faster than ever before. Initial results from the PACE-B trial have been published, showing that there were low rates of side effects after 2 years and suggesting that curative treatment can be given over a much-shortened period. This has positive implications for the patients experience of cancer treatment and subsequent quality of life.

Critical to the success of all these studies is the long-term follow-up of men after their initial radiotherapy treatment. Confidence that a patient is truly cured takes 10 years in men with localised prostate cancer as side effects can continue to develop over many years, a full estimation of the risks and benefits of a new treatment requires years of careful data collection.

Annie Gao focusses particularly on the long-term follow-up of patients. This enables the ICR to continue to monitor men for signs of cancer recurrence and side effects for long enough to be sure that the innovative radiotherapy treatment being tested is advantageous. The Unit continues to publish results in the highest calibre journals and publications.

#### **Key trials in long term follow-up:**

- The **IMRT (Intensity-Modulated Radiotherapy) trial** (495 patients) looked at targeting the prostate cancer more accurately, which in turn allowed for a larger dose of radiotherapy to be given. There were 5 groups of patients, each receiving slightly different doses of radiotherapy. The continued review of this comprehensive dataset enables us to learn more about which patients are likely to be cured with standard treatments and which require further escalation of therapy. Blood and biopsy translational work from this trial also sheds new light on the evolutionary genetics of prostate cancer.
- The **CHHiP trial** (398 patients recruited at RMH out of 3,200 in multi-centre trial) follows patients for up to 15 years after their treatment and is enabling us to know with greater certainty that shorter treatments are better for men with localised prostate cancer. The trial introduced prostate IMRT in the UK. This ongoing data collection has enabled the review of over 2000 prostate cancer samples to further investigate the effects of radiotherapy dose on prostate cancer in the laboratory.

---

## Bob Champion Cancer Trust

---

### Trustees' report (continued) For the year ended 30 June 2023

---

- The **DELINEATE trial** (316 patients), looks at new ways of planning and giving radiotherapy for localised prostate cancer. New types of scanning techniques have allowed us to differentiate between the cancer and normal prostate tissue with greater certainty. The aim is to target the cancerous area with increased accuracy and a higher dose without risking damage to the normal prostate tissue. The Trust has directly impacted this trial by allowing it to extend the patient follow-up period from 5 to 10 years. This data collection is critical as the cure rates have so far been unprecedented with up to 96.7 % of patients being free of any prostate cancer at the 5-year follow-up timepoint. Further follow-up of these patients is necessary to ensure these excellent results are maintained at 10 years.
- The **PACE-C trial** compares stereotactic body radiotherapy (5 visits – SBRT uses precise daily image guidance to give remarkably accurate radiotherapy) with the now conventional IMRT (20 visits – see IMRT trials above). Since the application last year, recruitment to this trial has exceeded expectations and the trial closed early having already met its target of 1182 patients. These men are now in long-term follow-up, assessing side effects, patient quality of life and long-term cancer control.

### Financial Review

The Trust incurred an overall deficit for the year of £44,860 (2022: £101,310). Included within the income and expenditure of the Trust for the year is a surplus on fundraising events of £105,137 (2022: £184,284) and dividends received of £46,366 (2022: £46,535). In addition, the unrealised gain on investments for the year to 30 June 2023 was £54,724 (2022: loss on investments of £87,321).

The Trustees are satisfied that the Trust's funds are available and adequate to fulfil its obligations in relation to their commitments.

The Declaration of Trust, signed on the 29th June 1993, states that "any money available for investment may be so invested in the names of the Trustees or their nominees in any way whatsoever, whether or not producing income, as the Trustees shall in their absolute discretion think fit, as if they were absolutely entitled to the Trust Fund beneficially."

It is the policy of the Trust to hold reserves in its General Fund that have not yet been committed or designated for any particular purpose. The Trustees have set aside these reserves in order to protect the future operations of the charity from the effects of any unforeseen variations in its income streams as part of a policy of good financial management practice.

### Plans for the Future

The Trustees continue to work towards the aims of the deed of declaration of Trust to find a cure for urological cancers, particularly prostate cancer, through scientific and clinical research at The Institute of Cancer Research and The Norwich Medical Research Park at UEA. To establish a clinical test to detect prostate cancer cells remains at the forefront of the Trusts current plans.

---

**Bob Champion Cancer Trust**

---

**Trustees' report (continued)**  
**For the year ended 30 June 2023**

---

The funding for the work of the Trust will continue to be raised from a full fundraising calendar run by the Executive Officer of the Charity, donations and legacies and the interest from the investment funds if required.

**Approval**

This report was approved by the Trustees and signed on its behalf by:

DocuSigned by:  
*Michael Cattermole*  
D17B32C730044CE...

**Michael Cattermole**  
Trustee

DocuSigned by:  
*Luke Ponsonby*  
079868F1D2FD4CA...

**Luke Ponsonby**  
Trustee

Date: 19 April 2024

---

**Bob Champion Cancer Trust**

---

**Statement of Trustees' responsibilities  
For the year ended 30 June 2023**

---

The Trustees are responsible for preparing the Trustees' report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

The law applicable to charities in England & Wales requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the Charity and of its incoming resources and application of resources, including its income and expenditure, for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles of the Charities SORP (FRS 102);
- make judgments and accounting estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards (FRS 102) have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Charity will continue in business.

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the Charity's transactions and disclose with reasonable accuracy at any time the financial position of the Charity and enable them to ensure that the financial statements comply with the Charities Act 2011, the Charity (Accounts and Reports) Regulations 2008 and the provisions of the Trust deed. They are also responsible for safeguarding the assets of the Charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Approved by order of the members of the board of Trustees and signed on its behalf by:

DocuSigned by:  
*Michael Cattermole*  
D17B32C730044CE...

**Michael Cattermole**

Trustee

Date: 19 April 2024

DocuSigned by:  
*Luke Ponsonby*  
079866F1D2FD4CA...

**Luke Ponsonby**

Trustee

---

**Bob Champion Cancer Trust**

---

**Independent Examiner's Report  
For the year ended 30 June 2023**

---

**Independent Examiner's Report to the Trustees of Bob Champion Cancer Trust ('the Charity')**

I report to the charity Trustees on my examination of the accounts of the Charity for the year ended 30 June 2023.

**Responsibilities and Basis of Report**

As the Trustees of the Charity you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ('the 2011 Act').

I report in respect of my examination of the Charity's accounts carried out under section 145 of the 2011 Act and in carrying out my examination I have followed the applicable Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

**Independent Examiner's Statement**

Your attention is drawn to the fact that the Charity has prepared the accounts in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) in preference to the Accounting and Reporting by Charities: Statement of Recommended Practice issued on 1 April 2005 which is referred to in the extant regulations but has been withdrawn.

I understand that this has been done in order for the accounts to provide a true and fair view in accordance with the Generally Accepted Accounting Practice effective for reporting periods beginning on or after 1 January 2015.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

1. accounting records were not kept in respect of the Charity as required by section 130 of the 2011 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

This report is made solely to the Charity's Trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008. My work has been undertaken so that I might state to the Charity's Trustees those matters I am required to state to them in an Independent examiner's report and for no other purpose. To the fullest extent permitted by law, I do not accept or assume responsibility to anyone other than the Charity and the Charity's Trustees as a body, for my work or for this report.

Signed:



Dated: 22 April 2024

Tracey Moore BFP ACA

**UHY Hacker Young**

Chartered Accountants

---

**Bob Champion Cancer Trust**


---

**Statement of financial activities  
For the year ended 30 June 2023**


---

	Note	Unrestricted funds 2023 £	Total funds 2023 £	Total funds 2022 £
<b>Income from:</b>				
Donations and legacies	4	6,295	6,295	12,001
Other trading activities - Fundraising	5	177,711	177,711	279,015
Investments	6	46,366	46,366	46,535
<b>Total income</b>		<u>230,372</u>	<u>230,372</u>	<u>337,551</u>
<b>Expenditure on:</b>				
Raising funds		72,574	72,574	94,169
Charitable activities		257,382	257,382	257,371
<b>Total expenditure</b>		<u>329,956</u>	<u>329,956</u>	<u>351,540</u>
<b>Net expenditure before net gains/(losses) on investments</b>		(99,584)	(99,584)	(13,989)
Net gains/(losses) on investments		54,724	54,724	(87,321)
<b>Net movement in funds</b>		<u>(44,860)</u>	<u>(44,860)</u>	<u>(101,310)</u>
<b>Reconciliation of funds:</b>				
Total funds brought forward		1,573,711	1,573,711	1,675,021
Net movement in funds		(44,860)	(44,860)	(101,310)
<b>Total funds carried forward</b>		<u>1,528,851</u>	<u>1,528,851</u>	<u>1,573,711</u>

The Statement of Financial Activities includes all gains and losses recognised in the year.

The notes on pages 13 to 24 form part of these financial statements.

---

**Bob Champion Cancer Trust**


---

**Balance sheet**  
**As at 30 June 2023**



---

	Note	2023 £	2022 £
<b>Fixed assets</b>			
Tangible assets	12	1,119	1,839
Investments	13	1,506,195	1,576,471
		<u>1,507,314</u>	<u>1,578,310</u>
<b>Current assets</b>			
Debtors	14	4,282	274
Cash at bank and in hand		90,538	60,553
		<u>94,820</u>	<u>60,827</u>
Creditors: amounts falling due within one year	15	(73,283)	(65,426)
<b>Net current assets / liabilities</b>		<u>21,537</u>	<u>(4,599)</u>
<b>Total net assets</b>		<u><u>1,528,851</u></u>	<u><u>1,573,711</u></u>
<b>Charity funds</b>			
Unrestricted funds	17	1,528,851	1,573,711
<b>Total funds</b>		<u><u>1,528,851</u></u>	<u><u>1,573,711</u></u>

The financial statements were approved and authorised for issue by the Trustees and signed on their behalf by:

DocuSigned by:  
  
 D17B32C730044CE ..

**Michael Cattermole**  
Trustee

DocuSigned by:  
  
 079866F1D2FD4CA ..

**Luke Ponsonby**  
Trustee

Date: 19 April 2024

The notes on pages 13 to 24 form part of these financial statements.

---

## **Bob Champion Cancer Trust**

---

### **Notes to the financial statements For the year ended 30 June 2023**

---

#### **1. General information**

Bob Champion Cancer Trust is a registered charity in England and Wales registered under the charity number 1024664. The registered office is 7 Square Rigger Row, Plantation Wharf, London, SW11 3TZ.

#### **2. Accounting policies**

##### **2.1 Basis of preparation of financial statements**

The financial statements have been prepared in accordance with the Charities SORP (FRS 102) - Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Charities Act 2011.

The financial statements have been prepared to give a 'true and fair' view and have departed from the Charities (Accounts and Reports) Regulations 2008 only to the extent required to provide a 'true and fair' view. This departure has involved following the Charities SORP (FRS 102) published in October 2019 rather than the Accounting and Reporting by Charities: Statement of Recommended Practice effective from 1 April 2005 which has since been withdrawn.

Bob Champion Cancer Trust meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

The charity has taken advantage of the exemption available to smaller charities from preparing a cash flow statement.

##### **2.2 Basis of non-consolidation**

In the opinion of the Trustees, the charity and its subsidiary undertakings comprise a small group. The subsidiary has been excluded as its inclusion would not be material from the point of view of providing a true and fair view.

##### **2.3 Going concern**

The Trustees consider that there are no material uncertainties about the Trust's ability to continue as a going concern for a period of at least twelve months after the date of signature of these accounts. The accounts have therefore been prepared on the going concern basis.

---

## Bob Champion Cancer Trust

---

### Notes to the financial statements For the year ended 30 June 2023

---

## 2. Accounting policies (continued)

### 2.4 Income

All income is recognised once the Charity has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably.

Donated services or facilities are recognised when the charity has control over the item, any conditions associated with the donated item have been met, the receipt of economic benefit from the use of the charity of the item is probable and that economic benefit can be measured reliably. In accordance with the Charities SORP (FRS 102), the general volunteer time is not recognised and refer to the Trustees' report for more information about their contribution.

On receipt, donated professional services and facilities are recognised on the basis of the value of the gift to the charity which is the amount it would have been willing to pay to obtain services or facilities of equivalent economic benefit on the open market; a corresponding amount is then recognised and refer to the Trustees' report for more information about their contribution.

Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Income tax recoverable in relation to investment income is recognised at the time the investment income is receivable.

### 2.5 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Staff costs are allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset's use.

Fundraising costs are those incurred in seeking voluntary contributions and do not include the costs of disseminating information in support of the charitable activities. Support costs are those costs incurred directly in support of expenditure on the objects of the charity and include management carried out by the Executive Officer. The Trust office is based on an office share which is donated to the Trust by the building owner.. Governance costs are those incurred in connection with administration of the charity and compliance with constitutional and statutory requirements.

Expenditure on raising funds includes all expenditure incurred by the Charity to raise funds for its charitable purposes and includes costs of all fundraising activities events and non-charitable trading.

Expenditure on charitable activities is incurred on directly undertaking the activities which further the Charity's objectives, as well as any associated support costs.

Grants payable are charged in the year when the offer is made except in those cases where the offer is conditional, such grants being recognised as expenditure when the conditions attaching are fulfilled. Grants offered subject to conditions which have not been met at the year end are noted as a commitment, but not accrued as expenditure.

All expenditure is inclusive of irrecoverable VAT.

---

**Bob Champion Cancer Trust**

---

**Notes to the financial statements  
For the year ended 30 June 2023**

---

**2. Accounting policies (continued)**

**2.6 Interest receivable**

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the Charity; this is normally upon notification of the interest paid or payable by the institution with whom the funds are deposited.

**2.7 Tangible fixed assets and depreciation**

Tangible fixed assets are initially recognised at cost. After recognition, under the cost model, tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. All costs incurred to bring a tangible fixed asset into its intended working condition should be included in the measurement of cost.

Depreciation is charged so as to allocate the cost of tangible fixed assets less their residual value over their estimated useful lives, on a reducing balance basis.

Depreciation is provided on the following basis:

Computer equipment	-	25% reducing balance
--------------------	---	----------------------

**2.8 Investments**

Fixed asset investments are a form of financial instrument and are initially recognised at their transaction cost and subsequently measured at fair value at the Balance sheet date, unless the value cannot be measured reliably in which case it is measured at cost less impairment. Investment gains and losses, whether realised or unrealised, are combined and presented as 'Gains/(Losses) on investments' in the Statement of financial activities.

Investments in subsidiaries are valued at cost less provision for impairment.

**2.9 Debtors**

Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

**2.10 Cash at bank and in hand**

Cash at bank and in hand includes cash and short-term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

**2.11 Liabilities and provisions**

Liabilities are recognised when there is an obligation at the Balance sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably.

Liabilities are recognised at the amount that the Charity anticipates it will pay to settle the debt or the amount it has received as advanced payments for the goods or services it must provide.

Provisions are measured at the best estimate of the amounts required to settle the obligation. Where the effect of the time value of money is material, the provision is based on the present value of those amounts, discounted at the pre-tax discount rate that reflects the risks specific to the liability. The unwinding of the discount is recognised in the Statement of financial activities as a finance cost.

---

**Bob Champion Cancer Trust**


---

**Notes to the financial statements  
For the year ended 30 June 2023**


---

**2. Accounting policies (continued)**
**2.12 Financial instruments**

The Charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

**2.13 Pensions**

The Charity operates a defined contribution pension scheme and the pension charge represents the amounts payable by the Charity to the fund in respect of the year.

**2.14 Fund accounting**

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the Charity and which have not been designated for other purposes.

Investment income, gains and losses are allocated to the appropriate fund.

**3. Critical accounting estimates and areas of judgment**

Estimates and judgments are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

Critical accounting estimates and assumptions:

The Trustees have not applied any significant estimates or judgments in the preparation of these financial statements.

**4. Income from donations and legacies**

	<b>Unrestricted funds 2023 £</b>	<b>Total funds 2023 £</b>	<i>Total funds 2022 £</i>
Legacies	1,393	1,393	4,952
Other	4,902	4,902	7,049
<b>Total 2023</b>	<u>6,295</u>	<u>6,295</u>	<u>12,001</u>

In both the current and prior year all income from donations and legacies was in relation to unrestricted funds.

---

**Bob Champion Cancer Trust**


---

**Notes to the financial statements**  
**For the year ended 30 June 2023**


---

**5. Income from other trading activities - fundraising**
**Income from fundraising events**

	<b>Unrestricted funds 2023 £</b>	<b>Total funds 2023 £</b>	<i>Total funds 2022 £</i>
General Fundraising	23,787	23,787	34,162
Christmas Season	12,670	12,670	26,769
Carols and Champagne	-	-	89,669
Shetland Pony Grand National	30,012	30,012	30,483
40for40	-	-	14,903
Plumpton Raceday	111,242	111,242	83,029
<b>Total 2023</b>	<u><u>177,711</u></u>	<u><u>177,711</u></u>	<u><u>279,015</u></u>

In both the current and prior year all income from fundraising was in relation to unrestricted funds.

**6. Investment income**

	<b>Unrestricted funds 2023 £</b>	<b>Total funds 2023 £</b>	<i>Total funds 2022 £</i>
Listed securities	46,293	46,293	46,531
Bank deposits	73	73	4
<b>Total 2023</b>	<u><u>46,366</u></u>	<u><u>46,366</u></u>	<u><u>46,535</u></u>

In both the current and prior year all income from investments was in relation to unrestricted funds.

---

**Bob Champion Cancer Trust**


---

**Notes to the financial statements**  
**For the year ended 30 June 2023**


---

**7. Research Grants**

	<b>Grants to Institutions 2023 £</b>	<b>Total funds 2023 £</b>	<i>Total funds 2022 £</i>
Professor Rosalind Eeles grant - Institute of Cancer Research (ICR)	72,574	72,574	94,169
Professor Colin Cooper grant - UEA	31,317	31,317	46,537
Clinician Annie Gao	31,543	31,543	31,543
<b>Total 2023</b>	<u>135,434</u>	<u>135,434</u>	<u>172,249</u>

Professor Ros Eeles, Prostate Cancer Sequencing Project at the ICR, commenced in August 2019 at cost of £282,509 over the three year grant period. Due to Covid-19, this grant was put on hold in 2020 as the ICR focused efforts on research of the virus. However, the grant resumed in 2021.

Professor Colin Cooper, The Role of Bacterial Infection in the Development of Human Prostate Cancer grant for Rachel Hurst was awarded in January 2020 for two years at a cost of £80,000. Professor Cooper is Professor of Cancer Genetics and Associate Dean of Research at UEA. This grant was due to end in December 2021 and, in November 2021, this grant was extended. The BCCT will continue to fund the project with Rachel Hurst with funds being taken up to, but no later, than 31st December 2024. It has been agreed that BCCT will pay 75% of the total grant, approximately £50,000 per annum.

In June 2021, a grant extension was offered to support Dan Brewer within Professor Colin Cooper's team on the DESNT project. The grant covers the project for one year at £30,000, with a deadline of completion of December 2023.

Furthermore, in July 2021 a grant was offered to Annie Gao within the Bob Champion Unit, Royal Marsden Hospital. The agreed funding for £42,000 per year is for 3 years (including standard on-costs) commencing from 1st September 2021.

The Trustees are satisfied that the charity will have sufficient resources to fulfil future research grant commitments. The charity has a strong balance sheet position, which includes listed investments of £1,506,193 that can be turned into cash as required.

---

**Bob Champion Cancer Trust**


---

**Notes to the financial statements**  
**For the year ended 30 June 2023**


---

**8. Support and governance costs**

	<b>Grant funding of activities 2023 £</b>	<b>Support costs 2023 £</b>	<b>Total funds 2023 £</b>	<i>Total funds 2022 £</i>
Premises costs	-	7,217	7,217	10,046
Other costs	-	21,298	21,298	7,407
Personnel costs	-	59,337	59,337	53,787
Governance costs	-	13,063	13,063	13,320
Professor Rosalind Eeles grant - Institute of Cancer Research	72,574	-	72,574	94,169
Professor Colin Cooper grant - UEA	31,317	-	31,317	46,537
Clinician Annie Gao	31,543	-	31,543	31,543
	<u>135,434</u>	<u>100,915</u>	<u>236,349</u>	<u>256,809</u>
<i>Total 2022</i>	<u>172,249</u>	<u>84,560</u>	<u>256,809</u>	

Governance costs comprise of bookkeeping fees, legal fees and independent examiner's fees.

**9. Independent examiner's remuneration**

	<b>2023 £</b>	<i>2022 £</i>
Fees payable to the Charity's independent examiner for the independent examination of the Charity's annual accounts	<u>5,940</u>	<u>9,120</u>

**10. Staff costs**

	<b>2023 £</b>	<i>2022 £</i>
Wages and salaries	56,000	50,520
Social security costs	1,657	1,751
Contribution to defined contribution pension schemes	1,680	1,516
	<u>59,337</u>	<u>53,787</u>

---

**Bob Champion Cancer Trust**


---

**Notes to the financial statements**  
**For the year ended 30 June 2023**


---

**10. Staff costs (continued)**

The average number of persons employed by the Charity during the year was as follows:

	<b>2023</b>	<i>2022</i>
	<b>No.</b>	<i>No.</i>
Employees	<u>1</u>	<u>1</u>

No employee received remuneration amounting to more than £60,000 in either year.

The total employment benefits of key management personnel were £59,337 (*2022: £53,787*).

**11. Trustees' remuneration and expenses**

During the year, no Trustees received any remuneration or other benefits (*2022 - £NIL*).

During the year ended 30 June 2023, no Trustee expenses have been incurred (*2022 - £NIL*).

**12. Tangible fixed assets**

	<b>Office equipment £</b>
<b>Cost</b>	
At 1 July 2022	6,782
At 30 June 2023	<u>6,782</u>
<b>Depreciation</b>	
At 1 July 2022	4,943
Charge for the year	720
At 30 June 2023	<u>5,663</u>
<b>Net book value</b>	
At 30 June 2023	<u>1,119</u>
<i>At 30 June 2022</i>	<u>1,839</u>

---

**Bob Champion Cancer Trust**


---

**Notes to the financial statements**  
**For the year ended 30 June 2023**


---

**13. Fixed asset investments**

	<b>Investments in subsidiary companies £</b>	<b>Listed investments £</b>	<b>Total £</b>
<b>Cost or valuation</b>			
At 1 July 2022	2	1,576,469	1,576,471
Disposals	-	(125,000)	(125,000)
Revaluations	-	54,724	54,724
At 30 June 2023	2	1,506,193	1,506,195

At 30 June 2023, CCLA Fund Managers Limited, an investment management company external to the charity, valued the investments held by the charity at £1,506,193 (2022: £1,576,469). This valuation was made on the basis of the value of the units on the open market in which they are traded. The gain/(loss) is included in the statement of financial activities.

**Subsidiary undertakings**

The following was a subsidiary undertaking of the Charity:

<b>Name</b>	<b>Holding</b>	<b>Included in consolidation</b>
Aldaniti Trading Company Limited	100%	Yes

The financial results of the subsidiary for the year were:

<b>Name</b>	<b>Net assets £</b>
Aldaniti Trading Company Limited	2

Aldaniti Trading Company Limited, a company incorporated in England and Wales, ceased trading on 30 June 2004 and has not traded since. On this date its trade and assets were transferred to the charity.

**14. Debtors**

	<b>2023 £</b>	<b>2022 £</b>
<b>Due within one year</b>		
Prepayments	4,282	274

---

**Bob Champion Cancer Trust**


---

**Notes to the financial statements**  
**For the year ended 30 June 2023**


---

**15. Creditors: Amounts falling due within one year**

	<b>2023</b>	<i>2022</i>
	£	£
Trade creditors	34,973	1,100
Amounts owed to group undertakings	2	2
Other taxation and social security	1,199	1,091
Other creditors	265	249
Accruals and deferred income	29,295	15,966
Grants committed	7,549	47,018
	<u>73,283</u>	<u>65,426</u>
	<b>2023</b>	<i>2022</i>
	£	£
Events income deferred during the year	<u>12,975</u>	<u>-</u>

**16. Financial instruments**

	<b>2023</b>	<i>2022</i>
	£	£
<b>Financial assets</b>		
Financial assets measured at fair value through income and expenditure	<u>1,506,193</u>	<u>1,576,469</u>

Financial assets measured at fair value through income and expenditure comprise fixed asset investments. Fair value has been determined on the basis of the value of the investment units on the open market in which they are traded.

---

**Bob Champion Cancer Trust**


---

**Notes to the financial statements**  
**For the year ended 30 June 2023**


---

**17. Statement of funds****Statement of funds - current year**

	<b>As restated Balance at 1 July 2022</b>	<b>Income</b>	<b>Expenditure</b>	<b>Gains/ (Losses)</b>	<b>Balance at 30 June 2023</b>
	£	£	£	£	£
<b>Unrestricted funds</b>					
Reserves	1,573,711	230,372	(329,956)	54,724	1,528,851
	<u>1,573,711</u>	<u>230,372</u>	<u>(329,956)</u>	<u>54,724</u>	<u>1,528,851</u>

**Statement of funds - prior year**

	<i>Balance at 1 July 2021</i>	<i>Income</i>	<i>As restated Expenditure</i>	<i>Gains/ (Losses)</i>	<i>As restated Balance at 30 June 2022</i>
	£	£	£	£	£
<b>Unrestricted funds</b>					
Reserves	1,675,021	337,551	(351,540)	(87,321)	1,573,711
	<u>1,675,021</u>	<u>337,551</u>	<u>(351,540)</u>	<u>(87,321)</u>	<u>1,573,711</u>

**18. Analysis of net assets between funds****Analysis of net assets between funds - current year**

	<b>Unrestricted funds 2023</b>	<b>Total funds 2023</b>
	£	£
Tangible fixed assets	1,119	1,119
Fixed asset investments	1,506,195	1,506,195
Current assets	94,820	94,820
Creditors due within one year	(73,283)	(73,283)
<b>Total</b>	<u>1,528,851</u>	<u>1,528,851</u>

---

**Bob Champion Cancer Trust**


---

**Notes to the financial statements**  
**For the year ended 30 June 2023**


---

**18. Analysis of net assets between funds (continued)****Analysis of net assets between funds - prior year**

	<i>Unrestricted funds 2022 £</i>	<i>Total funds 2022 £</i>
Tangible fixed assets	1,839	1,839
Fixed asset investments	1,576,471	1,576,471
Current assets	60,827	60,827
Creditors due within one year	(65,426)	(65,426)
<b>Total</b>	<u>1,573,711</u>	<u>1,573,711</u>

**19. Pension commitments**

The group operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the group in an independently administered fund. The pension cost charge represents contributions payable by the charity to the fund and amounted to £1,680 (2022: £1,516). Contributions totaling £265 (2022: £233) were payable to the fund at the balance sheet date and are included in creditors.

**20. Related party transactions**

During the year, the charity paid £29,879 (2022: £27,612) to the president of the charity, Mr. Bob Champion, in relation to fees and expenses incurred in fulfilling his duties. The amount outstanding at the year end was £7,479 (2022: £6,200). Bob Champion's retainer has been approved by the Charity Commission.

**BOB CHAMPION CANCER TRUST**

England & Wales - Charity number 1024664

---

# Accounts

---

---

**BOB CHAMPION CANCER TRUST**

---

**UNAUDITED**

**TRUSTEES' REPORT AND FINANCIAL STATEMENTS**

**FOR THE YEAR ENDED 30 JUNE 2022**

---

**BOB CHAMPION CANCER TRUST**

---

**CONTENTS**

---

	Page
<b>Reference and administrative details of the charity, its advisers</b>	1 - 2
<b>Trustees' report</b>	3 - 7
<b>Trustees' responsibilities statement</b>	8
<b>Independent examiner's report</b>	9
<b>Statement of financial activities</b>	10
<b>Balance sheet</b>	11
<b>Notes to the financial statements</b>	12 - 22

---

**BOB CHAMPION CANCER TRUST**

---

**REFERENCE AND ADMINISTRATIVE DETAILS OF THE CHARITY, ITS TRUSTEES AND ADVISERS  
FOR THE YEAR ENDED 30 JUNE 2022**

---

**FOUNDER**

Professor Sir Michael Peckham MD FRCP FRCR (deceased October 2021)

**PRESIDENT**

Bob Champion, C.B.E.

**MEDICAL ADVISOR**

Professor David Dearnaley

**VICE PRESIDENTS**

Clare Balding, O.B.E.

Willie Carson, O.B.E.

Kristina Cook

David Gower, M.B.E.

Chris Hughes

Jonjo O'Neill

Greg Rusedski, Esq

Peter Shilton, O.B.E.

Nick Skelton, C.B.E.

**TRUSTEES**

Michael I Cattermole, Esq. (Chairman)

Susie Burrage (appointed July 2021)

Alex Embiricos

Timothy Fox, Esq.

Andrew Franklin, Esq.

Catherine McAleavey

Catherine Nash

Luke Ponsonby, Esq.

Bridget Rosser

Carolyn Jane Zetter Wells

**TRUST OFFICERS**

Mrs Lucienne Wilkinson

---

**BOB CHAMPION CANCER TRUST**

---

**REFERENCE AND ADMINISTRATIVE DETAILS OF THE CHARITY, ITS TRUSTEES AND ADVISERS  
(CONTINUED)  
FOR THE YEAR ENDED 30 JUNE 2022**

---

**Charity registered number**

1024664

**Principal office**

7 Square Rigger Row  
Plantation Wharf  
London  
SW11 3TZ

**Secretary**

Mrs. Lucienne Wilkinson

**Chief executive officer**

Mrs. Lucienne Wilkinson

**Accountants**

Ecovis Wingrave Yeats UK Limited  
3rd Floor, Waverley House  
7-12 Noel Street  
London  
W1F 8GQ

---

## BOB CHAMPION CANCER TRUST

---

### TRUSTEES' REPORT FOR THE YEAR ENDED 30 JUNE 2022

---

The Trustees present their report and the accounts for the year ended 30th June 2022.

#### **Administrative Details**

A Declaration of Trust formed the Charity on 29 June 1993 registered number 1024664. The purpose of the establishment of this charitable trust was to take over and enlarge the work of the Bob Champion Cancer Trust that was set up by a Declaration of Trust dated 20 January 1983.

The number of Trustees shall not be less than three or more than ten. The power of appointing new Trustees is vested in the Trustees and may be exercised by a resolution in writing signed by all of the current Trustees and the new Trustee. The Trustees meet four times per calendar year in person or online.

Please see page 1 for Trustee details, legal and other administrative detail.

#### **Structure, Governance and Management**

The Trust was set up to support research into the causation, nature and treatment of patients with testicular cancer and other forms of malignant disease including those of the prostate.

The Trustees acknowledge their responsibility for ensuring that the major risks to which the Charity is exposed are identified and systems designed to mitigate those risks. During the year the Trustees completed a formal risk management process to assess business risks and risk management strategies.

The Trust has an independent Medical Advisor, Professor David Dearnaley, and is actively looking for another, to advise the board in their selection of grant awards and allow the Charity to operate in open competition with peer review.

#### **Objectives and Activities**

The Bob Champion Cancer Trust currently supports cancer research within the Institute of Cancer Research, The Royal Marsden Hospital in Sutton, Surrey and the Bob Champion Research and Education Building, situated in the Norwich Research Park at the University of East Anglia. The focus of this support is on urological cancers, especially those of the prostate and testis.

The Trust opened in collaboration with the Institute of Cancer Research the Bob Champion Research Centre in 2000, which forms part of the first male dedicated cancer research centre, in Europe. This centre is based at The Institute of Cancer Research in Sutton, Surrey.

In February 2015 the Trust with The University of East Anglia (UEA) opened The Bob Champion Research and Education Building at The Norwich Research Park, this facility is operated by the UEA in partnership with the Norfolk & Norwich Hospital. This centre provides state-of-the-art laboratories for researchers to explore new treatments not only for prostate cancer research but for diseases from antibiotic resistance to musculo-skeletal and gastrointestinal diseases.

The Trust is self-supporting and relies totally upon donations from the public that may be in the form of a legacy or donation with the benefit of claiming Gift Aid if applicable. Income is raised from a full fundraising calendar, with major events being held annually or biennially, supported by event committees, mailouts and active social media campaigns. The events range from themed parties, horse shows, golf events and race nights to personal challenges such as sponsored rides, marathons, including the London Marathon, and cycling events, these hopefully offer something for all our supporters and attracts new interest to the cause. A charity raceday at Plumpton is held, which is now an established and popular annual fundraiser for the Trust, with another very popular event being the carols service - Carols and Champagne - held at Chelsea Old Church in London held every other year. The Trust is adding a further two annual events in the 2023 calendar, a charity golf day at Naunton Downs, near Cheltenham, and another charity raceday, including a charity race, at Wincanton.

The Trust is delighted to be continuing its involvement with the Shetland Pony Grand National for the sixth year.

---

---

## BOB CHAMPION CANCER TRUST

---

### TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 30 JUNE 2022

---

The Shetland Pony Grand National is a major part of the London International Horseshow held at Excel. Races are held twice daily during the five days of the show with the grand finale on the final day. Bob Champion himself is heavily involved during the year, helping the children qualify for the Show, and attends and appears in the show ring every day during the Show in December. The young jockeys (aged between 9-14 years) once they qualify for the show commit to raise sponsorship in support of the Trust.

Since 1988 the Trust has produced its own, especially commissioned, double sided Christmas card. The card not only raises vital funds but spreads awareness of the cause and the work of the Trust. The artist/s is selected each year and kindly donate their time, or only charges for material costs, and skill in support of the Trust. A second, smaller card, has been added to create a choice for our supporters. The larger card offers a more classic card choice with the smaller card being more fun.

Bob Champion was awarded a CBE in The Queen's New Year Honours 2021 for his charitable works. He attends many of the events himself and continues to play an integral part in raising funds, and awareness, not only of the Charity's aims, but also of the disease itself. All events are organised from the office, often with the help of a specific event committee made up from a wide league of friends, volunteers and keen supporters. The Trust is always open to new fundraising ideas and how to help cancer sufferers, their families and friends.

#### **Achievements and performance**

Each year 52,000 men in the UK will be diagnosed with prostate cancer and more than 12,000 will die from their disease. At present we do not have good markers to predict who will have prostate cancer that behaves in an aggressive way and causes mortality.

For many cancers the fundamental mechanism of cancer development has been unravelled. Such studies reveal that the disease develops because of alterations or mutations within 'cancer genes'. Although cancer genes responsible for the development of, for example, colon cancer and breast cancer are well characterised, relatively little is known about the fundamental development of prostate cancer. This is bad news for sufferers of prostate cancer because cancer genes, once found, can be used to aid treatment and act as targets for new drugs.

A particular problem is the highly variable natural history of prostate cancer causes significant problems in its clinical management. Over-treatment of prostate cancers is a particular concern leading to impotence in a high proportion of cases. This is especially true for PSA screen-detected cancers that are mostly biologically irrelevant and in the absence of treatment would never become life threatening. Conversely, more conservative approaches to disease detection and management may leave potentially aggressive cancers untreated.

The Trust, within the Bob Champion Education and Research Building is continuing to fund a project aimed at identifying improved clinical markers (biomarkers) which allow radical therapies such as surgery and radiotherapy to be targeted to men with significant cancers, so that the remainder, with biologically unimportant disease, are spared the side-effects of treatment. Professor Cooper, Chair of Cancer Genetics at the University of East Anglia, is co-lead with Professor Ros Eeles (Institute of Cancer Research) on the global initiative PanProstate Cancer Group. The Pan Prostate Cancer Group (PPCG) consists of groups worldwide (UK, Germany, USA, Canada, France, Australia, Finland) that have whole genome, transcriptome and epigenome data from over 2000 prostate tumours linked to rich clinical outcome information. The consortium's data represent both localised and metastatic prostate cancers that also address differences in ethnicity, DNA repair gene carrier status, common germline variant polygenic risk status and variable age groups. Importantly, long-term outcome is also available on many of these patients and so clinic-genomic correlates can be made to determine novel factors that predict biochemical failure-free, and metastasis-free, survival. The major objective of the consortium is to identify markers that will allow us to distinguish between aggressive and non-aggressive prostate cancer at the time of diagnosis or metastasis. This represents a fundamental problem for around half of the 500,000 men diagnosed with prostate cancer in Europe and North America each year. Additionally, the data should provide insights into disease mechanism and identify possible new treatment paradigms.

Professor Cooper remains involved in Strategic Developments at UEA including facilitating translational research between the University and the Norwich Hospital where 5,000 patients are diagnosed with cancer each

**TRUSTEES' REPORT (CONTINUED)  
FOR THE YEAR ENDED 30 JUNE 2022**

---

year including 750 patients with prostate cancer and 10-20 with testicular cancer. These themes form the basis of three projects currently funded by the Trust at UEA/Bob Champion Research and Education Building.

Following the success of the Trust's five year grant at the Institute of Cancer Research, led by Professor Ros Eeles, on early on-set prostate cancer – diagnosed at 60 years or less - the Trustees have approved a further three year grant for the UKGPCS collection of germline DNA and data. The aim of this project is to analyse whole exome sequence from a unique and large collection of prostate cancer cases: 20,000 germline DNA samples from the UKGPCS in order to identify rare variants and their contribution to the risk of developing prostate cancer with specific phenotypes and potentially predict response to various treatments.

The UKGPCS was established in 1992, recruiting men from The Royal Marsden NHS Foundation Trust and Collaborative Centres (NHS Trust hospitals) throughout the UK and Northern Ireland, over 180 of which are from the National Cancer Research Network (NCRN).

The UKGPCS have collected a rich phenotype dataset for most of these samples: date of birth, diagnosis, and death if applicable; mode of detection; TNM Stage; Gleason score; primary treatment; vital status; geographic region based on referring hospital, or treatment hospital if information on the referring hospital was not available; self-reported BMI; self-reported ethnicity; and PSA at diagnosis for all patients, as well as for relatives, if available. The Information on risk factors for prostate cancer, demographic characteristics, and clinical data are also collected routinely as part of medical care and clinical follow-up. Over 78% of the cohort has clinical data on treatment and outcomes are being followed up at 2, 5 and 10 years post diagnosis; this collection is still in process.

For sequencing of whole exomes in germline samples a high-throughput automated approach will be used to prepare high-quality genomic DNA for exome capture. The exome will be captured and sequenced on the latest technology in use at the Regeneron Genetics Centre.

### **Publications**

1. Microbiomes of Urine and the Prostate Are Linked to Human Prostate Cancer Risk Groups. Hurst R, Meader E, Gihawi A, Rallapalli G, Clark J, Kay GL, Webb M, Manley K, Curley H, Walker H, Kumar R, Schmidt K, Crossman L, Eeles RA, Wedge DC, Lynch AG, Massie CE; CRUK-ICGC Prostate Group, Yazbek-Hanna M, Rochester M, Mills RD, Mithen RF, Traka MH, Ball RY, O'Grady J, Brewer DS, Wain J, Cooper CS. *Eur Urol Oncol.* 2022 Apr 18:S2588-9311(22)00056-6. doi: 10.1016/j.euo.2022.03.006. Online ahead of print. PMID: 35450835

2. Development of a multivariable risk model integrating urinary cell DNA methylation and cell-free RNA data for the detection of significant prostate cancer. Connell SP, O'Reilly E, Tuzova A, Webb M, Hurst R, Mills R, Zhao F, Bapat B, Cooper CS, Perry AS, Clark J, Brewer DS. *Prostate.* 2020 ;80(7):547-558. doi: 10.1002/pros.23968. PMID: 32153047

3. Integration of Urinary EN2 Protein & Cell-Free RNA Data in the Development of a Multivariable Risk Model for the Detection of Prostate Cancer Prior to Biopsy Shea P, Connell, Robert Mills, Hardev Pandha, Richard Morgan, Colin S. Cooper, Jeremy Clark, Daniel S. Brewer, The Movember GAP1 Urine Biomarker Consortium. *Cancers (Basel)* 2021; 13: 2102. doi: 10.3390/cancers13092102 PMID: 8123800

4. The Urine Biomarker PUR-4 Is Positively Associated with the Amount of Gleason 4 in Human Prostate Cancers. Richard Y. Ball, Ryan Cardenas, Mark S. Winterbone, Marcelino Y. Hanna, Chris Parker, Rachel Hurst, Daniel S. Brewer, Lauren D'Sa, Rob Mills, Colin S. Cooper, Jeremy Clark. *Life (Basel)* 2021; 11: 1172 doi: 10.3390/life11111172, PMCID: 8622091

5. Estimates of Alpha/Beta Ratios for Individual Late Rectal Toxicity Endpoints: An Analysis of the CHHiP Trial. Brand DH, Brüningk SC, Wilkins A, Fernandez K, Naismith O, Gao A, Syndikus I, Dearnaley DP, Tree AC, van As N, Hall E, Gulliford S; CHHiP Trial Management Group. *Int J Radiat Oncol Biol Phys.* 2021 Jun 1;110(2):596-608

**TRUSTEES' REPORT (CONTINUED)  
FOR THE YEAR ENDED 30 JUNE 2022**

---

The Trust is in the first year of a three year grant for Annie Gao, a Senior Radiotherapy Clinical Trials Co-ordinator at the Bob Champion Unit, Royal Marsden Hospital, Sutton. The Unit has supported and lead the PACE trials which looks to use stereotactic body radiotherapy to deliver to the patient the prostate cancer treatment in 5 visits over 1-2 weeks. This pioneering treatment can target the cancer with pinpoint accuracy. This means a reduction in healthy tissue damage and enables men to complete and recover from treatment much faster than ever before. Initial results from the PACE-B trial have been published, showing that there were low rates of side effects after 2 years and suggesting that curative treatment can be given over a much-shortened period. This has positive implications for the patients experience of cancer treatment and subsequent quality of life.

Critical to the success of all these studies is the long-term follow-up of men after their initial radiotherapy treatment. Confidence that a patient is truly cured takes 10 years in men with localised prostate cancer as side effects can continue to develop over many years, a full estimation of the risks and benefits of a new treatment requires years of careful data collection.

A Gao focusses particularly on the long-term follow-up of patients. This enables for ICR to continue to monitor men for signs of cancer recurrence and side effects for long enough to be sure that the innovative radiotherapy treatment being tested is advantageous. The Unit continues to publish results in the highest calibre journals and publications.

**Key trials in long term follow-up**

- The IMRT (Intensity-Modulated Radiotherapy) trial (495 patients) looked at targeting the prostate cancer more accurately, which in turn allowed for a larger dose of radiotherapy to be given. There were 5 groups of patients, each receiving slightly different doses of radiotherapy. The continued review of this comprehensive dataset enables us to learn more about which patients are likely to be cured with standard treatments and which require further escalation of therapy. Blood and biopsy translational work from this trial also sheds new light on the evolutionary genetics of prostate cancer.
- The CHHiP trial (398 patients recruited at RMH out of 3,200 in multi-centre trial) follows patients for up to 15 years after their treatment and is enabling us to know with greater certainty that shorter treatments are better for men with localised prostate cancer. The trial introduced prostate IMRT in the UK. This ongoing data collection has enabled the review of over 2000 prostate cancer samples to further investigate the effects of radiotherapy dose on prostate cancer in the laboratory.
- The DELINEATE trial (316 patients), looks at new ways of planning and giving radiotherapy for localised prostate cancer. New types of scanning techniques have allowed us to differentiate between the cancer and normal prostate tissue with greater certainty. The aim is to target the cancerous area with increased accuracy and a higher dose without risking damage to the normal prostate tissue. The Trust has directly impacted this trial by allowing it to extend the patient follow-up period from 5 to 10 years. This data collection is critical as the cure rates have so far been unprecedented with up to 96.7 % of patients being free of any prostate cancer at the 5-year follow-up timepoint. Further follow-up of these patients is necessary to ensure these excellent results are maintained at 10 years.
- The PACE-C trial compares stereotactic body radiotherapy (5 visits – SBRT uses precise daily image guidance to give remarkably accurate radiotherapy) with the now conventional IMRT (20 visits – see IMRT trials above). Since the application last year, recruitment to this trial has exceeded expectations and the trial closed early having already met its target of 1182 patients. These men are now in long-term follow-up, assessing side effects, patient quality of life and long-term cancer control.

**Financial Review**

The net outgoing resources for the year were £101,310 (2021: *net incoming of £119,556*) which include a surplus on fundraising events of £184,284 (2021: *£105,388*) and dividends received of £46,531 (2021: *£45,336*). In addition, unrealised losses on investments were £87,321 (2021: *unrealised gains of £215,043*).

The Trustees are satisfied that the charity's funds are available and adequate to fulfil its obligations in relation to their commitments.

---

**BOB CHAMPION CANCER TRUST**

---

**TRUSTEES' REPORT (CONTINUED)  
FOR THE YEAR ENDED 30 JUNE 2022**

---

The Declaration of Trust, signed on the 29th June 1993, states that “any money available for investment may be so invested in the names of the Trustees or their nominees in any way whatsoever, whether or not producing income, as the Trustees shall in their absolute discretion think fit, as if they were absolutely entitled to the Trust Fund beneficially.”

It is the policy of the charity to hold reserves in its General Fund that have not yet been committed or designated for any particular purpose. The Trustees have set aside these reserves in order to protect the future operations of the charity from the effects of any unforeseen variations in its income streams as part of a policy of good financial management practice.

**Plans for the Future**

The Trustees continue to work towards the aims of the deed of declaration of Trust to find a cure for urological cancers, particularly prostate cancer, through scientific and clinical research at The Institute of Cancer Research and The Norwich Medical Research Park at UEA. To establish a clinical test to detect prostate cancer cells remains at the forefront of the Trusts current plans.

The funding for the work of the Trust will continue to be raised from a full fundraising calendar run by the Executive Officer of the Charity, donations and legacies and the interest from the investment funds if required.


11 April 2023

Approved by order of the members of the board of Trustees on

and signed on their behalf by:



**Michael Cattermole**  
Trustee



**Timothy Fox**  
Trustee

---

**BOB CHAMPION CANCER TRUST**

---

**STATEMENT OF TRUSTEES' RESPONSIBILITIES  
FOR THE YEAR ENDED 30 JUNE 2022**

---

The Trustees are responsible for preparing the Trustees' report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

The law applicable to charities in England & Wales requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of its incoming resources and application of resources, including its income and expenditure, for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles of the Charities SORP (FRS 102);
- make judgments and accounting estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards (FRS 102) have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in business.

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the charity's transactions and disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Charities Act 2011, the Charity (Accounts and Reports) Regulations 2008 and the provisions of the Trust deed. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as the trustees are aware:

- there is no relevant information of which the charity's independent examiner is unaware; and
- the trustees have taken all steps that they ought to have taken to make themselves

Approved by order of the members of the board of Trustees on  
and signed on its behalf by: 11 April 2023

*Mike Cattermole*

**Michael Cattermole**  
Trustee

*Tim Fox*

**Timothy Fox**  
Trustee

---

## BOB CHAMPION CANCER TRUST

---

### INDEPENDENT EXAMINER'S REPORT FOR THE YEAR ENDED 30 JUNE 2022

---

#### Independent Examiner's Report to the Trustees of Bob Champion Cancer Trust ('the charity')

We report to the charity Trustees on our examination of the accounts of the charity for the year ended 30 June 2022.

This report is made solely to the charity's Trustees, as a body, in accordance with section 145 of the Charities Act 2011 and regulations made under section 154 of that Act. Our work has been undertaken so that we might state to the charity's Trustees those matters we are required to state to them in an independent examiner's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charity and the charity's Trustees, as a body, for our work or for this report.

#### Responsibilities and Basis of Report

As the Trustees of the charity you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ('the 2011 Act').

We report in respect of our examination of the charity's accounts carried out under section 145 of the 2011 Act and in carrying out our examination we have followed the applicable Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

#### Independent Examiner's Statement

Since the charity's gross income exceeded £250,000 your examiner must be a member of a body listed in section 145 of the 2011 Act. We confirm that we are qualified to undertake the examination because we are a member of ICAEW, which is one of the listed bodies.

We have completed our examination. We confirm that no matters have come to our attention in connection with the examination giving us cause to believe that in any material respect:

1. accounting records were not kept in respect of the charity as required by section 130 of the 2011 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination.

We have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

*Stuart Hinds*

Signed:

Dated: 16 April 2023

Stuart Hinds

ACA

**BOB CHAMPION CANCER TRUST**

**STATEMENT OF FINANCIAL ACTIVITIES  
FOR THE YEAR ENDED 30 JUNE 2022**

	Note	Unrestricted funds 2022 £	Total funds 2022 £	Total funds 2021 £
<b>Income from:</b>				
Donations and legacies	2	12,001	12,001	39,148
Charitable activities	3	279,015	279,015	155,918
Investments	4	46,535	46,535	45,337
Other income	5	-	-	6,444
<b>Total income</b>		<b>337,551</b>	<b>337,551</b>	<b>246,847</b>
<b>Expenditure on:</b>				
Raising funds		94,731	94,731	50,530
Charitable activities:				
Grants payable	6	172,249	172,249	187,222
Support costs	7	71,240	71,240	91,459
Governance	7	13,320	13,320	13,123
<b>Total expenditure</b>		<b>351,540</b>	<b>351,540</b>	<b>342,334</b>
<b>Net expenditure before net (losses)/gains on investments</b>				
		<b>(13,989)</b>	<b>(13,989)</b>	<b>(95,487)</b>
Net (losses)/gains on investments	10	(87,321)	(87,321)	215,043
<b>Net movement in funds</b>		<b>(101,310)</b>	<b>(101,310)</b>	<b>119,556</b>
<b>Reconciliation of funds:</b>				
Total funds brought forward		1,675,021	1,675,021	1,555,465
Net movement in funds		(101,310)	(101,310)	119,556
<b>Total funds carried forward</b>		<b>1,573,711</b>	<b>1,573,711</b>	<b>1,675,021</b>

The Statement of Financial Activities includes all gains and losses recognised in the year.

The notes on pages 12 to 22 form part of these financial statements.

**BOB CHAMPION CANCER TRUST**

**BALANCE SHEET  
AS AT 30 JUNE 2022**

	Note	2022 £	2021 £
<b>Fixed assets</b>			
Tangible assets	9	1,839	2,452
Investments	10	1,576,471	1,663,792
		<u>1,578,310</u>	<u>1,666,244</u>
<b>Current assets</b>			
Debtors	11	274	1,328
Cash at bank and in hand		60,553	75,742
		<u>60,827</u>	<u>77,070</u>
Creditors: amounts falling due within one year	12	(65,426)	(68,293)
<b>Net current assets</b>		<u>1,573,711</u>	<u>1,675,021</u>
<b>Total assets less current liabilities</b>		<u>1,573,711</u>	<u>1,675,021</u>
<b>Total net assets</b>		<u><u>1,573,711</u></u>	<u><u>1,675,021</u></u>
<b>Charity funds</b>			
Restricted funds		-	-
Unrestricted funds		1,573,711	1,675,021
<b>Total funds</b>		<u><u>1,573,711</u></u>	<u><u>1,675,021</u></u>

The financial statements were approved and authorised for issue by the Trustees on \_\_\_\_\_ and signed on their behalf by: 11 April 2023

*Mike Cattermole*

**Michael Cattermole**  
Trustee

*TIM FOX*

**Timothy Fox**  
Trustee

The notes on pages 12 to 22 form part of these financial statements.

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 30 JUNE 2022**

---

**1. Accounting policies**

**1.1 Basis of preparation of financial statements**

The financial statements have been prepared in accordance with the Charities SORP (FRS 102) - Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Charities Act 2011.

The financial statements have been prepared to give a 'true and fair' view and have departed from the Charities (Accounts and Reports) Regulations 2008 only to the extent required to provide a 'true and fair' view. This departure has involved following the Charities SORP (FRS 102) published in October 2019 rather than the Accounting and Reporting by Charities: Statement of Recommended Practice effective from 1 April 2005 which has since been withdrawn.

Bob Champion Cancer Trust meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

The charity has taken advantage of the exemption available to smaller charities from preparing a cash flow statement.

**1.2 Fund accounting**

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the charity and which have not been designated for other purposes.

**1.3 Income**

All income is recognised once the charity has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably.

Donated services or facilities are recognised when the charity has control over the item, any conditions associated with the donated item have been met, the receipt of economic benefit from the use of the charity of the item is probable and that economic benefit can be measured reliably. In accordance with the Charities SORP (FRS 102), the general volunteer time of the Friends is not recognised and refer to the Trustees' report for more information about their contribution.

On receipt, donated professional services and facilities are recognised on the basis of the value of the gift to the charity which is the amount it would have been willing to pay to obtain services or facilities of equivalent economic benefit on the open market; a corresponding amount is then recognised in expenditure in the period of receipt.

Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Income tax recoverable in relation to investment income is recognised at the time the investment income is receivable.

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 30 JUNE 2022**

---

**1. Accounting policies (continued)**

**1.4 Expenditure**

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset's use.

Fundraising costs are those incurred in seeking voluntary contributions and do not include the costs of disseminating information in support of the charitable activities. Support costs are those costs incurred directly in support of expenditure on the objects of the charity and include project management carried out at Headquarters. Governance costs are those incurred in connection with administration of the charity and compliance with constitutional and statutory requirements.

Costs of generating funds are costs incurred in attracting voluntary income, and those incurred in charitable activities that raise funds.

Charitable activities and Governance costs are costs incurred on the charity's operations, including support costs and costs relating to the governance of the charity apportioned to charitable activities.

Grants payable are charged in the year when the offer is made except in those cases where the offer is conditional, such grants being recognised as expenditure when the conditions attaching are fulfilled. Grants offered subject to conditions which have not been met at the Year end are noted as a commitment, but not accrued as expenditure.

**1.5 Going concern**

The Trustees consider that there are no material uncertainties about the Trust's ability to continue as a going concern for a period of at least twelve months after the date of signature of these accounts.

**1.6 Government grants**

Government grants are accounted for under the accruals model as permitted by the Charities SORP. In the prior year the Charity has received governmental support through the Coronavirus Job Retention Scheme. The government grants received in the year are of a revenue nature and are recognised in the Statement of Financial Activities in the same period as the related expenditure..

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 30 JUNE 2022**

---

**1. Accounting policies (continued)**

**1.7 Tangible fixed assets and depreciation**

Tangible fixed assets are initially recognised at cost. After recognition, under the cost model, tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. All costs incurred to bring a tangible fixed asset into its intended working condition should be included in the measurement of cost.

Depreciation is charged so as to allocate the cost of tangible fixed assets less their residual value over their estimated useful lives.

Depreciation is provided on the following basis:

Computer equipment	- 25% reducing balance
--------------------	------------------------

**1.8 Investments**

Fixed asset investments are a form of financial instrument and are initially recognised at their transaction cost and subsequently measured at fair value at the Balance sheet date, unless the value cannot be measured reliably in which case it is measured at cost less impairment. Investment gains and losses, whether realised or unrealised, are combined and presented as 'Gains/(Losses) on investments' in the Statement of financial activities.

**1.9 Interest receivable**

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the charity; this is normally upon notification of the interest paid or payable by the institution with whom the funds are deposited.

**1.10 Debtors**

Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

**1.11 Cash at bank and in hand**

Cash at bank and in hand includes cash and short-term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

**1.12 Liabilities and provisions**

Liabilities are recognised when there is an obligation at the balance sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably. Liabilities are recognised at the amount that the charity anticipates it will pay to settle the debt or the amount it has received as advanced payments for the goods or services it must provide. Provisions are measured at the best estimate of the amounts required to settle the obligation. Where the effect of the time value of money is material, the provision is based on the present value of those amounts, discounted at the pre-tax discount rate that reflects the risks specific to the liability. The unwinding of the discount is recognised within interest payable and similar charges.

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 30 JUNE 2022**

**1. Accounting policies (continued)**

**1.13 Financial instruments**

The charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

**1.14 Pensions**

The charity operates a defined contribution pension scheme and the pension charge represents the amounts payable by the charity to the fund in respect of the year.

**1.15 Critical accounting estimates and areas of judgement**

Estimates and judgments are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

The Trustees have not applied any significant estimates or judgments in the preparation of these financial statements.

**1.16 Basis of non-conclusion**

In the opinion of the Trustees, the charity and its subsidiary undertakings comprise a small group. The subsidiary has been excluded as its inclusion would not be material from the point of view of providing a true and fair view.

**2. Income from donations and legacies**

	<b>Unrestricted funds 2022 £</b>	<b>Total funds 2022 £</b>	<i>Total funds 2021 £</i>
Memorial	4,952	<b>4,952</b>	34,727
Other	7,049	<b>7,049</b>	4,421
<b>Total</b>	<u>12,001</u>	<u><b>12,001</b></u>	<u>39,148</u>

In both the current year and prior year all income from donations and legacies was in relation to unrestricted funds.

**BOB CHAMPION CANCER TRUST**

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 30 JUNE 2022**

**3. Income from charitable activities**

	<b>Unrestricted funds 2022 £</b>	<b>Total funds 2022 £</b>	<i>Total funds 2021 £</i>
General Fundraising	34,162	<b>34,162</b>	20,955
Christmas Season	26,769	<b>26,769</b>	29,282
Carols and Champagne	89,669	<b>89,669</b>	-
Shetland Pony Grand National*	30,483	<b>30,483</b>	-
40for40	14,903	<b>14,903</b>	100,883
Tennis Tournament*	-	-	20
Plumpton Raceday*	83,029	<b>83,029</b>	4,778
	<u>279,015</u>	<u><b>279,015</b></u>	<u>155,918</u>

\*These events were not able to take place during the prior year due to the Covid-19 pandemic.

**4. Investment income**

	<b>Unrestricted funds 2022 £</b>	<b>Total funds 2022 £</b>	<i>Total funds 2021 £</i>
Listed securities	46,531	<b>46,531</b>	45,336
Bank deposits	4	<b>4</b>	1
<b>Total</b>	<u>46,535</u>	<u><b>46,535</b></u>	<u>45,337</u>

In both the current year and prior year all investment income was in relation to unrestricted funds.

**5. Other income**

	<b>Unrestricted funds 2022 £</b>	<b>Total funds 2022 £</b>	<i>Total funds 2021 £</i>
Government grants - furlough income	-	-	6,444
	<u>-</u>	<u>-</u>	<u>6,444</u>

**BOB CHAMPION CANCER TRUST**

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 30 JUNE 2022**

**6. Research grants**

	<b>Grants to Institutions 2022 £</b>	<b>Total funds 2022 £</b>	<i>Total funds 2021 £</i>
Professor Rosalind Eeles grant - Institute of Cancer Research (ICR)	94,169	<b>94,169</b>	92,710
Bob Champion Cancer Trust Post Doctoral fellowship grant - ICR and UCL	-	-	55,125
Professor Colin Cooper grant - UEA	46,537	<b>46,537</b>	39,387
Clinician Annie Gao	31,543	<b>31,543</b>	-
<b>Total</b>	<u>172,249</u>	<u><b>172,249</b></u>	<u>187,222</u>

Professor Ros Eeles, Prostate Cancer Sequencing Project at the ICR, commenced in August 2019 at cost of £282,509 over the three year grant period. Due to Covid-19, this grant was put on hold in 2020 as the ICR focused efforts on research of the virus. However, the grant resumed in the prior year.

Dr Marianna Buongermino was appointed in November 2017 for three years at a cost of £188,000 to hold the position of the Bob Champion Post - doctoral fellowship within Dr Gert Attard's team at the ICR. Dr Gert Attard is Affiliate Team Leader for the Centre for Evolution and Cancer at the ICR and Team Leader of Treatment Resistance Research Group at UCL. In 2020, due to Covid-19, this grant was put on hold as the ICR has focused efforts on research of the virus. However, the grant resumed during the prior year.

Professor Colin Cooper, The Role of Bacterial Infection in the Development of Human Prostate Cancer grant for Rachel Hurst was awarded in January 2020 for two years at a cost of £80,000. Professor Cooper is Professor of Cancer Genetics and Associate Dean of Research at UEA. This grant was due to end in December 2021 and, in November 2021, this grant was extended. The BCCT will continue to fund the project with Rachel Hurst with funds being taken up to, but no later, than 31st December 2024. It has been agreed that BCCT will pay 75% of the total grant, approximately £50,000 per annum.

In June 2021, a grant extension was offered to support Dan Brewer within Professor Colin Cooper's team on the DESNT project. The grant covers the project for one year at £30,000, with a deadline of completion of December 2023.

Furthermore, in July 2021 a grant was offered to Annie Gao within the Bob Champion Unit, Royal Marsden Hospital. The agreed funding for £42,000 per year is for 3 years (including standard on-costs) commencing from 1st September 2021.

The Trustees are satisfied that the charity will have sufficient resources to fulfil future research grant commitments. The charity has a strong balance sheet position, which includes listed investments of £1,576,469 that can be turned into cash as required.

**BOB CHAMPION CANCER TRUST**

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 30 JUNE 2022**

**7. Support and governance costs**

	<b>Grant funding of activities 2022 £</b>	<b>Support costs 2022 £</b>	<b>Total funds 2022 £</b>	<i>Total funds 2021 £</i>
Premises costs	-	10,046	<b>10,046</b>	13,453
Other costs	-	7,407	<b>7,407</b>	15,077
Personnel costs	-	53,787	<b>53,787</b>	62,929
Governance costs	-	13,320	<b>13,320</b>	13,123
Professor Rosalind Eeles grant - Institute of Cancer Research	94,169	-	<b>94,169</b>	92,710
Dr. Gert Attard grant - ICR and UCL	-	-	-	55,125
Professor Colin Cooper grant - UEA	46,537	-	<b>46,537</b>	39,387
Clinician Annie Gao	31,543	-	<b>31,543</b>	-
<b>Total</b>	<u>172,249</u>	<u>84,560</u>	<u><b>256,809</b></u>	<u>291,804</u>

**8. Staff costs**

	<b>2022 £</b>	<i>2021 £</i>
Wages and salaries	<b>50,520</b>	58,920
Social security costs	<b>1,751</b>	2,241
Contribution to defined contribution pension schemes	<b>1,516</b>	1,768
	<u><b>53,787</b></u>	<u>62,929</u>

The average number of persons employed by the charity during the year was as follows:

	<b>2022 No.</b>	<i>2021 No.</i>
Employees	<u><b>1</b></u>	<u>2</u>

No employee received remuneration amounting to more than £60,000 in either year.

The total employment benefits of key management personnel were £50,520 (2021 - £50,250).

---

**BOB CHAMPION CANCER TRUST**

---

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 30 JUNE 2022**

---

**9. Tangible fixed assets**

	<b>Computer equipment £</b>
<b>Cost or valuation</b>	
At 1 July 2021	6,782
At 30 June 2022	<u>6,782</u>
<b>Depreciation</b>	
At 1 July 2021	4,330
Charge for the Year	613
At 30 June 2022	<u>4,943</u>
<b>Net book value</b>	
At 30 June 2022	<u><u>1,839</u></u>
<i>At 30 June 2021</i>	<u><u>2,452</u></u>

**BOB CHAMPION CANCER TRUST**

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 30 JUNE 2022**

**10. Fixed asset investments**

	Investments in subsidiary companies £	Listed investments £	Total £
<b>Cost or valuation</b>			
At 1 July 2021	2	1,663,790	1,663,792
Revaluations	-	(87,321)	(87,321)
At 30 June 2022	2	1,576,469	1,576,471
<b>Net book value</b>			
At 30 June 2022	2	1,576,469	1,576,471
At 30 June 2021	2	1,663,790	1,663,792

**Subsidiary undertakings**

The following was a subsidiary undertaking of the charity:

<b>Name</b>	<b>Holding</b>
Aldaniti Trading Company Limited	100%

The financial results of the subsidiary for the year were:

<b>Name</b>	<b>Aggregate of share capital and reserves £</b>
Aldaniti Trading Company Limited	2

At 30 June 2022, CCLA Fund Managers Limited, an investment management company external to the charity, valued the investments held by the charity at £1,576,469 (2021 - £1,663,790). This valuation was made on the basis of the value of the units on the open market in which they are traded. The loss is included in the statement of financial activities.

Aldaniti Trading Company Limited, a company incorporated in England and Wales, ceased trading on 30 June 2004 and has not traded since. On this date its trade and assets were transferred to the charity.

**BOB CHAMPION CANCER TRUST**

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 30 JUNE 2022**

**11. Debtors**

	<b>2022</b>	<b>2021</b>
	£	£
<b>Due within one year</b>		
Other debtors	-	10
Prepayments and accrued income	274	1,318
	<b>274</b>	<b>1,328</b>
	<b>274</b>	<b>1,328</b>

**12. Creditors: Amounts falling due within one year**

	<b>2022</b>	<b>2021</b>
	£	£
Creditors	1,100	1,419
Creditors - ICR and UEA grants	34,057	37,324
Amounts owed to group undertakings	2	2
Other taxation and social security	1,091	9
Other creditors	249	355
Accruals and deferred income	15,966	19,314
Accruals - UEA grants	12,961	9,870
	<b>65,426</b>	<b>68,293</b>
	<b>65,426</b>	<b>68,293</b>

**13. Financial instruments**

	<b>2022</b>	<b>2021</b>
	£	£
<b>Financial assets</b>		
Fixed asset investments	1,576,469	1,663,790
	<b>1,576,469</b>	<b>1,663,790</b>
	<b>1,576,469</b>	<b>1,663,790</b>

Financial assets measured at fair value through income and expenditure comprise fixed asset investments. Fair value has been determined on the basis of the value of the investment units on the open market in which they are traded.

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 30 JUNE 2022**

---

**14. Pension commitments**

The charity operates a defined contributions pension scheme. The assets of the scheme are held separately from those of the charity in an independently administered fund. The pension cost charge represents contributions payable by the charity to the fund and amounted to £1,516 (2021 - £1,768). Contributions totalling £233 (2021 - £233) were payable to the fund at the balance sheet date and are included in creditors.

**15. Related party transactions**

During the year, the charity paid £27,612 (2021 - £25,680) to the president of the charity, Mr. Bob Champion, in relation to fees and expenses incurred in fulfilling his duties. The amount outstanding at the year end was £6,200 (2021 - £6,200). Bob Champion's retainer has been approved by the Charity Commission.

**BOB CHAMPION CANCER TRUST**

England & Wales - Charity number 1024664

---

# Accounts

---

---

**BOB CHAMPION CANCER TRUST**

---

**UNAUDITED**

**TRUSTEES' REPORT AND FINANCIAL STATEMENTS**

**FOR THE YEAR ENDED 30 JUNE 2021**

---

**BOB CHAMPION CANCER TRUST**

---

**CONTENTS**

---

	Page
<b>Reference and administrative details of the charity, its trustees and advisers</b>	1 - 2
<b>Trustees' report</b>	3 - 7
<b>Independent examiner's report</b>	8
<b>Statement of financial activities</b>	9
<b>Balance sheet</b>	10
<b>Notes to the financial statements</b>	11 - 22

---

**BOB CHAMPION CANCER TRUST**

---

**REFERENCE AND ADMINISTRATIVE DETAILS OF THE CHARITY, ITS TRUSTEES AND ADVISERS  
FOR THE YEAR ENDED 30 JUNE 2021**

---

**FOUNDER**

Professor Sir Michael Peckham MD FRCP FRCR (deceased October 2021)

**PRESIDENT**

Bob Champion, C.B.E.

**MEDICAL ADVISOR**

Professor David Dearnaley

**VICE PRESIDENTS**

Clare Balding, O.B.E.

Willie Carson, O.B.E.

Kristina Cook

David Gower, M.B.E.

Chris Hughes (appointed April 2021)

Jonjo O'Neill

Greg Rusedski, Esq

Peter Shilton, O.B.E.

Nick Skelton, C.B.E.

**TRUSTEES**

Michael I Cattermole, Esq. (Chairman)

Susie Burrage (appointed July 2021)

Alex Embiricos

Timothy Fox, Esq.

Andrew Franklin, Esq.

Catherine McAleavey

Catherine Nash

Luke Ponsonby, Esq.

Bridget Rosser

Carolyn Jane Zetter Wells

**TRUST OFFICERS**

Mrs Lucienne Wilkinson

---

**BOB CHAMPION CANCER TRUST**

---

**REFERENCE AND ADMINISTRATIVE DETAILS OF THE CHARITY, ITS TRUSTEES AND ADVISERS  
(CONTINUED)  
FOR THE YEAR ENDED 30 JUNE 2021**

---

**Charity registered number**

1024664

**Principal office**

Unit D Molasses House  
Clove Hitch Quay  
Plantation Wharf  
London  
SW11 3TN

**Secretary**

Mrs. Lucienne Wilkinson

**Chief executive officer**

Mrs. Lucienne Wilkinson

**Accountants**

Ecovis Wingrave Yeats UK Limited  
Waverley House  
7-12 Noel Street  
London  
W1F 8GQ

---

## BOB CHAMPION CANCER TRUST

---

### TRUSTEES' REPORT FOR THE YEAR ENDED 30 JUNE 2021

---

The Trustees present their report and the accounts for the year ended 30th June 2021.

#### **Administrative Details**

A Declaration of Trust formed the Charity on 29 June 1993 registered number 1024664. The purpose of the establishment of this charitable trust was to take over and enlarge the work of the Bob Champion Cancer Trust that was set up by a Declaration of Trust dated 20 January 1983.

The number of Trustees shall not be less than three or more than ten. The power of appointing new Trustees is vested in the Trustees and may be exercised by a resolution in writing signed by all of the current Trustees and the new Trustee. The Trustees meet four times per calendar year, either in person or via zoom, dependant on Covid 19 restrictions.

Please see page 1 for Trustee details, legal and other administrative detail.

#### **Structure, governance and management**

The Trust was set up to support research into the causation, nature and treatment of patients with testicular cancer and other forms of malignant disease including those of the prostate.

The Trustees acknowledge their responsibility for ensuring that the major risks to which the Charity is exposed are identified and systems designed to mitigate those risks. During the year the Trustees completed a formal risk management process to assess business risks and risk management strategies.

The Trust has an independent Medical Advisor, Professor David Dearnaley, to advise the board in their selection of grant awards and allow the Charity to operate in open competition with peer review.

#### **Objectives and activities**

The Bob Champion Cancer Trust currently supports cancer research within the Institute of Cancer Research, The Royal Marsden Hospital in Sutton, Surrey and the Bob Champion Research and Education Building, situated in the Norwich Research Park at the University of East Anglia. The focus of this support is on urological cancers, especially those of the prostate and testis.

The Trust opened in collaboration with the Institute of Cancer Research the Bob Champion Research Centre in 2000, which forms part of the first male dedicated cancer research centre, in Europe. This centre is based at The Institute of Cancer Research in Sutton, Surrey.

In February 2015 the Trust with The University of East Anglia (UEA) opened The Bob Champion Research and Education Building at The Norwich Research Park, this facility is operated by the UEA in partnership with the Norfolk & Norwich Hospital. This centre provides state-of-the-art laboratories for researchers to explore new treatments not only for prostate cancer research but for diseases from antibiotic resistance to musculo-skeletal and gastrointestinal diseases.

The Trust is self-supporting and relies totally upon donations from the public that may be in the form of a legacy or donations with the benefit of claiming Gift Aid if applicable. Income is raised from active social media campaigns and appeals plus a full fundraising calendar, although the Covid -19 pandemic continued to have a restrictive effect on the ability to hold in person events. The fundraising team adapted as many events/appeals as possible to online but this presented another set of issues involving existing software and IT restrictions. The calendar has historically been made up of events ranging from cake stalls, coffee mornings and race nights to personal challenges, such as the London Marathon, and Gala Dinners. As many events as possible did take place, working within the government regulations, with the Trust mindful of protecting their supporters, participants, staff and volunteers. This was successfully achieved in relation to the adapted plans set in place to celebrate the 40th Anniversary of Bob Champion and Aldaniti's triumphant win at Aintree in the 1981 Grand National – Bob's 40FOR40 Anniversary Walk.

---

## BOB CHAMPION CANCER TRUST

---

### TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 30 JUNE 2021

---

#### Objectives and activities (continued)

The 40FOR40 event saw Bob Champion embark on a sponsored 191 mile walk. 191 miles representing the 191 days of gruelling cancer treatment he underwent from his diagnosis on 24th July 1979 to receiving the 'all clear' 31st January 1980. The distance was covered by 40 smaller walks at memorable stops on route to Findon, Aldaniti's training home, in Sussex. All 40 stops, starting with the iconic Aintree Racecourse and finishing at Findon, were connected to Bob's remarkable life story with each stop representing a year from 1981 to 2021. Members of the public were encouraged to sponsor him and towards the end of the five week journey, as Covid 19 regulations began to lift, members of the public could gain sponsorship to actually join on the day and walk with him. The majority of the 40 memorable stops took place at racehorse training yards that Bob had enjoyed connections to in his career and the mileage for that day (day's length ranged from 7 -14 miles) taken on the gallops and surrounding countryside. Other stops visited included the Royal Marsden Hospital and Institute of Cancer Research in Surrey, the site of the first research centre funded by the Trust, and Aldaniti's grave in Kirdford, Sussex.

The Trust is also involved every year with the Shetland Pony Grand National. The Shetland Pony Grand National is a major part of the London International Horseshow, races are held twice daily during the five days of the show with the grand finale on the final day. Sadly, due to the pandemic, the 2020 show at Olympia was cancelled and the show was moved to Excel in December 2021. Bob Champion is heavily involved during the year, helping the children qualify for the Show, and attends every day during the Show in December. The young jockeys (aged between 9-14 years) once they qualify for the show commit to raise sponsorship for the Trust.

A biennial Carol Concert, Carols and Champagne, is held at Chelsea Old Church in London. Due to the pandemic the 2020 concert was postponed to December 2021. A charity raceday is held annually at Plumpton Racecourse but, sadly, due to Covid -19 this was cancelled as racing was only allowed behind closed doors at that time. An online auction was held in replacement of the day with the event held again person with restricted numbers in October 2021.

Bob Champion took part in an ITV production to raise awareness of male cancers 'The Real Full Monty' which aired in December 2020 and was a huge success and managed to raise donations and increase the Trust's social media profile.

The Trust has produced, since 1988, its own, especially commissioned, double sided Christmas card. The card not only raises funds but spreads awareness of the cause and the work of the Trust. The artist/s is selected each year and kindly donates their time, or only charges for material costs, and skill in support of the Trust.

Bob Champion was awarded a CBE in The Queen's New Year Honours for his charitable works. He attends many of the events himself and continues to play an integral part in raising funds, and awareness, not only of the Charity's aims, but also of the disease itself. All events are organised from the office, often with the help of a specific event committee made up from a wide league of friends, volunteers and keen supporters. The Trust is always open to new fundraising ideas and how to help cancer sufferers, their family and friends.

**TRUSTEES' REPORT (CONTINUED)  
FOR THE YEAR ENDED 30 JUNE 2021**

---

**Achievements and performance**

Each year in the UK of the 48,000 men, who will be diagnosed with prostate cancer, more than 11,000 can expect to die from their disease. Significant improvements, therefore, also need to be made in the treatment of this disease.

For many cancers the fundamental mechanism of cancer development has been unravelled. Such studies reveal that the disease develops because of alterations or mutations within 'cancer genes'. Although cancer genes responsible for the development of, for example, colon cancer and breast cancer are well characterised, relatively little is known about the fundamental development of prostate cancer. This is bad news for sufferers of prostate cancer because cancer genes, once found, can be used to aid treatment and act as targets for new drugs.

A particular problem is the highly variable natural history of prostate cancer causes significant problems in its clinical management. Over-treatment of prostate cancers is a particular concern leading to impotence in a high proportion of cases. This is especially true for PSA screen-detected cancers that are mostly biologically irrelevant and in the absence of treatment would never become life threatening. Conversely, more conservative approaches to disease detection and management may leave potentially aggressive cancers untreated.

Following the recent discovery by the Bob Champion Cancer Trust identifying a new class of prostate cancer, we know that the patients with this new class, named DESNT cancer, sadly have a very poor outcome. Following that breakthrough the Trust is continuing to fund a project aimed at identifying improved clinical markers (biomarkers) which allow radical therapies such as surgery and radiotherapy to be targeted to men with significant cancers, so that the remainder, with biologically unimportant disease, are spared the side-effects of treatment. This project focuses on the use of urine exosomes (small fat covered vesicles given off by cancer cells) to monitor the cancer gene expression. This work forms part of a Global Urine Biomarker initiative, run by Professor Colin Cooper and involving Centres in Canada, USA, UK and Europe, aimed at identifying biomarkers of aggressive prostate cancer.

Professor Cooper, Chair of Cancer Genetics at the University of East Anglia, Associate Dean of Research in the Faculty of Medical Health runs the ICGC Prostate Cancer Project aimed at collecting whole genome DNA sequence from 250 prostate cancer samples including cancers from Shanghai. This is now being expanded to a global initiative called the PanProstate Cancer Group. Professor Cooper is also running a number of Strategic Developments including facilitating translational research between the University and the Norwich Hospital where 5,000 patients are diagnosed with cancer each year including 750 patients with prostate cancer and 10-20 with testicular cancer. These themes form the basis of three projects currently funded by the Trust at UEA.

At the Institute of Cancer Research the Trust's five year grant support in a cancer sequencing project, headed by Professor Ros Eeles, on early on-set prostate cancer – diagnosed at 60 years or less - has been extended for a further two years. This particular study aims to identify targets for personalised therapy and genetic changes in the DNA in order to offer targeted screening to their relatives who harbour these variants.

The Bob Champion post-doctoral fellowship, within Professor Gert Attard team, is divided between the ICR, computational team in the Centre for Evolution and Cancer (CEC) and the University College London Cancer Institute. The work involves whole genome sequencing data from plasma DNA which allows estimation of the amount of tumour material present in a patient's blood. In addition to analysing data from prostate cancer patients participating in several clinical trials, in collaboration with the Royal Marsden Hospital and ICR Urology Unit, which will be extended to patients with bladder or testicular cancer.

---

## BOB CHAMPION CANCER TRUST

---

### TRUSTEES' REPORT (CONTINUED) FOR THE YEAR ENDED 30 JUNE 2021

---

#### Achievements and performance (continued)

Understandably certain studies were interrupted until early 2021 as scientists and laboratory space was required for Covid-19 research and data analysis.

#### Publications:- No Presentations took place due to Covid - 19

1. Convergence of Prognostic Gene Signatures Suggests Underlying Mechanisms of Human Prostate Cancer Progression. Luca BA, Moulton V, Ellis C, Connell SP, Brewer DS, Cooper CS. *Genes (Basel)*. 2020;11:802. doi: 10.3390/genes11070802. PMID: 32708551

2. Development of a multivariable risk model integrating urinary cell DNA methylation and cell-free RNA data for the detection of significant prostate cancer.

Connell SP, O'Reilly E, Tuzova A, Webb M, Hurst R, Mills R, Zhao F, Bapat B, Cooper CS, Perry AS, Clark J, Brewer DS. *Prostate*. 2020 ;80(7):547-558. doi: 10.1002/pros.23968. PMID: 32153047

3. Integration of Urinary EN2 Protein & Cell-Free RNA Data in the Development of a Multivariable Risk Model for the Detection of Prostate Cancer Prior to Biopsy

Shea P, Connell, Robert Mills, Hardev Pandha, Richard Morgan, Colin S. Cooper, Jeremy Clark, Daniel S. Brewer, The Movember GAP1 Urine Biomarker Consortium. *Cancers (Basel)* 2021; 13: 2102. doi: 10.3390/cancers13092102 PMID: 8123800

4. The Urine Biomarker PUR-4 Is Positively Associated with the Amount of Gleason 4 in Human Prostate Cancers. Richard Y. Ball, Ryan Cardenas, Mark S. Winterbone, Marcelino Y. Hanna, Chris Parker, Rachel Hurst, Daniel S. Brewer, Lauren D'Sa, Rob Mills, Colin S. Cooper, Jeremy Clark. *Life (Basel)* 2021; 11: 1172 doi: 10.3390/life11111172, PMID: 8622091

#### Financial review

The net incoming resources for the year were £119,556 (2020: £37,675) which include a surplus on fundraising events of £105,388 (2020: £119,689) and dividends received of £45,336 (2020: £50,960). In addition, unrealised gain on investments was £215,043 (2020: £26,401).

The Trustees are satisfied that the charity's funds are available and adequate to fulfil its obligations in relation to their commitments.

The Declaration of Trust, signed on the 29th June 1993, states that "any money available for investment may be so invested in the names of the Trustees or their nominees in any way whatsoever, whether or not producing income, as the Trustees shall in their absolute discretion think fit, as if they were absolutely entitled to the Trust Fund beneficially."

It is the policy of the charity to hold reserves in its General Fund that have not yet been committed or designated for any particular purpose. The Trustees have set aside these reserves in order to protect the future operations of the charity from the effects of any unforeseen variations in its income streams as part of a policy of good financial management practice.

---

**BOB CHAMPION CANCER TRUST**

---

**TRUSTEES' REPORT (CONTINUED)  
FOR THE YEAR ENDED 30 JUNE 2021**

---

**Plans for the Future**

The Trustees continue to work towards the aims of the deed of declaration of Trust to find a cure for urological cancers, particularly prostate cancer, through scientific and clinical research at The Institute of Cancer Research and The Norwich Medical Research Park at UEA. To establish a clinical test to detect prostate cancer cells remains at the forefront of the Trusts current plans.

The funding for the work of the Trust will continue to be raised from a full fundraising calendar run by the Executive Officer of the Charity, donations and legacies and the interest from the investment funds if required.

**Statement of Trustees' responsibilities**

The trustees are responsible for preparing the Annual Report and the financial statements in accordance with applicable law and United Kingdom Generally Accepted Accounting Practice.

The trustees are required to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and the incoming resources and application of resources, including the net income or expenditure, for the year. In preparing those financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in business.

The trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the charity and to enable them to ensure that the financial statements comply with the Companies Act. The trustees are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as the trustees are aware:

- there is no relevant information of which the charity's independent examiner is unaware; and
- the trustees have taken all steps that they ought to have taken to make themselves.

Approved by order of the members of the board of Trustees on behalf by:

*Mike Cattermole*

**Michael Cattermole**  
Trustee

*2nd April 2022* and signed on their  
*Tim Fox*  
**Timothy Fox**  
Trustee

---

---

**BOB CHAMPION CANCER TRUST**

---

---

**INDEPENDENT EXAMINER'S REPORT  
FOR THE YEAR ENDED 30 JUNE 2021**

---

---

**Independent Examiner's Report to the Trustees of Bob Champion Cancer Trust ('the charity')**

We report to the charity Trustees on our examination of the accounts of the charity for the year ended 30 June 2021.

This report is made solely to the charity's Trustees, as a body, in accordance with section 145 of the Charities Act 2011 and regulations made under section 154 of that Act. Our work has been undertaken so that we might state to the charity's Trustees those matters we are required to state to them in an independent examiner's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charity and the charity's Trustees, as a body, for our work or for this report.

**Responsibilities and Basis of Report**

As the Trustees of the charity you are responsible for the preparation of the accounts in accordance with the requirements of the Charities Act 2011 ('the 2011 Act').

We report in respect of our examination of the charity's accounts carried out under section 145 of the 2011 Act and in carrying out our examination we have followed the applicable Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

**Independent Examiner's Statement**

We have completed our examination. We confirm that no matters have come to our attention in connection with the examination giving us cause to believe that in any material respect:

1. accounting records were not kept in respect of the charity as required by section 130 of the 2011 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination.

We have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Signed: *Stuart Hinds*

Dated: 06 April 2022

Stuart Hinds  
For and on behalf of

ACA

**Ecovis Wingrave Yeats UK Limited**

Waverley House  
7-12 Noel Street  
London  
W1F 8GQ

**BOB CHAMPION CANCER TRUST**

**STATEMENT OF FINANCIAL ACTIVITIES  
FOR THE YEAR ENDED 30 JUNE 2021**

	Note	Unrestricted funds 2021 £	Total funds 2021 £	Total funds 2020 £
<b>Income from:</b>				
Donations and legacies	2	39,148	39,148	26,380
Other charitable activities	3	155,918	155,918	217,564
Investments	4	45,337	45,337	50,975
Other income	5	6,444	6,444	1,988
		<u>246,847</u>	<u>246,847</u>	<u>296,907</u>
<b>Total income</b>				
<b>Expenditure on:</b>				
Raising funds		50,530	50,530	97,875
Charitable activities:				
Research grants	6	187,222	187,222	84,225
Support costs	7	91,459	91,459	93,693
Governance	7	13,123	13,123	9,840
		<u>342,334</u>	<u>342,334</u>	<u>285,633</u>
<b>Total expenditure</b>				
<b>Net (expenditure)/income before net gains on investments</b>				
		(95,487)	(95,487)	11,274
Net gains on investments	10	215,043	215,043	26,401
		<u>119,556</u>	<u>119,556</u>	<u>37,675</u>
<b>Net movement in funds</b>				
<b>Reconciliation of funds:</b>				
Total funds brought forward		1,555,465	1,555,465	1,517,790
Net movement in funds		119,556	119,556	37,675
		<u>1,675,021</u>	<u>1,675,021</u>	<u>1,555,465</u>
<b>Total funds carried forward</b>				

The Statement of Financial Activities includes all gains and losses recognised in the year.

The notes on pages 11 to 22 form part of these financial statements.

**BOB CHAMPION CANCER TRUST**

**BALANCE SHEET  
AS AT 30 JUNE 2021**

	Note	2021 £	2020 £
<b>Fixed assets</b>			
Tangible assets	9	2,452	3,268
Investments	10	1,663,792	1,448,749
		1,666,244	1,452,017
<b>Current assets</b>			
Debtors	11	1,328	6,674
Cash at bank and in hand		75,742	138,810
		77,070	145,484
Creditors: amounts falling due within one year	12	(68,293)	(42,036)
		8,777	103,448
<b>Net current assets</b>		8,777	103,448
<b>Total assets less current liabilities</b>		1,675,021	1,555,465
<b>Total net assets</b>		1,675,021	1,555,465
<b>Charity funds</b>			
Restricted funds		-	-
Unrestricted funds		1,675,021	1,555,465
<b>Total funds</b>		1,675,021	1,555,465

The financial statements were approved and authorised for issue by the Trustees on 2.4.22 and signed on their behalf by:

*Mike Cattermole*  
**Michael Cattermole**  
 Trustee

*Tim Fox*  
**Timothy Fox**  
 Trustee

The notes on pages 11 to 22 form part of these financial statements.

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 30 JUNE 2021**

---

**1. Accounting policies**

**1.1 Basis of preparation of financial statements**

The financial statements have been prepared in accordance with the Charities SORP (FRS 102) - Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Charities Act 2011.

The financial statements have been prepared to give a 'true and fair' view and have departed from the Charities (Accounts and Reports) Regulations 2008 only to the extent required to provide a 'true and fair' view. This departure has involved following the Charities SORP (FRS 102) published in October 2019 rather than the Accounting and Reporting by Charities: Statement of Recommended Practice effective from 1 April 2005 which has since been withdrawn.

Bob Champion Cancer Trust meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

The charity has taken advantage of the exemption available to smaller charities from preparing a cash flow statement.

**1.2 Fund accounting**

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the charity and which have not been designated for other purposes.

**1.3 Income**

All income is recognised once the charity has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably.

Donated services or facilities are recognised when the charity has control over the item, any conditions associated with the donated item have been met, the receipt of economic benefit from the use of the charity of the item is probable and that economic benefit can be measured reliably. In accordance with the Charities SORP (FRS 102), the general volunteer time of the Friends is not recognised and refer to the Trustees' report for more information about their contribution.

On receipt, donated professional services and facilities are recognised on the basis of the value of the gift to the charity which is the amount it would have been willing to pay to obtain services or facilities of equivalent economic benefit on the open market; a corresponding amount is then recognised in expenditure in the period of receipt.

Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Income tax recoverable in relation to investment income is recognised at the time the investment income is receivable.

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 30 JUNE 2021**

---

**1. Accounting policies (continued)**

**1.4 Expenditure**

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset's use.

Fundraising costs are those incurred in seeking voluntary contributions and do not include the costs of disseminating information in support of the charitable activities. Support costs are those costs incurred directly in support of expenditure on the objects of the charity and include project management carried out at Headquarters. Governance costs are those incurred in connection with administration of the charity and compliance with constitutional and statutory requirements.

Costs of generating funds are costs incurred in attracting voluntary income, and those incurred in charitable activities that raise funds.

Charitable activities and Governance costs are costs incurred on the charity's operations, including support costs and costs relating to the governance of the charity apportioned to charitable activities.

Grants payable are charged in the year when the offer is made except in those cases where the offer is conditional, such grants being recognised as expenditure when the conditions attaching are fulfilled. Grants offered subject to conditions which have not been met at the year end are noted as a commitment, but not accrued as expenditure.

**1.5 Going concern**

The Trustees consider that there are no material uncertainties about the Trust's ability to continue as a going concern for a period of at least twelve months after the date of signature of these accounts.

**1.6 Government grants**

Government grants are accounted for under the accruals model as permitted by the Charities SORP. During the year the Charity has received governmental support through the Coronavirus Job Retention Scheme. The government grants received in the year are of a revenue nature and are recognised in the Statement of Financial Activities in the same period as the related expenditure.

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 30 JUNE 2021**

---

**1. Accounting policies (continued)**

**1.7 Tangible fixed assets and depreciation**

A review for impairment of a fixed asset is carried out if events or changes in circumstances indicate that the carrying value of any fixed asset may not be recoverable. Shortfalls between the carrying value of fixed assets and their recoverable amounts are recognised as impairments. Impairment losses are recognised in the Statement of financial activities.

Tangible fixed assets are carried at cost, net of depreciation and any provision for impairment. Depreciation is provided at rates calculated to write off the cost of fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

Computer equipment	- 25% reducing balance
--------------------	------------------------

**1.8 Investments**

Fixed asset investments are a form of financial instrument and are initially recognised at their transaction cost and subsequently measured at fair value at the balance sheet date, unless the value cannot be measured reliably in which case it is measured at cost less impairment. Investment gains and losses, whether realised or unrealised, are combined and presented as 'Gains/(Losses) on investments' in the Statement of financial activities.

**1.9 Interest receivable**

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the charity; this is normally upon notification of the interest paid or payable by the institution with whom the funds are deposited.

**1.10 Debtors**

Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

**1.11 Cash at bank and in hand**

Cash at bank and in hand includes cash and short-term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

**1.12 Liabilities and provisions**

Liabilities are recognised when there is an obligation at the balance sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably. Liabilities are recognised at the amount that the charity anticipates it will pay to settle the debt or the amount it has received as advanced payments for the goods or services it must provide. Provisions are measured at the best estimate of the amounts required to settle the obligation. Where the effect of the time value of money is material, the provision is based on the present value of those amounts, discounted at the pre-tax discount rate that reflects the risks specific to the liability. The unwinding of the discount is recognised within interest payable and similar charges.

NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 30 JUNE 2021

---

**1. Accounting policies (continued)**

**1.13 Financial instruments**

The charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

**1.14 Pensions**

The charity operates a defined contribution pension scheme and the pension charge represents the amounts payable by the charity to the fund in respect of the Year.

**1.15 Critical accounting estimates and areas of judgement**

Estimates and judgments are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

The Trustees have not applied any significant estimates or judgments in the preparation of these financial statements.

**1.16 Basis of non-conclusion**

In the opinion of the Trustees, the charity and its subsidiary undertakings comprise a small group. The subsidiary has been excluded as its inclusion would not be material from the point of view of providing a true and fair view.

**BOB CHAMPION CANCER TRUST**

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 30 JUNE 2021**

**2. Income from donations and legacies**

	<b>Unrestricted funds 2021 £</b>	<b>Total funds 2021 £</b>	<i>Total funds 2020 £</i>
League of Friends	-	-	10,050
Memorial	34,727	<b>34,727</b>	6,230
Other	4,421	<b>4,421</b>	10,100
<b>Total</b>	<u>39,148</u>	<u><b>39,148</b></u>	<u>26,380</u>

In both the current year and prior year all income from donations and legacies was in relation to unrestricted funds.

**3. Activities for generating funds**

**Income from non charitable trading activities**

	<b>Unrestricted funds 2021 £</b>	<b>Total funds 2021 £</b>	<i>Total funds 2020 £</i>
Shetland Pony Grand National*	-	-	38,258
Tennis tournament*	20	<b>20</b>	414
40for40	100,883	<b>100,883</b>	-
Christmas Season	29,282	<b>29,282</b>	29,251
General fundraising	20,955	<b>20,955</b>	37,809
Plumpton Raceday*	4,778	<b>4,778</b>	111,832
<b>Total</b>	<u>155,918</u>	<u><b>155,918</b></u>	<u>217,564</u>

\*These events were not able to take place during the year due to the Covid-19 pandemic.

---

---

**BOB CHAMPION CANCER TRUST**

---

---

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 30 JUNE 2021**

---

**4. Investment income**

	<b>Unrestricted funds 2021 £</b>	<b>Total funds 2021 £</b>	<i>Total funds 2020 £</i>
Listed securities	45,336	<b>45,336</b>	50,960
Bank deposits	1	<b>1</b>	15
<b>Total</b>	<u>45,337</u>	<u><b>45,337</b></u>	<u>50,975</u>

In both the current year and prior year all investment income was in relation to unrestricted funds.

**5. Other income**

	<b>Unrestricted funds 2021 £</b>	<b>Total funds 2021 £</b>	<i>Total funds 2020 £</i>
Government grants - furlough income	6,444	<b>6,444</b>	1,988

**BOB CHAMPION CANCER TRUST**

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 30 JUNE 2021**

**6. Research grants**

	<b>Grants to Institutions 2021 £</b>	<b>Total funds 2021 £</b>	<i>Total funds 2020 £</i>
Professor Rosalind Eeles grant - Institute of Cancer Research (ICR)	92,710	<b>92,710</b>	23,056
Bob Champion Cancer Trust Post Doctoral fellowship grant - ICR and UCL	55,125	<b>55,125</b>	28,030
Professor Colin Cooper grant - UEA	39,387	<b>39,387</b>	33,139
<b>Total</b>	<u>187,222</u>	<u><b>187,222</b></u>	<u>84,225</u>

Professor Ros Eeles, Prostate Cancer Sequencing Project at the ICR, commenced in August 2019 at a cost of £282,509 over the three year grant period. Due to Covid-19, this grant was put on hold in the prior year as the ICR focused efforts on research of the virus. However, the grant resumed in the current year.

Dr Marianna Buongiorno was appointed in November 2017 for three years at a cost of £188,000 to hold the position of the Bob Champion Post - doctoral fellowship within Dr Gert Attard's team at the ICR. Dr Gert Attard is Affiliate Team Leader for the Centre for Evolution and Cancer at the ICR and Team Leader of Treatment Resistance Research Group at UCL. Due to Covid-19, this grant was put on hold in the prior year as the ICR has focused efforts on research of the virus. However, the grant resumed during the current year with Dr Marianna Buongiorno being replaced by Dr Mahedi Hassan in the Bob Champion Post Doctoral Fellowship position.

Professor Colin Cooper, The Role of Bacterial Infection in the Development of Human Prostate Cancer grant for Rachel Hurst was awarded in January 2020 for two years at a cost of £80,000. Professor Cooper is Professor of Cancer Genetics and Associate Dean of Research at UEA. This grant is due to end in December 2021 and, post year end, in November 2021, this grant was extended. The BCCT will continue to fund the project with Rachel Hurst with funds being taken up to, but no later, than 31st December 2024. It has been agreed that BCCT will pay 75% of the total grant, approximately £50,000 per annum.

Furthermore, prior to the year end in June 2021, a grant extension was offered to support Dan Brewer within Professor Colin Cooper's team on the DESNT project. The grant covers the project for one year at £30,000, with a deadline of completion of December 2023. No accounting entries nor payments were made towards this grant during the year.

Lastly, post year end in July 2021 a grant was offered to Annie Gao within the Bob Champion Unit, Royal Marsden Hospital. The agreed funding is £42,000 for 3 years (including standard on-costs) to commence not before 1st September 2021. No accounting entries nor payments were made towards this grant during the year.

**BOB CHAMPION CANCER TRUST**

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 30 JUNE 2021**

**7. Analysis of expenditure by activities**

	<b>Grant funding of activities 2021 £</b>	<b>Support costs 2021 £</b>	<b>Total funds 2021 £</b>	<i>Total funds 2020 £</i>
Premises costs	-	13,453	<b>13,453</b>	13,142
Other costs	-	15,077	<b>15,077</b>	9,232
Personnel costs	-	62,929	<b>62,929</b>	71,319
Governance costs	-	13,123	<b>13,123</b>	9,840
Professor Rosalind Eeles grant - Institute of Cancer Research	92,710	-	<b>92,710</b>	23,056
Dr. Gert Attard grant - ICR and UCL	55,125	-	<b>55,125</b>	28,030
Professor Colin Cooper grant - UEA	39,387	-	<b>39,387</b>	33,139
<b>Total</b>	<b>187,222</b>	<b>104,582</b>	<b>291,804</b>	<b>187,758</b>

**8. Staff costs**

	<b>2021 £</b>	<i>2020 £</i>
Wages and salaries	<b>58,920</b>	65,478
Social security costs	<b>2,241</b>	3,909
Contribution to defined contribution pension schemes	<b>1,768</b>	1,932
	<b>62,929</b>	71,319

The average number of persons employed by the charity during the year was as follows:

	<b>2021 No.</b>	<i>2020 No.</i>
Employees	<b>2</b>	2

No employee received remuneration amounting to more than £60,000 in either year.

The total employment benefits of key management personnel were £50,520 (2020 - £50,520).

---

**BOB CHAMPION CANCER TRUST**

---

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 30 JUNE 2021**

---

**9. Tangible fixed assets**

	<b>Computer equipment £</b>
<b>Cost or valuation</b>	
At 1 July 2020	6,782
At 30 June 2021	<u>6,782</u>
<b>Depreciation</b>	
At 1 July 2020	3,514
Charge for the Year	816
At 30 June 2021	<u>4,330</u>
<b>Net book value</b>	
At 30 June 2021	<u><u>2,452</u></u>
<i>At 30 June 2020</i>	<u><u>3,268</u></u>

**BOB CHAMPION CANCER TRUST**

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 30 JUNE 2021**

**10. Fixed asset investments**

	Investments in subsidiary companies £	Listed investments £	Total £
<b>Cost or valuation</b>			
At 1 July 2020	2	1,448,747	1,448,749
Revaluations	-	215,043	215,043
	2	1,663,790	1,663,792
At 30 June 2021	2	1,663,790	1,663,792
<b>Net book value</b>			
At 30 June 2021	2	1,663,790	1,663,792
At 30 June 2020	2	1,448,747	1,448,749
	2	1,448,747	1,448,749

**Subsidiary undertakings**

The following was a subsidiary undertaking of the charity:

<b>Name</b>	<b>Holding</b>
Aldaniti Trading Company Limited	100%

The financial results of the subsidiary for the year were:

<b>Name</b>	<b>Aggregate of share capital and reserves £</b>
Aldaniti Trading Company Limited	2

At 30 June 2021, CCLA Fund Managers Limited, an investment management company external to the charity, valued the investments held by the charity at £1,663,790 (2020 - £1,448,747). This valuation was made on the basis of the value of the units on the open market in which they are traded. The gain is included in the statement of financial activities.

Aldaniti Trading Company Limited, a company incorporated in England and Wales, ceased trading on 30 June 2004 and has not traded since. On this date its trade and assets were transferred to the charity.

**BOB CHAMPION CANCER TRUST**

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 30 JUNE 2021**

**11. Debtors**

	2021 £	2020 £
<b>Due within one year</b>		
Other debtors	10	4,998
Prepayments and accrued income	1,318	1,676
	<b>1,328</b>	<b>6,674</b>
	<b>1,328</b>	<b>6,674</b>

**12. Creditors: Amounts falling due within one year**

	2021 £	2020 £
Creditors	1,419	959
Creditors - ICR and UEA grants	37,324	11,366
Amounts owed to group undertakings	2	2
Other taxation and social security	9	2,598
Other creditors	355	272
Accruals and deferred income	19,314	17,318
Accruals - UEA grants	9,870	9,521
	<b>68,293</b>	<b>42,036</b>
	<b>68,293</b>	<b>42,036</b>

**13. Financial instruments**

	2021 £	2020 £
<b>Financial assets</b>		
Financial assets measured at fair value through income and expenditure	1,663,790	1,448,747
	<b>1,663,790</b>	<b>1,448,747</b>

Financial assets measured at fair value through income and expenditure comprise fixed asset investments. Fair value has been determined on the basis of the value of the investment units on the open market in which they are traded.

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 30 JUNE 2021**

---

**14. Pension commitments**

The charity operates a defined contributions pension scheme. The assets of the scheme are held separately from those of the charity in an independently administered fund. The pension cost charge represents contributions payable by the charity to the fund and amounted to £1,768 (2020 - £1,932). Contributions totalling £233 (2020 - £272) were payable to the fund at the balance sheet date and are included in creditors.

**15. Related party transactions**

During the year, the charity paid £25,680 (2020 - £28,630) to the president of the charity, Mr. Bob Champion, in relation to fees and expenses incurred in fulfilling his duties. The amount outstanding at the year end was £6,200 (2020 - £4,960). Bob Champion's retainer has been approved by the Charity Commission. Bob Champion took a 20% cut to his retainer for the lockdown period as support for the cause.